EP1303527A1 - Matrix metalloproteinase inhibitors - Google Patents

Matrix metalloproteinase inhibitors

Info

Publication number
EP1303527A1
EP1303527A1 EP01949275A EP01949275A EP1303527A1 EP 1303527 A1 EP1303527 A1 EP 1303527A1 EP 01949275 A EP01949275 A EP 01949275A EP 01949275 A EP01949275 A EP 01949275A EP 1303527 A1 EP1303527 A1 EP 1303527A1
Authority
EP
European Patent Office
Prior art keywords
oxo
acetohydroxamic acid
oxazaphosphorinane
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01949275A
Other languages
German (de)
French (fr)
Other versions
EP1303527B1 (en
Inventor
Morten Dahl Sorensen
Lars Kristian Albert Blaehr
Mette Knak Christensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of EP1303527A1 publication Critical patent/EP1303527A1/en
Application granted granted Critical
Publication of EP1303527B1 publication Critical patent/EP1303527B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring

Definitions

  • the present invention relates to a hitherto unknown class of compounds comprising new matrix metalloproteinase inhibitors, which are 1,3,2-oxazaphos- phacycloalkane based hydroxamic acids, carboxylic acids, phosphonic acids or thiols, to pharmaceutical compositions containing said compounds, to methods of treating patients with said compounds, and to the use of such compounds in the preparation of medicine.
  • the compounds are inhibitors of matrix metalloproteinases involved in tissue degradation.
  • Some of the compounds of the invention are, in addition, inhibitors of the release of tumour necrosis factor- ⁇ (TNF- ⁇ ) from cells.
  • Matrix metalloproteinases are a family of zinc endopeptidases, which exhibit proteolytic activity towards most if not all of the constituents of the extracellular matrix, such as the interstitial and basement membrane collagens, fibro- nectin, and laminin. They play a key role in both physiological and pathological tissue degradation. At least 17 different and yet highly homologous MMP-species have been characterised. They share a catalytic domain with the VAAHEXGHXXGXXH motif responsible for ligating zinc, which is essential for the catalytic function. MMP family members differ from each other structurally by the presence or absence of additional domains that contribute to activities, such as substrate specificity, inhibitor binding, matrix binding and cell-surface localisation. [H.
  • MMPs degrade fibrillar collagen
  • stromelysins prefer proteoglycans and glycoproteins as substrates and gelatinases are particularly potent in degradation of nonfibrillar and denatured collagens (gelatine).
  • MMPs are also believed to be important in the processing, or secretion, of biologically important cell mediators, such as TNF- ⁇ , and the post translational proteolysis processing, or shedding, of biologically important membrane proteins, such as the low affinity IgE receptor CD 23 (for a more complete list see N. M. Hooper er a/. : Biochem. J. (1997) 321, 265-279).
  • Potential therapeutic indications of MMP inhibitors have been discussed in the literature [e.g. T.H. Vu, Z. Werb. (1998) (In: Matrix Metalloproteinases. 1998. Edited by W.C. Parks and R.P. Mecham. Ppll5-148. Academic Press. ISBN 0-12- 545090-7); D.E.
  • Compounds which have the property of inhibiting the action of matrix metalloproteinases are thought to be potentially useful for, but not restricted to, the treatment or prophylaxis of conditions involving tissue breakdown and inflammation, for example rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, skin ageing and tumour metastasis, tumour invasion and tumour growth.
  • MMP inhibitors are also of potential value in the treatment of neuroinflammatory disorders, including those involving myelin degradation, for example multiple sclerosis, as well as in the management of angiogenesis dependent diseases, which include arthritic conditions and solid tumour growth as well as psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angio fibromas and hemangiomas.
  • angiogenesis dependent diseases which include arthritic conditions and solid tumour growth as well as psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angio fibromas and hemangiomas.
  • TNF- ⁇ is a cytokine which is produced as a 28-kDa precursor and released in an active 17-kDa form.
  • This active form can mediate a large number of deleterious effects in vivo, including inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase responses, similar to those seen during acute infections and shock states.
  • Chronic administration of TNF- ⁇ can cause cachexia and anorexia; accumulation of excess TNF- ⁇ can be fatal.
  • TNF- ⁇ Compounds which inhibit the production or action of TNF- ⁇ are therefore thought to be potentially useful for the treatment or prophylaxis of many inflammatory, infectious, immunological and malignant diseases. These include, but are not limited to, septic shock, haemodynamic shock and sepsis syndrome, post ischaemic reperfusion injury, Crohn's disease, mycobacterial infection, meningitis, psoriasis, congestive heart failure, cancer, rheumatoid arthritis and multiple sclerosis.
  • TNF- ⁇ convertase is a metalloprotease involved in the biosynthesis of TNF- ⁇ . Inhibition of TNF- ⁇ convertase inhibits production of TNF- ⁇ . Since excessive TNF- ⁇ production has been noted in several disease conditions characterised by MMP- mediated tissue degradation, including multiple sclerosis, arthritis and cancer, compounds which inhibit both MMPs and TNF- ⁇ production may have particular advantages in the treatment or prophylaxis of diseases or conditions in which both mechanisms are involved.
  • MMP inhibitors are peptide derivatives, based on naturally occurring amino acids, and are analogues of the cleavage sites in the natural substrates of the MMPs.
  • Other known MMP inhibitors are less peptidic in structure, and may be viewed as pseudopeptides or peptidomimetics, e.g. sulfonamides.
  • Such compounds usually have a zinc binding group, which most often is a hydroxamic acid, reverse hydroxamic acid, carboxylic acid, sulphhydryl, and oxygenated phosphorous (e.g. phosphinic acid and phosphonamides including aminophosphonic acid) groups.
  • MMP inhibitors with potent in vitro activities are known, many have not been suitable for further development as medicines, since they have lacked any useful activity when administered orally at pharmaceutically acceptably doses.
  • a number of factors influence oral bioavailability, the design of enzyme inhibitors with high oral bioavailability is far from straightforward. Finding a series of compounds that permits a good balance of intrinsic level of activity, water solubility, oral absorption, and favourable pharmacokinetic properties is a continuing problem in the art, since those properties can vary in an unpredictable way in relation to the structure. Identifying MMP inhibitors having such properties remains a challenge.
  • Prior art has consisted of simple peptidic compounds as well as linear and cyclic sulfonamide compounds, e.g. EP-A-0489577, WO 96/16931, WO 96/33991, WO 97/44315 and WO 00/09485.
  • Prior art has depicted only 1,3,2-oxazaphosphorocycloalkanes with simple phenyl and alkyl substituents, however they do not contain the requisite hydroxamic acid or other zinc binding groups (e.g.
  • novel 1,3,2-oxazaphoshacycloalkane based compounds of general formula (I) of the present invention are potent MMP inhibitors.
  • Preferred compounds of the present invention display nanomolar to micromolar potency in inhibiting MMPs, such as MMP-13, MMP-9 and MMP-3.
  • the present invention relates to a novel class of compounds of the general formula I wherein Y is 0 or S; n is 1, 2, 3 or 4;
  • X represents hydroxamic acid, carboxylic acid, phosphonic acid, acetylthiomethyl group or a mercaptomethyl group
  • E when present represents, a bond or optionally substituted methylene or ethylene; s and t are independently 0, 1, 2 or 3;
  • a and A' independently represent a bond, or a saturated or unsaturated, optionally substituted cyclic or heterocyclic hydrocarbon di- or triradical;
  • Z represents a bond, O, S, C(O), C(0)NR7, NR7C(0) or NR7, wherein R7 is hydrogen, hydroxy, branched or straight, saturated or unsaturated, optionally substituted hydrocarbon radical;
  • R5 represents a bond, alkane or alkene diradical, one or more ether diradicals (R-
  • R and R' independently represent alkane or alkene diradicals with a C-content from 0 to 3;
  • R6 represents hydrogen, hydroxy, halogen, cyano, nitro, branched or straight, saturated or unsaturated, optionally substituted hydrocarbon radical, unsaturated optionally substituted cyclic or heterocyclic hydrocarbon radical, NR8R9,
  • each R8 and R9 independently represent hydrogen, halogen, a branched or straight, saturated or unsaturated, optionally substituted hydrocarbon radical;
  • R2 represents hydrogen, (C ⁇ _ 8 )alkyl, (C 2 . 6 )alkenyl, (C 3 . 8 )cycloalkyl, aryl(C 0 . 6 )alkyl or heteroaryl(C 0 -6)all ⁇ yl; provided that if A, A', Z and R5 are all bonds, and s and t are both 0 (zero), then R6 is different from hydrogen; or a salt, hydrate or solvate thereof.
  • Alkyl refers to a straight or branched chain alkyl moiety, consisting solely of carbon and hydrogen, containing no unsaturation and having the number of carbon atoms specified, including for example methyl, n-propyl, isobutyl, t-butyl, hexyl and dodecyl.
  • (C 2 -C 6 )alkenyl refers to a straight or branched chain alkenyl moiety having 2 to 6 carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. This term would include, for example, vinyl, allyl, 1- and 2- butenyl and 2-methyl-2-propenyl.
  • alkoxy is intended to indicate a radical of formula OR, wherein R is alkyl as defined above, e.g. methoxy, ethoxy, propoxy, butoxy, etc.
  • alkoxycarbonyl is intended to indicate a radical of formula -COOR wherein R is alkyl as defined above, e.g. methoxycarbonyl, ethoxycabonyl, n-propoxycarbonyl, isopropoxycarbonyl, etc.
  • saturated cyclic hydrocarbon is intended to indicate cyclic compounds, optionally fused bicyclic rings, containing hydrogen and carbon, which are saturated, such as cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, hydrindane and decaline.
  • unsaturated cyclic hydrocarbon is intended to indicate cyclic compounds, optionally fused bicyclic rings, containing hydrogen and carbon, in which one or more carbon-carbon bond is unsaturated, such as cyclopentene, cyclohexene, cyclohexadiene, cycloheptene, benzene, naphtene and 1,4- dihydronaphtene, indane and indene.
  • heterocyclic hydrocarbon is intended to indicate saturated or unsaturated cyclic compounds of hydrogen, carbon, and one or more heteroatoms selected from O, S, N and P, such as pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyrrolidine, pyridine, pyrimidine, tetrahydrotiophene, tetrahydrofuran, piperidine, piperazine, phosphalane, phosphorinane and phosporepane.
  • Aryl refers to phenyl or naphtyl.
  • Cycloalkyl means a saturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclopentyl, cyclohexyl, and cyclooctyl.
  • Heteroaryl refers to pyridyl, indolyl, thienyl or imidazolyl.
  • substituted as applied to any moiety herein means substituted with up to four substituents, each of which independently may be a (C ⁇ - 6 )alkoxy, (C ⁇ - 6 )alkyl, phenyl, hydroxy, thio, (C ⁇ - 6 )alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), cyano, cyanomethyl, trifluoromethyl, nitro, carboxy, -CONH2, haloalkyl, alkylamino, hydroxyalkyl, alkylcarbonyl, -CONHR12 or -CONR12R12 wherein R12 is a (Ci-C JalkyI group or the residue of a natural ⁇ -amino acid.
  • Salts of the compounds of the invention can be formed with bases.
  • Such salts include salts derived from inorganic or organic bases, for example metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
  • salts may also be formed with pharmaceutically acceptable inorganic or organic acids, such as hydrochloric, hydrobromic, and hydroiodic acid, phosphoric acid, sulphuric acid, nitric acid, p-toluenesulphonic acid, methanesulphonic acid, formic acid, acetic acid, propionic acid, citric acid, tartaric acid, succinic acid, benzoic acid, maleic acid, these examples being considered as non-limiting for the invention.
  • pharmaceutically acceptable inorganic or organic acids such as hydrochloric, hydrobromic, and hydroiodic acid, phosphoric acid, sulphuric acid, nitric acid, p-toluenesulphonic acid, methanesulphonic acid, formic acid, acetic acid, propionic acid, citric acid, tartaric acid, succinic acid, benzoic acid, maleic acid, these examples being considered as non-limiting for the invention.
  • Preferred compounds of formula (I) are those in which X represents CONHOH. More preferred compounds of formula (I) are those in which X represents
  • n 1 or 2 and Y represents oxygen.
  • Rl is selected from the group consisting of alkoxyphenyl, phenoxyphenyl optionally substituted with halogen, halogen substituted hydrocarbon radical or cyano, phenylalkyl or naphtylalkyl both optionally substituted with halogen, phenyl optionally substituted with halogen or nitro, hydrocarbon radical, biphenyl optionally substituted with halogen, benzylphenoxyl, phenyl-(NH)-C(0)-phenyl optionally substituted with halogen or cyano and methoxy.
  • Rl groups include 4-methoxyphenyl, 4-(4-chloro- phenoxy)-phenyl, 4-(4-bromophenoxy)-phenyl, 4-(4-trifluoromethylphenoxy)- phenyl, 4 ' bromo-4-biphenylyl, ⁇ /-(4-chlorbenzoyl)-4-aminophenyl, 4-nitrophenyl,
  • R2 is selected from the group consisting of hydrogen
  • R2 groups include hydrogen, isopropyl, allyl, isobutyl, n- butyl, n-octyl and benzyl.
  • (+)- ⁇ -Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1).
  • ( ⁇ )- ⁇ -Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2).
  • (+)- ⁇ -Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 2,).
  • ( ⁇ )- ⁇ -Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1,).
  • (+)- ⁇ -Butyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (+)- ⁇ -Butyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2).
  • the compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesised using the methods outlined below, together with methods known in the art of synthetic organic chemistry, or variations thereof as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.
  • the novel compounds of formula (I) may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and suitable for the transformations being effected.
  • esters of formula (III) may be prepared from phosphonyl dichlorides (IV) and amino alcohols (V) in the presence of a base.
  • esters of formula (III) may also be prepared from phosphonyl dichlorides (IV) and amino alcohols (VI) in the presence of a base and subsequent alkylation of the intermediate oxazaphosphacycloalkane (VII) utilising haloesters (VIII) in the presence of a base.
  • Compounds containing a phosphonic acid as a zinc-binding group may be- prepared by alkylation of oxazaphosphacycloalkanes (VII) with alkyl or silyl phosphonate halides (IX), in the presence of base, followed by deprotection.
  • the deprotection of alkyl phosphonates is carried out by treatment with TMSI.
  • Silyl phosphonates are readily converted to phosphonic acids by treatment with water.
  • Compounds containing an acetylthiomethyl moiety (XII) as a zinc binding group may be prepared by alkylation of oxazaphosphacycloalkanes (VII) with an acetylthioethyl halide (XI) in the presence of base.
  • Compounds with a mercaptomethyl zinc-binding group (XIII) may prepared by removal of the acetyl group from compound (XII) with aqueous base.
  • the present compounds are intended for use in pharmaceutical compositions which are useful in the treatment of the above mentioned diseases.
  • a suitable dose of a compound of formula I for systemic treatment is 0.1 to 200 mg/kg body weight, the most preferred dosage being 0.2 to 50 mg/kg of mammal body weight, administered one or more times daily.
  • the active ingredient comprises from 0.1% to 100% by weight of the formulation.
  • dosage units of a formulation contain between 0.07 mg and 1 g of the active ingredient, preferably from about 0.5 mg to about 500 mg of the active ingredient, more preferably about 50 mg, e.g. for oral administration.
  • the active ingredient preferably comprises from 1% to 20% by weight of the formulation but the active ingredient may comprise as much as 50% w/w.
  • Formulations suitable for nasal or buccal administration may comprise 0.1% to 20% w/w for example about 2% w/w of active ingredient.
  • dosage unit a unitary, i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.
  • the formulations, both for veterinary and human medical use, of the present invention comprise an active ingredient in association with a pharmaceutically acceptable carrier therefore and optionally other therapeutic ingredient(s).
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.
  • the formulations include those in a form suitable for oral, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular and intravenous), transdermal, intra-articular, topical, nasal, or buccal administration.
  • the formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion.
  • the active ingredient may also be administered in the form of a bolus, electuary or paste.
  • Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and a carrier such as cocoa butter, or in the form of an enema.
  • Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient.
  • Formulations suitable for intra-articular administration may be in the form of a sterile aqueous preparation of the active ingredient which may be in microcrystal- line form, for example, in the form of an aqueous microcrystalline suspension.
  • Liposomal formulations or biodegradable polymer systems may also be used to present the active ingredient for both intra articular and ophthalmic administra ⁇ tion.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops.
  • Formulations suitable for administration to the nose or buccal cavity include powder, self-propelling and spray formulations, such as aerosols and atomisers.
  • the formulations of this invention may include one or more additional ingredients.
  • compositions may further contain other therapeutically active compounds usually applied in the treatment.
  • the invention is further illustrated by the following general procedures, preparations and examples.
  • Preparation 28 ( ⁇ )-Ethyl ⁇ -butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorepane-3-acetate (diastereomers 1, compound 228).
  • General procedure 4 Starting materials: 4-Methoxyphenylphosphonic dichloride and ⁇ /-(4- hydroxybutyl)-( ⁇ )-norleucine ethyl ester.
  • Preparation 66 ( ⁇ ?)-Methyl 2-(4-biphenylyl)-2-oxo- ⁇ -phenylmethyl-l f 3,2- oxazaphosphorinane-3-acetate (diastereomer 1, compound 266).
  • General procedure 4 Starting materials: 4-Biphenylylphosphonic dichloride and ⁇ /-(3-hydroxypropyl)-D- phenylalanine methyl ester.
  • Preparation 78 f ⁇ /?)-Methyl 2- r4-(4-chlorophenoxy)-phenyl1 - ⁇ -(2-methylethyl)- 2-oxo-l,3 r 2-oxazaphosphorinane-3-acetate (diastereomer 1, compound 278).
  • General procedure 4 Starting materials: 4-(4-Chlorophenoxy)phenylphosphonic dichloride and ⁇ /-(3- hydroxypropyl)-D-valine methyl ester.
  • Preparation 150 ( ⁇ )-2-r/v-(4-Chlorobenzoyl)-4-aminophenyl1-2-oxo-l,3,2- oxazaphosphorepane-3-acetic acid (compound 350).
  • Example 1 ( ⁇ )-2-(4-Chlorophenoxy)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohvdroxamic acid (compound 101).
  • Example 4 (+)-2-r(4-Biphenylyl)methyll-2-oxo-l f 3 r 2-oxazaphosphorinane-3- acetohydroxamic acid (compound 104).
  • General procedure 2. Starting material: Compound 213.
  • X H NMR (DMSO-d 6 ) ⁇ 11.0-8.0 (bs, 2H), 7.65 (m, 2H), 7.59 (m, 2H), 7.46 (m, 2H), 7.42-7.30 (m, 3H), 4.24 (m, 2H), 3.65-3.15 (m, 5H), 3.02 (m, IH), 1.94 (m, IH), 1.51 (m IH).
  • Example 9 (+)-2-Oxo-2-r4-(phenylamino)phenyll-l f 3,2-oxazaphosphorinane-3- acetohydroxamic acid (compound 109).
  • General procedure 2 Starting material: Compound 218. *H NMR (DMSO-d 6 ) ⁇ 11.0-9.8 (bs, IH), 9.15-8.50 (m, 2H), 7.59 (m, 2H), 7.30 (m, 2H), 7.16 (m, 2H), 7.09 (m, 2H), 6.95 (m, IH), 4.29 (m, IH), 4.08 (m, IH), 3.70-2.80 (m, 4H), 2.00 (m, IH), 1.88 (m, IH).
  • Example 10 ( ⁇ )-2-Oxo-2-phenyl-l f 3 r 2-oxazaphosphorinane-3-acetohydroxamic acid (compound 110).
  • General procedure 2 Starting material: Compound 219.
  • Example 11 (+)-2-Oxo-2-phenyl-l,3 f 2-oxazaphosphorepane-3-acetohydroxamic acid (compound 111).
  • General procedure 2 Starting material: Compound 220.
  • Example 12 2-Oxo-2-phenyl-l,3,2-oxazaphosphoronane-3-acetohydroxamic acid (compound 112).
  • Example 14 ( ⁇ )- ⁇ -Butyl-2-oxo-2-phenyl-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (compound 114).
  • General procedure 1 Starting material: Compound 308.
  • X H NMR (DMSO-de) ⁇ 10.60 (bs, IH), 8.86 (bs, IH), 7.72 (m, 2H), 7.56 (m, IH), 7.49 (m, 2H), 4.34 (m, IH), 4.11 (m, IH), 3.94 (m, IH), 2.84 (m, IH), 1.86-1.49 (m, 5H), 1.26 (m, IH), 1.09 (m, 2H), 0.85 (m, 2H), 0.67 (t, 3H).
  • Example 15 ( ⁇ )-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (compound 115).
  • Example 17 (+)-2-(4-Methoxyphenyl)-2-oxo-l r 3,2-oxazaphosphoronane-3- acetohydroxamic acid (compound 117).
  • Example 18 ( ⁇ R)-2-(4-Methoxyphenyl)- ⁇ -(l-methylethyl)-2-oxo-l r 3 f 2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer l f compound 118).
  • Example 19 f ⁇ fl ) -2- ( 4-Methoxyphenyl)- ⁇ -(l-methylethyl)-2-oxo-l f 3 r 2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 2, compound 119).
  • General procedure 1 Starting material: Compound 301. 13 C NMR (DMSO-d 6 ) ⁇ 167.9, 161.8, 133.6, 122.2, 113.7, 66.3, 60.4, 55.2, 25.7, 25.6, 19.3, 19.3.
  • Example 21 (+)- ⁇ -Butyl-2-(4-methoxyphenyl)-2-oxo-l,3 f 2-oxazaphosphorinane- 3-acetohydroxamic acid (diastereomers 2, compound 121).
  • General procedure 1 Starting material: Compound 312. 13 C NMR (CDCI 3 ) ⁇ 168.7, 163.3, 134.6, 119.6, 114.0, 66.4, 55.4, 55.0, 40.5, 27.8, 26.6, 26.3, 22.1, 13.9.
  • Example 24 f ⁇ ) - ⁇ -Butyl-2-(4-methoxyphenyl)-2-oxo-l,3 f 2-oxazaphosphorocane- 3-acetohvdroxamic acid (diastereomers 1, compound 124).
  • General procedure 1 Starting material: Compound 315.
  • Example 26 (+)- ⁇ -Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane- 3-acetohydroxamic acid (diastereomers 1, compound 126).
  • General procedure 1 Starting material: Compound 317.
  • Example 27 (+)- ⁇ -Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane- 3-acetohvdroxamic acid (diastereomers 2, compound 127).
  • Example 30 (g ⁇ )-2-(4-Methoxyphenyl)- ⁇ -(2-methylpropyl)-2-oxo-l,3.2- oxazaphosphorinane-3-acetohvdroxamic acid (diastereomer l f compound 130).
  • General procedure 1 Starting material: Compound 319.
  • Example 31 ( ⁇ fl)-2-(4-Methoxyphenyl)- ⁇ -(2-methylpropyl)-2-oxo-l r 3,2- oxazaphosphorinane-3-acetohvdroxamic acid (diastereomer 2, compound 131).
  • General procedure 1 Starting material: Compound 320.
  • Example 32 ( ⁇ S)-2-(4-Methoxyphenyl)- ⁇ -(2-methylpropyl)-2-oxo-l f 3 r 2- oxazaphosphorinane-3-acetohvdroxamic acid (diastereomer 1, compound 132).
  • General procedure 1 Starting material: Compound 323.
  • Example 33 ( ⁇ S)-2-(4-Methoxyphenyl)- ⁇ -(2-methylpropyl)-2-oxo-l f 3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 2, compound 133).
  • Example 34 ( ⁇ )-2-(4-MethoxyphenyD- ⁇ -(2-methylpropyl)-2-oxo-l,3,2- oxazaphosphorepane-3-acetohydroxamic acid (diastereomers 1, compound 134).
  • Example 36 (+)-2-(4-MethoxyphenyO- ⁇ -propyl-2-oxo-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomers 1, compound 136).
  • Example 37 ( ⁇ )-2-(4-MethoxyphenyD- ⁇ -propyl-2-oxo-1.3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomers 2, compound 137).
  • General procedure 1 Starting material: Compound 330. *H NMR (DMSO-de) ⁇ 10.57 (bs, IH), 8.86 (bs, IH), 7.67 (m, 2H), 7.06 (m,
  • Example 39 (+)-2-(4-Methoxyphenyl)- ⁇ -octyl-2-oxo-l,3,2-oxazaphosphorepane- 3-acetohydroxamic acid (diastereomers 2, compound 139).
  • General procedure 1 Starting material: Compound 326.
  • Example 40 ( ⁇ /?)-2-(4-Methoxyphenyl)-2-oxo- ⁇ -phenylmethyl-l,3.2- oxazaphosphorinane-3-acetohvdroxamic acid (diastereomer 1, compound 140).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A compound of the general formula (I) wherein Y is O or S; n is 1, 2, 3 or 4; X represents hydroxamic acid, carboxylic acid, phosphonic acid, acetylthiomethyl group or a mercaptomethyl group; R2 represents hydrogen, (C1-8)alkyl, (C2-6)alkenyl, (C3-8)cycloalkyl, aryl(C0-6)alkyl or heteroaryl(C0-6)alkyl; provided that if A, A', Z and R5 are all bonds, and s and t are both 0 (zero), then R6 is different from hydrogen; or a salt, hydrate or solvate thereof. The compounds are valuable for human and veterinary therapy.

Description

Matrix Metalloproteinase Inhibitors
The present invention relates to a hitherto unknown class of compounds comprising new matrix metalloproteinase inhibitors, which are 1,3,2-oxazaphos- phacycloalkane based hydroxamic acids, carboxylic acids, phosphonic acids or thiols, to pharmaceutical compositions containing said compounds, to methods of treating patients with said compounds, and to the use of such compounds in the preparation of medicine. In particular, the compounds are inhibitors of matrix metalloproteinases involved in tissue degradation. Some of the compounds of the invention are, in addition, inhibitors of the release of tumour necrosis factor-α (TNF-α) from cells.
Background of the Invention
Matrix metalloproteinases (MMPs) are a family of zinc endopeptidases, which exhibit proteolytic activity towards most if not all of the constituents of the extracellular matrix, such as the interstitial and basement membrane collagens, fibro- nectin, and laminin. They play a key role in both physiological and pathological tissue degradation. At least 17 different and yet highly homologous MMP-species have been characterised. They share a catalytic domain with the VAAHEXGHXXGXXH motif responsible for ligating zinc, which is essential for the catalytic function. MMP family members differ from each other structurally by the presence or absence of additional domains that contribute to activities, such as substrate specificity, inhibitor binding, matrix binding and cell-surface localisation. [H. Birkedal- Hansen, W. G. Moore, M. K. Bodden, C. J. Windsor, B. Birkedal-Hansen, A. DeCarlo: Crit. Rev. Oral Biol. Med. (1993) 4, 197-250 and A. F. Chambers, L. M. Matristan: J. Natl. Cancer Inst (1997) 89(17), 1260-1270]. There are three major groups of MMPs, identified by their substrate preferences: collagenases degrade fibrillar collagen, stromelysins prefer proteoglycans and glycoproteins as substrates and gelatinases are particularly potent in degradation of nonfibrillar and denatured collagens (gelatine).
MMPs are also believed to be important in the processing, or secretion, of biologically important cell mediators, such as TNF-α, and the post translational proteolysis processing, or shedding, of biologically important membrane proteins, such as the low affinity IgE receptor CD 23 (for a more complete list see N. M. Hooper er a/. : Biochem. J. (1997) 321, 265-279). Potential therapeutic indications of MMP inhibitors have been discussed in the literature [e.g. T.H. Vu, Z. Werb. (1998) (In: Matrix Metalloproteinases. 1998. Edited by W.C. Parks and R.P. Mecham. Ppll5-148. Academic Press. ISBN 0-12- 545090-7); D.E. Mullins er a/. : Biochem. Biophys. Acta (1983) 695, 117-214; B. Henderson er a/. : Drugs of the Future (1990) 15, 495-508; R. Reich er a/. : Cancer Res. (1988) 48, 3307-3312]. Compounds which have the property of inhibiting the action of matrix metalloproteinases are thought to be potentially useful for, but not restricted to, the treatment or prophylaxis of conditions involving tissue breakdown and inflammation, for example rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, skin ageing and tumour metastasis, tumour invasion and tumour growth. MMP inhibitors are also of potential value in the treatment of neuroinflammatory disorders, including those involving myelin degradation, for example multiple sclerosis, as well as in the management of angiogenesis dependent diseases, which include arthritic conditions and solid tumour growth as well as psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angio fibromas and hemangiomas. However, the relative contributions of individual MMPs in any of the above disease states is not yet fully understood. TNF-α is a cytokine which is produced as a 28-kDa precursor and released in an active 17-kDa form. This active form can mediate a large number of deleterious effects in vivo, including inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase responses, similar to those seen during acute infections and shock states. Chronic administration of TNF-α can cause cachexia and anorexia; accumulation of excess TNF-α can be fatal.
Compounds which inhibit the production or action of TNF-α are therefore thought to be potentially useful for the treatment or prophylaxis of many inflammatory, infectious, immunological and malignant diseases. These include, but are not limited to, septic shock, haemodynamic shock and sepsis syndrome, post ischaemic reperfusion injury, Crohn's disease, mycobacterial infection, meningitis, psoriasis, congestive heart failure, cancer, rheumatoid arthritis and multiple sclerosis.
TNF-α convertase is a metalloprotease involved in the biosynthesis of TNF-α. Inhibition of TNF-α convertase inhibits production of TNF-α. Since excessive TNF-α production has been noted in several disease conditions characterised by MMP- mediated tissue degradation, including multiple sclerosis, arthritis and cancer, compounds which inhibit both MMPs and TNF-α production may have particular advantages in the treatment or prophylaxis of diseases or conditions in which both mechanisms are involved.
Many known MMP inhibitors are peptide derivatives, based on naturally occurring amino acids, and are analogues of the cleavage sites in the natural substrates of the MMPs. Other known MMP inhibitors are less peptidic in structure, and may be viewed as pseudopeptides or peptidomimetics, e.g. sulfonamides. Such compounds usually have a zinc binding group, which most often is a hydroxamic acid, reverse hydroxamic acid, carboxylic acid, sulphhydryl, and oxygenated phosphorous (e.g. phosphinic acid and phosphonamides including aminophosphonic acid) groups.
Although numerous MMP inhibitors with potent in vitro activities are known, many have not been suitable for further development as medicines, since they have lacked any useful activity when administered orally at pharmaceutically acceptably doses. Although it is known that a number of factors influence oral bioavailability, the design of enzyme inhibitors with high oral bioavailability is far from straightforward. Finding a series of compounds that permits a good balance of intrinsic level of activity, water solubility, oral absorption, and favourable pharmacokinetic properties is a continuing problem in the art, since those properties can vary in an unpredictable way in relation to the structure. Identifying MMP inhibitors having such properties remains a challenge.
Prior art has consisted of simple peptidic compounds as well as linear and cyclic sulfonamide compounds, e.g. EP-A-0489577, WO 96/16931, WO 96/33991, WO 97/44315 and WO 00/09485. Only a single example of a prior art patent publication exists depicting simple linear phosphinamide compounds [WO 98/08853] . These are structurally diverse from the cyclic compounds of general formula (I). Prior art has depicted only 1,3,2-oxazaphosphorocycloalkanes with simple phenyl and alkyl substituents, however they do not contain the requisite hydroxamic acid or other zinc binding groups (e.g. PL 149593, FR 2567129, Izv. Akad. Nauk., Ser. Khim (1995) (11), 2241-9). It has now surprisingly been found that the novel 1,3,2-oxazaphoshacycloalkane based compounds of general formula (I) of the present invention are potent MMP inhibitors. Preferred compounds of the present invention display nanomolar to micromolar potency in inhibiting MMPs, such as MMP-13, MMP-9 and MMP-3.
The present invention relates to a novel class of compounds of the general formula I wherein Y is 0 or S; n is 1, 2, 3 or 4;
X represents hydroxamic acid, carboxylic acid, phosphonic acid, acetylthiomethyl group or a mercaptomethyl group;
Rl is
wherein E, when present represents, a bond or optionally substituted methylene or ethylene; s and t are independently 0, 1, 2 or 3;
A and A' independently represent a bond, or a saturated or unsaturated, optionally substituted cyclic or heterocyclic hydrocarbon di- or triradical; Z represents a bond, O, S, C(O), C(0)NR7, NR7C(0) or NR7, wherein R7 is hydrogen, hydroxy, branched or straight, saturated or unsaturated, optionally substituted hydrocarbon radical;
R5 represents a bond, alkane or alkene diradical, one or more ether diradicals (R-
O-R') or amine diradicals (R-N-R7), wherein R and R' independently represent alkane or alkene diradicals with a C-content from 0 to 3;
R6 represents hydrogen, hydroxy, halogen, cyano, nitro, branched or straight, saturated or unsaturated, optionally substituted hydrocarbon radical, unsaturated optionally substituted cyclic or heterocyclic hydrocarbon radical, NR8R9,
C(0)NR8R9, C(0)R8, CO(0)R8, S(0)2R9, wherein each R8 and R9 independently represent hydrogen, halogen, a branched or straight, saturated or unsaturated, optionally substituted hydrocarbon radical;
R2 represents hydrogen, (Cι_8)alkyl, (C2.6)alkenyl, (C3.8)cycloalkyl, aryl(C0.6)alkyl or heteroaryl(C0-6)all<yl; provided that if A, A', Z and R5 are all bonds, and s and t are both 0 (zero), then R6 is different from hydrogen; or a salt, hydrate or solvate thereof.
As used in the specification, unless specified to the contrary, the following terms have the meaning indicated: "Alkyl" refers to a straight or branched chain alkyl moiety, consisting solely of carbon and hydrogen, containing no unsaturation and having the number of carbon atoms specified, including for example methyl, n-propyl, isobutyl, t-butyl, hexyl and dodecyl.
"(C2-C6)alkenyl" refers to a straight or branched chain alkenyl moiety having 2 to 6 carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. This term would include, for example, vinyl, allyl, 1- and 2- butenyl and 2-methyl-2-propenyl.
The term "alkoxy" is intended to indicate a radical of formula OR, wherein R is alkyl as defined above, e.g. methoxy, ethoxy, propoxy, butoxy, etc.
The term "alkoxycarbonyl" is intended to indicate a radical of formula -COOR wherein R is alkyl as defined above, e.g. methoxycarbonyl, ethoxycabonyl, n-propoxycarbonyl, isopropoxycarbonyl, etc.
The term "saturated cyclic hydrocarbon" is intended to indicate cyclic compounds, optionally fused bicyclic rings, containing hydrogen and carbon, which are saturated, such as cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, hydrindane and decaline.
The term "unsaturated cyclic hydrocarbon" is intended to indicate cyclic compounds, optionally fused bicyclic rings, containing hydrogen and carbon, in which one or more carbon-carbon bond is unsaturated, such as cyclopentene, cyclohexene, cyclohexadiene, cycloheptene, benzene, naphtene and 1,4- dihydronaphtene, indane and indene.
The term "heterocyclic hydrocarbon" is intended to indicate saturated or unsaturated cyclic compounds of hydrogen, carbon, and one or more heteroatoms selected from O, S, N and P, such as pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyrrolidine, pyridine, pyrimidine, tetrahydrotiophene, tetrahydrofuran, piperidine, piperazine, phosphalane, phosphorinane and phosporepane. "Aryl" refers to phenyl or naphtyl.
"Cycloalkyl" means a saturated alicyclic moiety having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclopentyl, cyclohexyl, and cyclooctyl.
"Heteroaryl" refers to pyridyl, indolyl, thienyl or imidazolyl.
Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with up to four substituents, each of which independently may be a (Cι-6)alkoxy, (Cι-6)alkyl, phenyl, hydroxy, thio, (Cι-6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), cyano, cyanomethyl, trifluoromethyl, nitro, carboxy, -CONH2, haloalkyl, alkylamino, hydroxyalkyl, alkylcarbonyl, -CONHR12 or -CONR12R12 wherein R12 is a (Ci-C JalkyI group or the residue of a natural α-amino acid.
Salts of the compounds of the invention can be formed with bases. Such salts include salts derived from inorganic or organic bases, for example metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
If the compounds of the invention contain basic moieties, salts may also be formed with pharmaceutically acceptable inorganic or organic acids, such as hydrochloric, hydrobromic, and hydroiodic acid, phosphoric acid, sulphuric acid, nitric acid, p-toluenesulphonic acid, methanesulphonic acid, formic acid, acetic acid, propionic acid, citric acid, tartaric acid, succinic acid, benzoic acid, maleic acid, these examples being considered as non-limiting for the invention. There are chiral centres in the compounds according to the invention due to the presence of an asymmetric carbon atom and an asymmetric phosphorous atom. The presence of several chiral centres gives rise to a number of diastereoisomers with R or S stereochemistry at each chiral centre. Likewise, the occurrence of carbon-carbon double bonds and ringsystems gives rise to the presence of geometric and stereo isomeric forms. General formula (I), and (unless specified otherwise) all other formulae in this specification are to be understood to include all such isomers, in pure form, or as mixtures thereof. In the compounds of the invention, the preferred stereochemistry is in general as follows: C atom carrying the R2 group -(R), but mixtures in which the above configurations predominate are also contemplated. Without limiting the generality of the foregoing:
Preferred compounds of formula (I) are those in which X represents CONHOH. More preferred compounds of formula (I) are those in which X represents
CONHOH, n = 1 or 2 and Y represents oxygen.
In a preferred embodiment, Rl is selected from the group consisting of alkoxyphenyl, phenoxyphenyl optionally substituted with halogen, halogen substituted hydrocarbon radical or cyano, phenylalkyl or naphtylalkyl both optionally substituted with halogen, phenyl optionally substituted with halogen or nitro, hydrocarbon radical, biphenyl optionally substituted with halogen, benzylphenoxyl, phenyl-(NH)-C(0)-phenyl optionally substituted with halogen or cyano and methoxy.
Examples of particular Rl groups include 4-methoxyphenyl, 4-(4-chloro- phenoxy)-phenyl, 4-(4-bromophenoxy)-phenyl, 4-(4-trifluoromethylphenoxy)- phenyl, 4 ' bromo-4-biphenylyl, Λ/-(4-chlorbenzoyl)-4-aminophenyl, 4-nitrophenyl,
Λ/-benzoyl-4-aminophenyl, 4-phenoxyphenyl.
In a preferred embodiment, R2 is selected from the group consisting of hydrogen,
(Cι-8)alkyl, (C2.6)alkenyl and aryl(C0.6)alkyl. Examples of particular R2 groups include hydrogen, isopropyl, allyl, isobutyl, n- butyl, n-octyl and benzyl.
Examples of the invention are:
(±)-2-(4-Chlorophenoxy)-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid. (±)-2-(4-Chlorophenoxy)-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(+)-2-[(4-Bromophenyl)methyl]-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2-[(4-Biphenylyl)methyl]-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2-(4-Biphenylyl)-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-(4-Biphenylyl)-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(±)-2-Heptyl-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic
(±)-2-Heptyl-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid. (±)-2-Oxo-2-[4-(phenylamino)phenyl]-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2-Oxo-2-phenyl-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(+)-2-Oxo-2-phenyl-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid. (±)-2-Oxo-2-phenyl-l,3,2-oxazaphosphoronane-3-acetohydroxamic acid
(+)-α-Butyl-2-oxo-2-phenyl-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(±)-α-Butyl-2-oxo-2-phenyl-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(+)-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(±)-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphoronane-3-acetohydroxamic acid. (α/?)-2-(4-Methoxyphenyl)-α-(l-methylethyl)-2-oxo-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 1).
(α/?)-2-(4-Methoxyphenyl)-α-(l-methylethyl)-2-oxo-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 2).
(±)- α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 1).
(+)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 2).
(+)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1). (±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2).
(±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorocane-3- acetohydroxamic acid (diastereomers 1).
(±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorocane-3- acetohydroxamic acid (diastereomers 2).
(+)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 1).
(+)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 2,). (±)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1,).
(±)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2).
(α/?)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorinane- 3-acetohydroxamic acid (diastereomer 1, compound 130).
(α/?)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 2). (αS)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 1).
(αS)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 2). (±)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorepane-
3-acetohydroxamic acid (diastereomers 1).
(±)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorepane-
3-acetohydroxamic acid (diastereomers 2).
(+)-2-(4-Methoxyphenyl)- α-propyl-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 1).
(+)-2-(4-Methoxyphenyl)- α-propyl-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 2,).
(±)-2-(4-Methoxyphenyl)- α-octyl-2-oxo-l,3,2-oxazaphosphorepane-3- aceto hydroxamic acid (diastereomers 1). (+)-2-(4-Methoxyphenyl)- α-octyl-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2,).
(α/?)-2-(4-Methoxyphenyl)-2-oxo-α-phenylmethyl-l,3,2-oxazaphosphorinane-3- aceto hydroxamic acid (diastereomer 1).
(αS)-2-(4-Methoxyphenyl)-2-oxo-α-phenylmethyl-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomer 1).
(αS)-2-(4-Methoxyphenyl)-2-oxo-α-phenylmethyl-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomer 2).
(+)-2-Oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid. (±)-2-Oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(±)-2-Oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorocane-3-acetohydroxamic acid.
(+)-α-Allyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 1.).
(±)-α-Allyl-2-oxo-2-(4-phenoxyphenyl)-l,3/2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 2).
(αR)-α-(2-Methylpropyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 1). (αt?)-α-(2-Methylpropyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 2).
(α/?)-α-(2-Methylethyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomer 1). (α/?)-α-(2-Methylethyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomer 2).
(±)-α-Butyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1). (+)-α-Butyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2).
+)-α-Octyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1).
(±)- α-Octyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2).
(±)-2-Oxo-2-(2-phenylethyl)-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(+)-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorocane-3-acetohydroxamic acid.
(±)-2-Oxo-2-phenyl-l,3,2-oxazaphosphorocane-3-acetohydroxarnic acid. (±)-2-Heptyl-2-oxo-l,3,2-oxazaphosphorocane-3-acetohydroxamic acid
(compound 159).
(α/?)-2-(4-Biphenylyl)-α-(l-methylethyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomer 2).
(±)-2- [4-(4-Chlorophenyloxy)-phenyl]-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid.
(±)-2- [4-(4-Chlorophenyloxy)-phenyl]-2-oxo-l,3,2-oxazaphosphorocane-3- acetohydroxamic acid.
(α/?)-2- [4-(4-Chlorophenyloxy)-phenyl]-α-(2-methylethyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid. (±)-2-(4'-Bromo-4-biphenylyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2-(4'-Bromo-4-biphenylyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid.
(±)-2-(4'-Bromo-4-biphenylyl)-2-oxo-l,3,2-oxazaphosphorocane-3- acetohydroxamic acid.
(±)- 2-[2-(l-Naphtyl)-ethyl]-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-Phenyl-2-thioxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-Phenyl-2-thioxo-l,3,2-oxazaphosphorepane-3-acetamide. (±)-2-Phenyl-2-thioxo-l,3,2-oxazaphosphorocane-3-acetamide.
(±)-2- [4-(4-Chlorophenyloxy)-phenyl] -2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid. (±)-2-(4-BromophenyI)-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-(4-Bromophenyl)-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid. (±)-2-Oxo-2-(4-phenylmethoxyphenyl)-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2-Oxo-2-(4-phenylmethoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid.
(±)-2-Oxo-2-(4-phenylmethoxyphenyl)-l,3,2-oxazaphosphorocane-3- acetohydroxamic acid.
(±)-2- [2-(4-Chlorophenoxy)-phenyl] -2-oxo-l,3, 2-oxazaphosphorepane-3- acetohydroxamic acid
(±)-2-Oxo-2-[4-(4-trifluoromethylphenoxy)-phenyl]-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid. (±)-2-Oxo-2-[4-(4-trifluoromethylphenoxy)-phenyl]-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid.
(αfl)-α-(2-Methylethyl)-2-oxo-2-[4-(4-trifluoromethylphenoxy)-phenyl]-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 1,).
(αR)-α-(2-Methylethyl)-2-oxo-2-[4-(4-trifluoromethylphenoxy)-phenyl]-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 2).
(±)-2- [4-(4-Bromophenoxy)-phenyl] -2-oxo-l,3, 2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2- [4-(4-Bromophenoxy)-phenyl] -2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid. (±)-2-(4-nitrophenyl)-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid
(±)-2-[/V-(4-Chlorobenzoyl)-4-aminophenyl]-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid.
(±)-2-( V-Benzoyl-4-aminophenyl-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid; and the corresponding carboxylic acids.
The compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of organic synthesis. The compounds of the present invention can be synthesised using the methods outlined below, together with methods known in the art of synthetic organic chemistry, or variations thereof as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The novel compounds of formula (I) may be prepared using the reactions and techniques described in this section. The reactions are performed in solvents appropriate to the reagents and materials employed and suitable for the transformations being effected. Also, in the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of experiment and work-up procedures, are chosen to be conditions of standard for that reaction, which should be readily recognised by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the educt molecule must be compatible with the reagents and reactions proposed. Not all compounds of formula (I) falling into a given class may be compatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are compatible with the reaction conditions will be readily apparent to one skilled in the art and alternate methods can be used.
Compounds according to the present invention in which X is a hydroxamic acid group -CONHOH may be prepared from compounds of the invention in which X is a carboxylic acid group -COOH. That process comprises reacting an acid of general formula (II) (in these and the following formulae Rl, R2, Y and n have the above meanings unless otherwise specifically indicated; R13 represents an alkyl; R14 represents an alkyl or a silyl).
[II]
with hydroxylamine, O-protected hydroxylamine, N,0-diprotected hydroxylamine. Other substituents of the acids (II) may themselves be protected from such reaction, then removing any protecting groups from the resulting hydroxamic acid moiety and from any protected substituents in Rl, and R2. The condensation is carried out using any of the many methods for the formation of amide bonds known to one skilled in the art of organic synthesis, e.g. the mixed carbonic anhydride (isobutyl chloroformate) method. Compounds according to the present invention in which X is a hydroxamic acid group -CONHOH may also be prepared from esters of general formula (III). That process comprises reacting an ester of general formula (III) with hydroxylamine or O-protected hydroxylamine in the presence of a base.
I
Compounds according to the present invention in which X is a carboxylic acid group -COOH may be prepared from esters of general formula (III) by basic hydrolysis.
The esters of formula (III) may be prepared from phosphonyl dichlorides (IV) and amino alcohols (V) in the presence of a base.
IV V III
The esters of formula (III) may also be prepared from phosphonyl dichlorides (IV) and amino alcohols (VI) in the presence of a base and subsequent alkylation of the intermediate oxazaphosphacycloalkane (VII) utilising haloesters (VIII) in the presence of a base.
IV VI VII
VII VIII
Starting materials (IV), (V), (VI) and (VIII) are either known compounds or prepared by known routine synthetic methods.
Compounds containing a phosphonic acid as a zinc-binding group (X) may be- prepared by alkylation of oxazaphosphacycloalkanes (VII) with alkyl or silyl phosphonate halides (IX), in the presence of base, followed by deprotection. The deprotection of alkyl phosphonates is carried out by treatment with TMSI. Silyl phosphonates are readily converted to phosphonic acids by treatment with water.
VII IX XI
Compounds containing an acetylthiomethyl moiety (XII) as a zinc binding group may be prepared by alkylation of oxazaphosphacycloalkanes (VII) with an acetylthioethyl halide (XI) in the presence of base. Compounds with a mercaptomethyl zinc-binding group (XIII) may prepared by removal of the acetyl group from compound (XII) with aqueous base.
VII XI XII
XII XIII
The present compounds are intended for use in pharmaceutical compositions which are useful in the treatment of the above mentioned diseases.
The amount required of a compound of formula I (hereinafter referred to as the active ingredient) for therapeutic effect will, of course, vary both with the particular compound, the route of administration and the mammal under treatment. A suitable dose of a compound of formula I for systemic treatment is 0.1 to 200 mg/kg body weight, the most preferred dosage being 0.2 to 50 mg/kg of mammal body weight, administered one or more times daily.
While it is possible for an active ingredient, such as a compound according to this invention, to be administered alone as the raw chemical, it is preferable to administer a compound of the invention as a pharmaceutical formulation. Conveniently, the active ingredient comprises from 0.1% to 100% by weight of the formulation. Conveniently, dosage units of a formulation contain between 0.07 mg and 1 g of the active ingredient, preferably from about 0.5 mg to about 500 mg of the active ingredient, more preferably about 50 mg, e.g. for oral administration. For topical administration, the active ingredient preferably comprises from 1% to 20% by weight of the formulation but the active ingredient may comprise as much as 50% w/w. Formulations suitable for nasal or buccal administration may comprise 0.1% to 20% w/w for example about 2% w/w of active ingredient. By the term "dosage unit" is meant a unitary, i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.
The formulations, both for veterinary and human medical use, of the present invention comprise an active ingredient in association with a pharmaceutically acceptable carrier therefore and optionally other therapeutic ingredient(s). The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof. The formulations include those in a form suitable for oral, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular and intravenous), transdermal, intra-articular, topical, nasal, or buccal administration. The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion. The active ingredient may also be administered in the form of a bolus, electuary or paste.
Formulations for rectal administration may be in the form of a suppository incorporating the active ingredient and a carrier such as cocoa butter, or in the form of an enema.
Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient. Formulations suitable for intra-articular administration may be in the form of a sterile aqueous preparation of the active ingredient which may be in microcrystal- line form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems may also be used to present the active ingredient for both intra articular and ophthalmic administra¬ tion.
Formulations suitable for topical administration, including eye treatment, include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops.
Formulations suitable for administration to the nose or buccal cavity include powder, self-propelling and spray formulations, such as aerosols and atomisers. In addition to the aforementioned ingredients, the formulations of this invention may include one or more additional ingredients.
The compositions may further contain other therapeutically active compounds usually applied in the treatment.
The invention is further illustrated by the following general procedures, preparations and examples.
General Procedures, Preparations and Examples
The exemplified compounds are listed in Table 4, exemplified compounds of general formula (II) in Table 3, intermediates of general formula (III) in Table 2, and intermediates of general formula (VII) in Table 1. All melting points are uncorrected. For 1H nuclear magnetic resonance (NMR) spectra (300 MHz) and 13C NMR (75.6 MHz) chemical shift values (δ) (in ppm) are quoted, unless otherwise specified, for deuteriochloroform solutions relative to internal tetramethylsilane (δ = 0.00) or chloroform (δ = 7.25) or deuteriochloroform (δ = 76.81 for 13C NMR) standards. The value of a multiplet, either defined (doublet (d), triplet (t), quartet (q)) or not (m) at the approximate mid point is given unless a range is quoted, (bs) indicates a broad singlet. Mass spectra were recorded on a QUATTRO II (Micromass). The organic solvents used were anhydrous. Chromatography was performed on silica gel. The following abbreviations have been used throughout:
MS Mass spectroscopy
NMM Λ/-methylmorpholine
NMR Nuclear magnetic resonance rt Room temperature
THF Tetrahydrofuran
TMSI Trimethylsilyliodid dba Tris(dibenzylidenacetone)dipalladium (0)
Ph phenyl
Table 1 Some compounds of general formula (VII)
Comp. Prep no Rl Y n
No.
201 1 phenyl 0 1
202 2 phenyl 0 2
203 3 phenyl 0 3
204 4 4-methoxy- 0 1 phenyl
205 5 4-methoxy- 0 2 phenyl
206 6 4-phenoxy- 0 2 phenyl
207 7 2-phenyl-ethyl 0 1
208 8 n-heptyl 0 1
209 9 4-biphenylyl 0 1
Table 2 Some compounds of general formula (III)
Comp. Prep. Rl R2 R13 Y no. No.
210 10 (4-CI-phenyl)- H Et O oxy 211 11 (4-CI-phenyl)- H Me 0 2 oxy
212 12 (4-Br-phenyl)- H Et 0 1 methyl
213 13 4-biphenylyl- H Et 0 1 methyl
214 14 4-biphenylyl H Et 0 1
215 15 4-biphenylyl H Me 0 2
216 16 n-heptyl H Et 0 1
217 17 n-heptyl H Me 0 2
218 18 (Λ -phenyl)-4- H Et 0 1 aminophenyl
219 19 phenyl H Et 0 1
220 20 phenyl H Me 0 2
221 21 phenyl n-Bu Et 0 2 (isomers 1)
222 22 phenyl n-Bu Et 0 2 (isomers 2)
223 23 4-methoxy- H Et 0 1 phenyl
224 24 4-methoxy- H Me 0 2 phenyl
225 25 4-methoxy- H Et 0 4 phenyl
226 26 4-methoxy- i-Pr (R) Me 0 1 phenyl (isomer 1)
227 27 4-methoxy- i-Pr (R) Me 0 1 phenyl (isomer 2)
228 28 4-methoxy- n-Bu Et 0 2 phenyl (isomers 1)
229 29 4-methoxy- n-Bu Et 0 2 phenyl (isomers 2)
230 30 4-methoxy- n-Bu Et 0 3 phenyl (isomers 1)
231 31 4-methoxy- n-Bu Et 0 3 phenyl (isomers 2)
232 32 4-methoxy- allyl Me 0 1 phenyl (isomers 1)
233 33 4-methoxy- allyl Me 0 1 phenyl (isomers 2)
234 34 4-methoxy- allyl Et 0 2 phenyl (isomers 1)
235 35 4-methoxy- allyl Et 0 2 phenyl (isomers 2) 236 36 4-methoxy- i-Bu (/?) Me 0 1 phenyl (isomer 1)
237 37 4-methoxy- i-Bu (R) Me O 1 phenyl (isomer 2)
238 38 4-methoxy- i-Bu Et O 2 phenyl (isomers 1)
239 39 4-methoxy- i-Bu Et O 2 phenyl (isomers 2)
240 40 4-methoxy- i-Bu (S) Me O 1 phenyl (isomer 1)
241 41 4-methoxy- i-Bu (S) Me 0 1 phenyl (isomer 2)
242 42 4-methoxy- n-Octyl Et O 2 phenyl (isomers 1)
243 43 4-methoxy- n-Octyl Et O 2 phenyl (isomers )
244 44 4-methoxy- Bn (S) Et O 1 phenyl (isomer 1)
245 45 4-methoxy- Bn (S) Et 0 1 pheny (isomer 2)1
246 46 4-methoxy- Bn (R) Me 0 1 phenyl (isomer 1)
247 47 4-methoxy- Bn (R) Me O 1 phenyl (isomer 2)
248 48 4-phenoxy- H Et O 1 phenyl
249 49 4-phenoxy- H Me O 2 phenyl
250 50 4-phenoxy- H Me 0 3 phenyl
251 51 4-phenoxy- allyl Me 0 1 pheny (isomers 1)1
252 52 4-phenoxy- allyl Me O 1 phenyl (isomers 2)
253 53 4-phenoxy- n-Bu Et 0 2 phenyl (isomers 1)
254 54 4-phenoxy- n-Bu Et O 2 phenyl (isomers 2)
255 55 4-phenoxy- i-Bu (/?) Me O 1 phenyl (isomer 1) 256 56 4-phenoxy- i-Bu (R) Me 0 1 phenyl (isomer 2)
257 57 4-phenoxy- n-Octyl Et 0 2 phenyl (isomers 1)
258 58 4-phenoxy- n-Octyl Et 0 2 phenyl (isomers 2)
259 59 4-phenoxy- i-Pr (R) Me 0 1 phenyl (isomer 1)
260 60 2-phenylethyl H Et 0 1
261 61 4- H Me 0 3 methoxyphenyl
262 62 phenyl H Me 0 3
263 63 n-heptyl H Me 0 3
264 64 4-biphenylyl i-Pr (R) Me 0 1 (Isomer 1)
265 65 4-biphenylyl i-Pr (R) Me 0 1 (Isomer 2)
266 66 4-biphenylyl phenyl- Me 0 1 (Isomer 1) methyl
(R)
267 67 4-biphenylyl phenyl- Me 0 1 (Isomer 2) methyl
(K)
268 68 4-(4-CI- H Et 0 2 phenyloxy)- phenyl
269 69 4-(4-CI- H Et 0 3 phenyloxy)- phenyl
270 70 4'-Br-4- H Et 0 1 biphenylyl
271 71 4'-Br-4- H Et 0 2 biphenylyl
272 72 4'-Br-4- H Me 0 3 biphenylyl
273 73 2-(l-napthyl)- H Et 0 1 ethyl
274 74 phenyl H Et S 1
275 75 phenyl H Et S 2
276 76 phenyl H Me S 3
277 77 4-(4-CI- H Et 0 1 phenyloxy)- phenyl
278 78 4-(4-CI- i-Pr (R) Me 0 1 phenyloxy)- phenyl (isomer 1)
279 79 4-(4-CI- i-Pr (R) Me 0 1 phenyloxy)- phenyl (isomer 2)
280 80 4-bromophenyl H Et 0 1
281 81 4-bromophenyl H Et 0 2
282 82 4-benzyloxy- H Et 0 1 phenyl
283 83 4-benzyloxy- H Et 0 2 phenyl
284 84 4-benzyloxy- H Et 0 3 phenyl
285 85 4-(4-CF3)- H Et 0 1 phenyloxy- phenyl
286 86 4-(4-CF3)- H Et 0 2 phenyloxy- phenyl
287 87 4-(4-CF3)- i-Pr (R) Me 0 1 phenyloxy- phenyl (isomer 1)
288 88 4-(4-CF3)- i-Pr (R) Me 0 1 phenyloxy- phenyl (isomer 2)
289 89 4-(4-Br- H Et 0 1 phenyloxy)- phenyl
290 90 4-(4-Br- H Et 0 2 phenyloxy)- phenyl
291 91 4-nitro-phenyl H Et 0 2
292 92 (Λ/-(4-CI- H Et 0 .2 benzoyl)-4- aminophenyl
293 93 Λ/-benzoyl- H Et 0 2 aminophenyl
294 94 4-phenoxy- i-Pr (R) Me 0 1 phenyl (isomer 1)
295 95 4-methoxy- n-Bu Et 0 1 pheny (isomers 1)1
296 96 4-methoxy- n-Bu Et 0 1 phenyl (isomers 2)
297 97 phenyl H Et 0 4 Table 3 Some compounds of general formula (II)
Comp. Prep. Rl R2 Y n
No. No.
300 100 4-methoxy- i-Pr (R) 0 1 phenyl (isomer
1)
301 101 4-methoxy- i-Pr (R) 0 1 phenyl (isomer 2)
302 102 4-biphenylyl i-Pr (R) 0 1 (isomer 1)
303 103 4-biphenylyl phenyl- 0 1 (isomer 1) methyl
(R)
304 104 4-biphenylyl phenyl- 0 1 (isomer 2) methyl
(R)
305 105 phenyl H 0 2
306 106 phenyl H 0 3
307 107 phenyl n-Bu 0 2 (isomers 1)
308 108 phenyl n-Bu 0 2 (isomers 2)
309 109 4-methoxy- H 0 1 phenyl
310 110 4-methoxy- H 0 2 phenyl
311 111 4-methoxy- n-Bu 0 1 phenyl (isomers 1)
312 112 4-methoxy- n-Bu 0 1 phenyl (isomers 2)
313 113 4-methoxy- n-Bu 0 2 phenyl (isomers 1)
314 114 4-methoxy- n-Bu 0 2 phenyl (isomers 2)
315 115 4-methoxy- n-Bu 0 3 phenyl (isomers 1) 316 116 4-methoxy- n-Bu 0 3 phenyl (isomers 2)
317 117 4-methoxy- allyl 0 1 phenyl (isomers 1)
318 118 4-methoxy- allyl 0 1 phenyl (isomers 2)
319 119 4-methoxy- i-Bu (R) 0 1 phenyl (isomer 1)
320 120 4-methoxy- i-Bu (R) 0 1 phenyl (isomer 2)
321 121 4-methoxy- i-Bu 0 2 phenyl (isomers 1)
322 122 4-methoxy- i-Bu 0 2 pheny (isomers 2)1
323 123 4-methoxy- i-Bu (S) 0 1 phenyl (isomer 1)
324 124 4-methoxy- i-Bu (S) 0 1 phenyl (isomer 2)
325 125 4-methoxy- n-Oct 0 2 pheny (isomers 1)1
326 126 4-methoxy- n-Oct 0 2 phenyl (isomers 2)
327 127 4-methoxy- Bn (R) 0 1 phenyl (isomer 1)
328 128 4-methoxy- Bn (R) O 1 pheny (isomer 2)1
329 129 4-methoxy- n-Pr O 1 phenyl (isomers 1)
330 130 4-methoxy- n-Pr 0 1 phenyl (isomers 2)
331 131 4-methoxy- allyl 0 2 phenyl (isomers 1)
332 132 4-methoxy- allyl 0 2 phenyl(isomers 2)
333 133 4-phenoxy- allyl 0 1 phenyl (isomers 1)
334 134 4-phenoxy- allyl 0 1 phenyl (isomers 2)
335 135 4-phenoxy- n-Bu O 2 phenyl (isomers 1)
336 136 4-phenoxy- n-Bu 0 2 phenyl (isomers 2)
337 137 4-phenoxy- i-Bu (R) O 1 phenyl (isomer 1)
338 138 4-phenoxy- i-Bu (/?) O 1 phenyl (isomer 2)
339 139 4-phenoxy- n-Oct 0 2 pheny (isomers 1)1
340 140 4-phenoxy- n-Oct 0 2 phenyl (isomers 2)
341 141 4-phenoxy- i-Pr (R) 0 1 phenyl (isomer 1)
342 142 4-phenoxy- i-Pr (R) O 1 phenyl (isomer 2)
343 143 4-(4-CI- H 0 2 phenoxy)-phenyl
344 144 4-(4-CI- i-Pr (R) O 1 phenoxy)-phenyl (isomer 1)
345 145 4-(4-CF3- i-Pr (R) O 1 phenoxy)-phenyl (isomer 2)
346 146 4-(4-CF3- i-Pr ( ?) O 1 phenoxy)-phenyl (isomer 1)
347 147 4-(4-Br- H 0 1 phenoxy)-phenyl (isomer 2)
348 148 4-(4-Br- H 0 2 phenoxy)-phenyl
349 149 4-nitrophenyl H 0 2
350 150 (Λ/-(4-CI- H 0 2 benzoyl))-4- aminophenyl
351 151 (Λ/-benzoyl)-4- H 0 2 aminophenyl
352 152 phenyl H S I
353 153 phenyl H S 2 Table 4 Exemplified compounds (I)
n
Comp. Ex. No. Rl R2
No.
101 1 (4-CI-phenyl)- H 0 1 oxy
102 2 (4-CI-phenyl)- H 0 2 oxy
103 3 (4-Br-phenyl)- H 0 1 methyl
104 4 4-biphenylyl- H 0 1 methyl
105 5 4-biphenylyl H 0 1
106 6 4-biphenylyl H 0 2
107 7 n-heptyl H 0 1
108 8 n-heptyl H 0 2
109 9 (/V-phenyl)-4- H 0 1 aminophenyl
110 10 phenyl H 0 1
111 11 phenyl H 0 2
112 12 phenyl H 0 4
113 13 phenyl n-Bu 0 2 (isomers 1)
114 14 phenyl n-Bu 0 2 (isomers 2)
115 15 4-methoxy- H 0 1 phenyl
116 16 4-methoxy- H 0 2 phenyl
117 17 4-methoxy- H 0 4 phenyl
118 18 4-methoxy- i-Pr (R) 0 1 phenyl (isomer 1)
119 19 4-methoxy- i-Pr (R) 0 1 phenyl (isomer 2)
120 20 4-methoxy- n-Bu 0 1 phenyl (isomers 1)
121 21 4-methoxy- n-Bu 0 1 phenyl (isomers 2)
122 22 4-methoxy- n-Bu 0 2 phenyl (isomers 1)
123 23 4-methoxy- n-Bu 0 2 phenyl (isomers 2)
124 24 4-methoxy- n-Bu 0 3 phenyl (isomers 1)
125 25 4-methoxy- n-Bu 0 3 phenyl (isomers 2)
126 26 4-methoxy- allyl 0 1 phenyl (isomers 1)
127 27 4-methoxy- allyl 0 1 phenyl (isomers 2)
128 28 4-methoxy- allyl 0 2 phenyl (isomers 1)
129 29 4-methoxy- allyl 0 2 phenyl (isomers 2)
130 30 4-methoxy- i-Bu 0 1 phenyl (R) (isomer 1)
131 31 4-methoxy- i-Bu 0 1 phenyl (isomer 2)
132 32 4-methoxy- i-Bu 0 1 phenyl (S) (isomer 1)
133 33 4-methoxy- i-Bu 0 1 phenyl (S) (isomer 2)
134 34 4-methoxy- i-Bu 0 2 phenyl (isomers 1)
135 35 4-methoxy- i-Bu 0 2 phenyl (isomers 2)
136 36 4-methoxy- n-Pr 0 1 phenyl (isomers 1)
137 37 4-methoxy- n-Pr 0 1 phenyl (isomers 2)
138 38 4-methoxy- n-Oct 0 2 phenyl (isomers 1)
139 39 4-methoxy- n-Oct 0 2 phenyl (isomers 2) 140 40 4-methoxy- Bn (R) 0 1 phenyl (isomer 1)
141 41 4-methoxy- Bn (S) 0 1 phenyl (isomer 1)
142 42 4-methoxy- Bn (S) O 1 phenyl (isomer 2)
143 43 4-phenoxy- H O I phenyl
144 44 4-phenoxy- H 0 2 phenyl
145 45 4-phenoxy- H O 3 phenyl
146 46 4-phenoxy- allyl 0 1 phenyl (isomers 1)
147 47 4-phenoxy- allyl 0 1 phenyl (isomers 2)
148 48 4-phenoxy- i-Bu O 1 phenyl (R)
(isomer 1)
149 49 4-phenoxy- i-Bu 0 1 phenyl (R)
(isomer 2)1
150 50 4-phenoxy- i-Pr (R) O 1 phenyl (isomer 1)
151 51 4-phenoxy- i-Pr (R) O 1 phenyl (isomer 2)
152 52 4-phenoxy- n-Bu O 2 phenyl (isomers 1)
153 53 4-phenoxy- n-Bu 0 2 phenyl (isomers 2)
154 54 4-phenoxy- n-Oct 0 2 phenyl (isomers 1)
155 55 4-phenoxy- n-Oct 0 2 phenyl (isomers 2)
156 56 2-phenylethyl H O I
157 57 4-methoxy- H O 3 phenyl
158 58 phenyl H 0 3
159 59 n-heptyl H 0 3
160 60 4-biphenylyl i-Pr (R) O 1
(isomer 2)
161 61 4-(4-CI- H O 2 phenyloxy)- phenyl 162 62 4-(4-CI- H 0 3 phenyloxy)- phenyl
163 63 4-(4-CI- i-Pr (R) 0 1 phenyloxy)- phenyl (isomer 1)
164 64 4'-Br-4- H 0 1 biphenylyl
165 65 4'-Br-4- H 0 2 biphenylyl
166 66 4'-Br-4- H 0 3 biphenylyl
167 67 2-(l-napthyl)- H 0 1 ethyl
168 68 phenyl H S 1
169 69 phenyl H S 2
170 70 phenyl H S 3
171 71 4-(4-CI- H 0 1 phenyloxy)- phenyl
172 72 4-bromophenyl H 0 1
173 73 4-bromophenyl H 0 2
174 74 4-benzyloxy- H 0 1 phenyl
175 75 4-benzyloxy- H 0 2 phenyl
176 76 4-benzyloxy- H 0 3 phenyl
177 77 2-(4-CI- H 0 2 phenoxy-phenyl)
178 78 4-(4-CF3- H 0 1 phenoxy)-phenyl
179 79 4-(4-CF3- H 0 2 phenoxy)-phenyl
180 80 4-(4-CF3- i i-Pr (R) 0 1 phenoxy)-phenyl (isomer 1)
181 81 4-(4-CF3- i i-Pr (R) 0 1 phenoxy)-phenyl (isomer 2)
182 82 4-(4-Br- H 0 1 phenyloxy)- phenyl
183 83 4-(4-Br- H 0 2 phenyloxy)- phenyl
184 84 4-nitrophenyl H 0 2
185 85 (Λ/-(4-CI- H 0 2 benzoyl))-4- aminophenyl
186 86 (Λ/-benzoyl)-4- H 0 2 aminophenyl General Procedure 1 : Formation of hydroxamic acids of general formula (I) from the corresponding carboxylic acids of general formula (II). A solution of carboxylic acid with general formula (II) (2.9 mmol) in THF (45 ml) was cooled to -10 °C under argon. NMM (0.3 ml, 3.0 mmol) and isobutyl chloroformate (0.4 ml, 3.0 mmol) were then added with stirring. After stirring overnight at -10 °C, Otrimethylsilyl hydroxylamine (0.4 ml, 3.2 mmol) was added, and the mixture was left at -10 °C for 5h. The mixture was then acidified with 4 M acetic acid, extracted with EtOAc/H2θ. The aqueous layer was back- extracted with EtOAc, and the combined organic layers were washed with brine, dried (MgSO-r) and concentrated. The residue was purified by chromatography
(chloroform/methanol/NH3 (25%) 90: 10:1) or crystallisation to afford the hydroxamic acid of general formula (I).
General Procedure 2: Formation of hydroxamic acids of general formula (I) from the corresponding esters of general formula (HI).
To a solution of ester with general formula (III) (0.20 mmol) in dry methanol (2 ml) was added O-trimethylsilyl-hydroxylamine (72 μl, 0.60 mmol) and sodium methoxide (1.4 M, 214 μl, 0.30 mmol). After stirring at rt for 1 hour, the solution was acidified with 4 M AcOH to pH 4, concentrated under reduced pressure and extracted with EtOAc/H2θ. The aqueous layer was back-extracted with EtOAc, and the combined organic layers were washed with brine, dried (MgSO^.) and concentrated under reduced pressure. The residue was purified by chromatography (chloroform/methanol/NH3 (25% aq.) 90: 10: 1) or crystallisation to afford the hydroxamic acid of general formula (I).
General Procedure 3: Formation of carboxylic acids of general formula (II") from the corresponding oxazaphosphacycloalkane esters of general formula (HI). A solution of ester with general formula (III) (0.26 mmol) in methanol (2 ml) and aqueous sodium hydroxide (2 M, 2 ml) was stirred overnight at rt, acidified with 4 M AcOH and extracted with EtOAc/H2θ. The aqueous phase was back-extracted with EtOAc, and the combined layers were washed with brine, dried (MgSθ4) and concentrated under reduced pressure. The residue was purified by chromatography (chloroform/methanol/acetic acid 80:20: 1) or by crystallisation to afford the carboxylic acid of general formula (II). General Procedure 4: Formation of oxazaphosphacycloalkane esters of general formula (HI") by cyclisation of phosphonyldichlorides of general formula (IV1 with amino alcohols of general formula (V).
A solution of amino alcohol of general formula (V) (0.42 mmol) and NMM (0.85 mmol) in dry CH2CI2 (20 ml) was cooled to -40 °C under argon, and a solution phosphonyldichloride of general formula (IV) (0.42 mmol) in dry CH2CI2 (10 ml) was added. The mixture was stirred at -40 °C for 1 hour, then at rt overnight. After quenching with water, the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried (MgSθ4) and concentrated under reduced pressure. The residue was purified by chromatography (chloroform/methanol) to afford the oxazaphosphacycloalkane ester of general formula (III).
General Procedure 5. Formation of oxazaphosphacycloalkanes of general formula (VIP by cyclisation of phosphonyldichlorides of general formula (IV) with amino alcohols of general formula (VI).
A solution of amino alcohol of general formula (VI) (9.57 mmol) and N- ethylmorpholine (19.1 mmol) in dry CH2CI2 and a solution of phosphonyldichloride of general formula (IV) in dry CH2CI2 (each with a total volume of 9 ml) were added simultaneously to 22 ml dry CH2CI2 at 0 °C with stirring over a period of 2 hours. After the addition was completed, the suspension was stirred overnight at rt and extracted with EtOAc/H2θ. The aqueous phase was back-extracted thoroughly with EtOAc, and the combined organic extracts were dried (MgSθ4) and concentrated under reduced pressure. The residue was purified by crystallisation to afford the oxazaphosphacycloalkane of general formula (VII).
General Procedure 6. Formation of oxazaphosphacycloalkane esters of general formula (HI) by alkylation of oxazaphosphacycloalkanes of general formula (VII) with bromoacetic acid esters of general formula (VIII').
A solution of oxazaphosphacycloalkane of general formula (VII) (0.76 mmol) in dry THF (4 ml) was cooled to -70 °C, and n-butyllithium (0.76 mmol) was added dropwise followed by a solution of bromo- or iodoacetic acid ester of general formula (VIII) (0.76 mmol) in dry THF (1.5 ml). The mixture was removed from the cooling bath and stirred at rt for 4 hours, quenched with water and extracted with EtOAc/H2θ. The aqueous phase was back-extracted with EtOAc, and the combined organic layers were washed with water and brine, dried (MgSU4) and concentrated under reduced pressure. The residue was purified by chromatography to afford the oxazaphosphacycloalkane ester of general formula (III).
Preparation 1 : (+)-2-Oxo-2-phenyl-l,3.2-oxazaphosphorinane (compound 201). General procedure 5.
Starting materials: 3-Amino-l-propanol and phenylphosphonic dichloride. *H NMR (CDCI3) δ 7.87-7.75 (ιm, 2H), 7.56-7.40 (m, 3H), 4.45 (m, IH), 4.12 (m, IH), 3.74 (bs, IH), 3.43 (m, IH), 3.20 (m, IH), 2.06 (m, IH), 1.73 (m, IH).
Preparation 2: (±)-2-Oxo-2-phenyl-lr3r2-oxazaphosphorepane (compound 202 . General procedure 5.
Starting materials: 4-Amino-l-butanol and phenylphosphonic dichloride. 13C NMR (CDCI3) δ 131.5, 131.4, 130.9, 128.3, 65.4, 41.2, 31.9, 29.9.
Preparation 3: (+)-2-Oxo-2-phenyl-lf3f2-oxazaphosphorocane(connpound 203). General procedure 5.
Starting materials: 5-Amino-l-pentanol and phenylphosphonic dichloride. 13C NMR (CDCI3) δ 131.5, 131.4, 130.9, 128.3, 66.0, 41.3, 29.7, 29.2, 24.2.
Preparation 4: (±)-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane (compound 204). General procedure 5. Starting materials: 3-Amino-l-propanol and 4-methoxyphenylphosphonic dichloride.
XH NMR (CDCI3) δ 7.75 (m, 2H), 6.96 (m, 2H), 4.45 (m, IH), 4.12 (m, IH), 3.85 (s, 3H), 3.43 (m, 2H), 3.21 (m, IH), 2.04 (m, IH), 1.76 (m, IH).
Preparation 5: (±)-2-(4-Methoxyphenyl)-2-oxo-lr3f2-oxazaphosphorepane
(compound 205)
General procedure 5.
Starting materials: 4-Amino-l-butanol and 4-methoxyphenylphosphonic dichloride. 13C NMR (CDCI3) δ 162.2, 132.8, 122.8, 113.9, 65.2, 55.3, 41.2,
32.0, 30.0. Preparation 6: (±)-2-Oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane (compound 206) General procedure 5.
Starting materials: 4-Amino-l-butanol and phenylphosphonic dichloride. 13C NMR (CDCI3) δ 160.6, 156.0, 132.9, 129.9, 125.2, 124.2, 119.8, 117.8, 65.4, 41.2, 32.0, 30.0
Preparation 7: (+)-2-Oxo-2-(2-phenylethyl)-l,3,2-oxazaphosphorinane (compound 207). General procedure 5.
Starting materials: 3-Amino-l-propanol and 2-phenylethyl phosphonic dichloride. *H NMR (CDCI3) δ 7.30 (m, 2H), 7.22 (m, 3H), 4.41 (m, IH), 4.16 (m, IH), 3.33 (m, IH), 3.15 (m, IH), 2.69 (m, 3H), 2.12 (m, 2H), 1.98 (m, IH), 1.76 (m, IH).
Preparation 8: (±)-2-Heptyl-2-oxo-l,3f2-oxazaphosphorinane (compound 208).
General procedure 5.
Starting materials: 3-Amino-l-propanol and n-heptylphosphonic dichloride.
*H NMR (CDCI3) δ 4.41 (m, IH), 4.17 (m, IH), 3.35 (m, IH), 3.19 (m, IH), 2.91
(bs, IH), 1.98 (m, IH), 1.77 (m, 2H), 1.62 (m, 2H), 1.48-1.20 (m, 9H), 0.88 (t, 3H).
Preparation 9: (±)-2-(4-Biphenylyl)-2-oxo-l,3,2-oxazaphosphorinane (compound 209).
General procedure 5. Starting materials: 3-Amino-l-propanol and 4-biphenylylphosphonic dichloride. Hi NMR (CDCI3) δ 7.88 (m, 2H), 7.68 (m, 2H), 7.60 (m, 2H), 7.43 (m, 3H), 4.50 (m, IH), 4.18 (m, IH), 3.46 (m, 2H), 3.27 (m, IH), 2.08 (m, IH), 1.79 (m, IH).
Preparation 10: (±)-Ethyl 2-(4-chlorophenoxy)-2-oxo-l,3r2-oxazaphosphorinane- 3-acetate (compound 210).
General procedure 4.
Starting materials: 4-Chlorophenylphosphoryl dichloride and N-(3- hydroxypropyl)glycine ethyl ester. i3C NMR (CDCI3) δ 169.7, 149.6, 129.9, 129.7, 121.4, 70.0, 61.2, 49.8, 48.0, 25.9, 14.2.
Preparation 11 : (±)-Methyl 2-(4-chlorophenoxy)-2-oxo-lf3f2-oxazaphospho- repane-3-acetate (compound 211). General procedure 4.
Starting materials: 4-Chlorophenylphosphoryl dichloride and Λ/-(4-hydroxy- butyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.1, 149.6, 130.1, 129.5, 122.1, 67.1, 52.1, 49.9, 48.2, 29.6, 26.3.
Preparation 12: (±)-Ethyl 2-r(4-bromophenyl)methyl1-2-oxo-l,3f2-oxaza- phosphorinane-3-acetate (compound 212).
General procedure 4. Starting materials: 4-Bromophenylphosphonic dichloride and N-(3- hydroxypropyl)glycine ethyl ester.
*H NMR (CDCI3) δ (d, 2H), 7.27 (dd, 2H), 4.32 (m, IH), 4.24-3.98 (m, 2H), 4.19
(q, 2H), 3.57 (dd, IH), 3.23 (m, 3H), 2,97 (m, IH), 1.88 (m, IH), 1.33 (m, IH),
1.28 (t, 3H).
Preparation 13: (±)-Ethyl 2-r(4-biphenylyl)methyπ-2-oxo-lr3r2-oxazaphos- phorinane-3-acetate (compound 213).
Procedure: A mixture of compound 210 (0.21 mmol) and Pd(PPh3)4 (0.0105 mmol) in toluene (1.5 ml) was stirred for 30 min under an argon atmosphere, after which phenyl boronic acid (0.42 mmol) and Na2C03 (0.46 mmol in 230 μl
H2O) was added, and the mixture was stirred at 110 °C overnight. The mixture was diluted with ether, filtered through Celite, concentrated under reduced pressure, and purified by flash chromatography to afford compound 211. JH NMR (CDCI3) δ 7.58(m, 4H), 7.43 (m, 4H), 7.33 (m, IH), 4.34 (m, IH), 4.25- 4.00 (m, 2H), 4.20 (q, 2H), 3.63 (dd, IH), 3.45-3.18 (m, 3H), 2.99 (m, IH), 1.87(m, IH), 1.36 (m, IH), 1.28 (t, 3H).
Preparation 14: (±)-Ethyl 2-(4-biphenylyl)-2-oxo-lf3f2-oxazaphosphorinane-3- acetate (compound 214). General procedure 6.
Starting materials: Compound 209 and ethyl bromoacetate. XH NMR (CDCI3) δ 7.95 (m, 2H), 7.68 (m, 2H), 7.61 (m, 2H), 7.46 (m, 2H), 7.40 (m, IH), 4.53 (m, IH), 4.25 (m, IH), 4.20-4.00 (m, 3H), 3.75 (dd, IH), 3.47 (m, IH), 3.31 (m, IH), 2.14 (m, IH), 2.05 (m, IH), 1.23 (t, 3H).
Preparation 15: (±)-Methyl 2-(4-biphenylyl)-2-oxo-lf3f2-oxazaphosphorepane-3- acetate (compound 21 5). General procedure 4. Starting materials: 4-Biphenylylphosphonic dichloride and Λ/-(4- hydroxybutyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.9, 144.4, 140.3, 131.8, 129.2, 128.9, 127.9, 127.3, 127.0, 65.3, 51.9, 48.5, 47.5, 29.5, 26.6.
Preparation 16: (±)-Ethyl 2-heptyl-2-oxo-l,3f2-oxazaphosphorinane-3-acetate (compound 216). General procedure 4.
Starting materials: n-Heptylphosphonic dichloride and Λ/-(3-hydroxypropyl)glycine ethyl ester.
XH NMR (CDCI3) δ 4.39 (m, IH), 4.18 (q, 2H), 4.17 (m, 2H), 3.60 (dd, IH), 3.43 (m, IH), 3.05 (m, IH), 2.10 (m, IH), (m, 3H), 1.61 (m, 2H), 1.46-1.20 (m, 8H), 1.27 (t, 3H), 0.88 (t, 3H).
Preparation 17: (±)-Methyl 2-heptyl-2-oxo-lr3,2-oxazaphosphorepane-3-acetate
(compound 217).
General procedure 4.
Starting materials: n-Heptylphosphonic dichloride and Λ/-(4-hydroxybutyl)glycine methyl ester. 13C NMR (CDCI3) δ 172.2, 64.4, 51.9, 48.5, 47.6, 31.7, 30.9, 29.4, 28.9, 26.9,
26.5, 22.6, 22.5, 14.1.
Preparation 18: (±)-Ethyl 2-oxo-2-r4-(phenylamino)phenyl1-l,3,2- oxazaphosphorinane-3-acetate (compound 218). Procedure: A mixture of aniline (0.25 mmol), compound 244 (0.27 mmol),
Pd2(dba)3 (0.006 mmol), 2,2'-bis(diphenylphosphino)-l,l'-binapthyl (BINAP,
0.02 mmol), and CSCO4 (0.35 mmol) in dioxane (1 ml) under an argon atmosphere was heated to 100 °C overnight. The suspension was then diluted with ether, filtered, concentrated under reduced pressure, and purified by flash chromatography to afford compound 216.
XH NMR (CDCI3) δ 7.73 (m, 2H), 7.32 (m, 2H), 7.15 (m, 2H), 7.04 (m, 3H), 6.10 (bs, IH), 4.48 (m, IH), 4.30-4.05 (m, 3H), 3.98 (dd, IH), 3.65 (dd, IH), 3.5-3.2 (m, 2H), 2.05 (m, 2H), 1.23 (t, 3H).
Preparation 19: (±)-Ethyl 2-oxo-2-pheny|-l,3,2-oxazaphosphorinane-3-acetate (compound 219). General procedure 6. Starting materials: Compound 201 and ethyl bromoacetate. XH NMR (CDCI3) δ 7.88 (m, 2H), 7.47 (m, 3H), 4.51 (m, IH), 4.3-4.1 (m, IH), 4.13 (q, 2H), 4.03 (dd, IH), 3.73 (dd, IH), 3.44 (m, IH), 3.28 (m, IH), 2.14 (m, IH), 2.00 (m, IH), 1.35-1.17 (t, 3H).
Preparation 20: (+)-Ethyl 2-oxo-2-phenyl-l,3,2-oxazaphosphorepane-3-acetate (compound 220). General procedure 4.
Starting materials: Phenylphosphonic dichloride and Λ/-(4-hydroxybutyl)glycine methyl ester. 13C NMR (CDCI3) δ 171.3, 131.6, 131.3, 130.6, 128.3, 65.3, 61.0, 48.6, 47.4, 29.5, 26.5, 14.2.
Preparation 21 : (±)-Ethyl α-Butyl-2-oxo-2-phenyl-lf3,2-oxazaphosphorepane-3- acetate (diastereomers 1, compound 221). General procedure 6.
Starting materials: Compound 202 and ethyl 2-iodohexanoate. 13C NMR (CDCI3) δ 172.5, 131.5, 131.4, 136.0, 128.0, 65.4, 60.4, 59.2, 43.9, 30.7, 29.8, 29.4, 28.6, 22.5, 14.0, 13.8.
Preparation 22: (±)-Ethyl α-Butyl-2-oxo-2-phenyl-lr3,2-oxazaphosphorepane-3- acetate (diastereomers 2, compound 222).
General procedure 6.
Starting materials: Compound 202 and ethyl 2-iodohexanoate.
13C NMR (CDCI3) δ 173.3, 131.5, 131.4, 131.2, 128.2, 65.3, 60.9, 57.8, 41.7, 29.6, 29.0, 28.5, 27.7, 22.3, 14.2, 13.8.
Preparation 23: (±)-Ethyl 2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane- 3-acetate (compound 223). General procedure 6. Starting materials: Compound 204 and ethyl bromoacetate.
XH NMR (CDCI3) δ 7.83(m, 2H), 6.96 (m, 2H), 4.49 (m, IH), 4.30-4.05 (m, 3H), 3.98 (dd, IH), 3.84 (s, 3H), 3.65 (dd, IH), 3.41 (m, IH), 3.28 (m, IH), 2.07 (m, 2H), 1.23 (t, 3H).
Preparation 24: (±)-Methyl 2-(4-methoxyphenyl)-2-oxo-l,3r2-oxazaphospho- repane-3-acetate (compound 224). General procedure 4. Starting materials: 4-MethoxyphenyIphosphonic dichloride and Λ/-(4- hydroxybutyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.9, 162.3, 133.2, 122.0, 113.8, 65.2, 55.3, 51.9, 48.4, 47.4, 29.5, 26.5.
Preparation 25: (±)-Ethyl 2-(4-methoxyphenyl)-2-oxo-lr3,2- oxazaphosphoronane-3-acetate (compound 225). General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(5- hydroxypentyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.2, 162.3, 133.8, 121.7, 113.8, 60.9, 60.5, 55.3, 45.9, 42.3, 27.7, 24.3, 19.1, 18.5, 14.2.
Preparation 26: (αR)-Methyl 2-(4-methoxyphenyl)-α-(l-methylethyl)-2-oxo- l,3.2-oxazaphosphorinane-3-acetate (diastereomer 1, compound 226).
General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-valine methyl ester.
*H NMR (CDCI3) δ 7.64 (m, 2H), 6.94 (m, 2H), 4.44 (m, IH), 4.20 (m, IH), 3.85 (t, IH), 3.84 (s, 3H), 3.45 (s, 3H), 3.43 (m, 2H), 2.16 (m, 2H), 1.96 (m, IH),
1.14 (d, 3H), 0.90 (d, 3H).
Preparation 27: (α#)-Methyl 2-(4-methoxyphenyl)-α-(l-methylethyl)-2-oxo- l,3,2-oxazaphospho nane-3-acetate (diastereomer 2. compound 227). General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-valine methyl ester.
XH NMR (CDCI3) δ 7.78 (m, 2H), 6.95 (m, 2H), 4.49 (m, IH), 4.24 (m, IH), 3.85 (s, 3H), 3.76 (s, 3H), 3.68 (m, IH), 3.46 (dd, IH), 3.22 (m, IH), 2.08 (m, 3H), 0.80 (d, 3H), 0.70 (d, 3H).
Preparation 28: (±)-Ethyl α-butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorepane-3-acetate (diastereomers 1, compound 228). General procedure 4. Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(4- hydroxybutyl)-(±)-norleucine ethyl ester.
13C NMR (CDCI3) δ 172.7, 162.2, 133.4, 122.5, 113.5, 65.3, 60.4, 59.2, 55.3, 43.9, 30.8, 29.8, 29.5, 28.6, 22.5, 14.0, 13.9. Preparation 29: (±)-Ethyl α-butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorepane-3-acetate (diastereomers 2, compound 229). General procedure 4. Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(4- hydroxybutyl)-(±)-norleucine ethyl ester.
13C NMR (CDCI3) δ 173.4, 162.2, 133.3, 122.7, 113.7, 65.2, 60.9, 57.8, 52.3, 41.6, 29.6, 29.0, 28.5, 27.7, 22.3, 14.2, 13.8.
Preparation 30: (±)-Ethyl α-butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorocane-3-acetate (diastereomers 1, compound 230).
General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(5- hydroxypentyl)-(±)-norleucine ethyl ester. 13C NMR (CDCI3) δ 172.4, 162.1, 133.3, 122.3, 113.5, 65.2, 60.4,
59.1, 55.3, 44.0, 31.6, 29.3, 29.1, 28.9, 24.4, 22.6, 14.0.
Preparation 31 : (±)-Ethyl α-butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorocane-3-acetate (diastereomers 2, compound 231). General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(5- hydroxypentyl)-(+)-norleucine ethyl ester.
Calcd. for C20H32NO5P: 397.20; Found [M+H]+ = 398, [M+Na]+ = 420.
Preparation 32: (±)-Methyl α-allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetate (diastereomers lf compound 232).
General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-(+)-allylglycine methyl ester. 13C NMR (CDCI3) δ 172.3, 162.5, 134.1, 133.8, 121.8, 117.9, 113.9, 66.7, 57.0,
55.3, 51.7, 41.3, 34.4, 26.7.
Preparation 33: (±)-Methyl α-allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetate (diastereomers 2r compound 233). General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-(±)-allylglycine methyl ester.
13C NMR (CDCI3) δ 172.7, 162.5, 134.1, 134.0, 122.0, 117.9, 113.8, 66.2, 57.3, 55.3, 52.1, 40.8, 34.3, 26.3.
Preparation 34: (+)-Ethyl α-allyl-2-(4-methoxyphenyl)-2-oxo-l,3r2- oxazaphosphorepane-3-acetate (diastereomers 1, compound 234).
General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(4- hydroxybutyl)-(+)-allylglycine methyl ester.
13C NMR (CDCI3) δ 172.0, 162.2, 134.8, 133.4, 122.4, 117.9, 113.5, 65.3, 60.6,
58.9, 55.3, 43.9, 35.2, 29.5, 29.3, 13.9.
Preparation 35: (±)-Ethyl α-allyl-2-(4-methoxyphenyl)-2-oxo-l,3f2- oxazaphosphorepane-3-acetate (diastereomers 2, compound 235). General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(4- hydroxybutyl)-(±)-allylglycine methyl ester.
13C NMR (CDCI3) δ 172.6, 162.2, 133.9, 133.4, 122.6, 117.9, 113.7, 65.2, 61.0, 57.8, 55.3, 42.1, 34.0, 29.6, 27.7, 14.2.
Preparation 36: (αβ)-Methyl 2-(4-methoxyphenyl)- α-(2-methylpropyl)-2-oxo- lf3f2-oxazaphosphorinane-3-acetate (diastereomer lr compound 236).
General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-leucine methyl ester.
*H NMR (CDCI3) δ 7.75 (m, 2H), 6.95 (m, 2H), 4.43 (m, IH), 4.34 (m, IH), 4.17 (m, IH), 3.84 (s, 3H), 3.56 (s, 3H), 3.37 (m, 2H), 2.10-1.55 (m, 5H), 1.03 (d,
3H), 0.97 (d, 3H).
Preparation 37: (α ?)-Methyl 2-(4-methoxyphenyD- «-(2-methylpropyl)-2-oxo- 1.3.2-oxazaphosphorinane-3-acetate (diastereomer 2, compound 237). General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-leucine methyl ester.
13C NMR (CDCI3) δ 173.7, 162.5, 133.8, 122.2, 113.9, 66.0, 55.4, 55.3, 52.0, 40.4, 38.5, 26.5, 24.5, 22.8, 21.5.
Preparation 38: (±)-Ethyl 2-(4-methoxypheny0- ra-(2-methylpropyl)-2-oxo-l,3,2- oxazaphosphorepane-3-acetate (diastereomers 1 r compound 238). General procedure 6. Starting materials: Compound 205 and ethyl 2-iodo-4-methylvaleroate. 13C NMR (CDCI3) δ 172.9, 162.1, 133.4, 122.5, 113.5, 65.3, 60.5, 57.3, 55.3, 43.8, 39.9, 29.8, 29.5, 24.9, 23.0, 22.0, 13.9.
Preparation 39: (±)-Ethyl 2-(4-methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3f2- oxazaphosphorepane-3-acetate (diastereomers 2, compound 239). General procedure 6.
Starting materials: Compound 205 and ethyl 2-iodo-4-methylvaleroate. 13C NMR (CDCI3) δ 173.6, 162.2, 133.2, 122.8, 113.7, 65.2, 60.9, 55.9, 55.3, 41.7, 38.4, 29.6, 27.7, 24.6, 22.7, 22.3, 14.2.
Preparation 40: (αS)-Methyl 2-(4-methoxyphenyl)- α-(2-methylpropyl)-2-oxo- l,3.2-oxazaphosphorinane-3-acetate (diastereomer lr compound 240). General procedure 4. Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-L-leucine methyl ester.
13C NMR (CDCI3) δ 173.5, 162.5, 133.8, 121.7, 113.9, 66.7, 55.7, 55.3, 51.6, 41.2, 38.6, 26.9, 24.7, 23.1, 21.7.
Preparation 41 : (αS)-Methyl 2-(4-methoxyphenyl)- α-(2-methylpropyl)-2-oxo- l,3,2-oxazaphosphorinane-3-acetate (diastereomer 2, compound 241).
General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-L-leucine methyl ester. 13C NMR (CDCI3) δ 173.7, 162.5, 133.9, 122.2, 113.9, 66.0, 55.4,
55.3, 52.0, 40.4, 38.5, 26.5, 24.5, 22.8, 21.5.
Preparation 42: (±)-Ethyl 2-(4-methoxyphenvD- α-octyl-2-oxo-l,3,2- oxazaphosphorepane-3-acetate (diastereomers 1. compound 242). General procedure 6.
Starting materials: Compound 205 and ethyl 2-iododecanoate. XH NMR (CDCI3) δ 7.74 (m, 2H), 6.91 (m, 2H), 4.61 (m, IH), 4.34 (m, IH), 4.16 (m, IH), 3.89 (dq, 2H), 3.82 (s, 3H), 3.20 (m, IH), 3.07 (m, IH), 2.02-1.10 (m, 18H), 0.98 (t, 3H), 0.88 (bt, 3H).
Preparation 43: (±)-Ethyl 2-(4-methoxyphenvD- α-octyl-2-oxo-lr3f2- oxazaphosphorepane-3-acetate (diastereomers 2. compound 243). General procedure 6. Starting materials: Compound 205 and ethyl 2-iododecanoate.
13C NMR (CDCI3) δ 173.4, 162.2, 133.3, 122.7, 113.7, 65.2, 60.9,
57.8, 55.3, 41.6, 31.8, 29.6, 29.3, 29.2, 29.1, 27.7, 26.3, 22.6, 14.2, 14.1.
Preparation 44: (αS)-Ethyl 2-(4-methoxyphenyl)-2-oxo-α-phenylmethyl-l 3f2- oxazaphosphorinane-3-acetate (diastereomer 1, compound 244). General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-L-phenylalanine ethyl ester. λH NMR (CDCI3) δ 7.75 (m, 2H), 7.35-7.16 (m, 5H), 6.93 (ιm, 2H), 4.58 (m, IH), 4.29-4.02 (m, 2H), 3.95 (q, 2H), 3.83 (s, 3H), 3.54-3.26 (m, 3H), 3.14 (dd, IH), 1.89 (m, 2H), 1.04 (t, 3H).
Preparation 45: (αS)-Ethyl 2-(4-methoxyphenyl)-2-oxo-α-phenylmethyl-l,3.2- oxazaphosphorinane-3-acetate (diastereomer 2, compound 245).
General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and /-(3- hydroxypropyl)-L-phenylalanine ethyl ester.
XH NMR (CDCI3) δ 7.23-7.05 (m, 7H), 6.70 (m, 2H), 4.60 (m, IH), 4.50 (m, IH), 4.21 (q, 2H), 4.12 (m, IH), 3.81 (s, 3H), 3.60 (m, IH), 3.20 (m, 2H), 2.91 (dd,
IH), 2.20 (m, IH), 1.83 (m, IH), 1.28 (t, 3H).
Preparation 46: (α )-Methyl 2-(4-methoxyphenyl)-2-oxo-α-phenylmethyl-l,3,2- oxazaphosphorinane-3-acetate (diastereomer 1. compound 246).
General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-phenylalanine methyl ester.
13C NMR (CDCI3) δ 172.2, 162.5, 136.8, 133.8, 129.4, 128.4, 126.7, 121.7, 113.9, 66.2, 58.5, 55.3, 51.6, 41.1, 36.3, 26.7.
Preparation 47: (gβ)-Methyl 2-(4-methoχyphenyl)-2-oxo-α-phenylmethyl-l,3,2- oxazaphosphorinane-3-acetate (diastereomer 2r compound 247). Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-phenylalanine methyl ester.
13C NMR (CDCI3) δ 172.8, 162.1, 137.2, 133.5, 129.2, 128.7, 126.8, 121.4, 113.8, 66.5, 59.2, 55.3, 52.2, 41.0, 35.6, 26.2. Preparation 48: (±)-Ethyl 2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane- 3-acetate (compound 248). General procedure 4.
Starting materials: 4-Phenoxyphenylphosphonic dichloride and Λ/-3- hydroxypropyl)glycine ethyl ester.
*H NMR (CDCI3) δ 7.85 (m, 2H), 7.38 (m, 2H), 7.18 (m, IH), 7.04 (m, 4H), 4.50 (m, IH), 4.23 (m, IH), 4.14 (q, 2H), 4.02 (dd,lH), 3.68 (dd, IH), 3.41 (m, IH), 3.28 (m, IH), 2.12 (m, IH), 2.03 (m, IH), 1.23 (t, 3H).
Preparation 49: (±)-Methyl 2-oxo-2-(4-phenoxyphenyl)-lf3f2-oxazaphospho- repane-3-acetate (compound 249).
General procedure 4.
Starting materials: 4-Phenoxyphenylphosphonic dichloride and N-(4- hydroxybutyl)glycine methyl ester. XH NMR (CDCI3) δ 7.87 (m, 2H), 7.37 (m, 2H), 7.16 (m, IH), 7.03 (m,4H), 4.54
(m, IH), 4.37 (m, IH), 4.15 (m, IH), 3,85 (dd, IH), 3.70 (s, 3H), 3.16 (m, IH),
2.94 (m, IH), 1.77 (m, 4H).
Preparation 50: (±)-Methyl 2-oxo-2-(4-phenoxyphenyl)-lf3f2-oxazaphospho- rocane-3-acetate (compound 250).
General procedure 4.
Starting materials: 4-Phenoxyphenylphosphonic dichloride and /-(5- hydroxypentyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.6, 160.6, 155.9, 133.5, 129.9, 124.7, 124.2, 119.9, 117.6, 66.1, 51.8, 46.0, 45.4, 28.6, 25.1, 24.4.
Preparation 51: (±)-Methyl α-allyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorinane-3-acetate (diastereomers lf compound 251). General procedure 4. Starting materials: 4-Phenoxyphenylphosphonic dichloride and V-(3- hydroxypropyl)-(±)-allylglycine methyl ester.
13C NMR (CDCI3) δ 172.3, 160.9, 155.8, 134.1, 133.9, 130.0, 124.4, 124.3, 120.0, 118.0, 117.7, 66.9, 57.0, 51.8, 41.4, 34.4, 26.7.
Preparation 52: (±)-Methyl α-allyl-2-oxo-2-(4-phenoxyphenyl)-1.3,2- oxazaphosphorinane-3-acetate (diastereomers 2f compound 252). General procedure 4. Starting materials: 4-Phenoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-(±)-allylglycine methyl ester.
13C NMR (CDCI3) δ 172.6, 160.9, 155.8, 134.0, 134.0, 130.0, 124.6, 124.4, 119.9, 118.0, 117.6, 66.3, 57.3, 52.1, 40.8, 34.3, 26.3.
Preparation 53: (±)-Ethyl α-butyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorepane-3-acetate (diastereomers lf compound 253). General procedure 6.
Starting materials: Compound 206 and ethyl 2-iodohexanoate. 13C NMR (CDCI3) δ 172.6, 160.5, 156.0, 133.5, 129.9, 125.0, 124.2, 119.8, 117.5, 65.4, 60.5, 59.2, 43.9, 30.8, 29.8, 29.4, 28.7, 22.5, 14.0, 13.9.
Preparation 54: (±)-Ethyl α-butyl-2-oxo-2-(4-phenoxyphenyl)-lf3r2- oxazaphosphorepane-3-acetate (diastereomers 2, compound 254). General procedure 6.
Starting materials: Compound 206 and ethyl 2-iodohexanoate.
X3C NMR (CDCI3) δ 173.3, 160.5, 155.9, 133.4, 130.0, 125.2, 124.2, 119.8,
117.7, 65.3, 60.9, 57.8, 41.7, 29.6, 29.0, 28.5, 27.7, 22.3, 14.2, 13.8.
Preparation 55: (αR)-Methyl α-(2-methylpropyl)-2-oxo-2-(4-phenoxyphenyl)- l,3,2-oxazaphosphorinane-3-acetate (diastereomer 1. compound 255).
General procedure 4.
Starting materials: 4-Phenoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-leucine methyl ester. 13C NMR (CDCI3) δ 173.4, 160.8, 155.8, 133.9, 130.0, 124.3, 124.3, 119.9,
117.7, 66.9, 55.7, 51.7, 41.2, 38.6, 26.9, 24.7, 23.2, 21.7.
Preparation 56: (αfl)-Methyl α-(2-methylpropyl)-2-oxo-2-(4-phenoxyphenyl)- 1.3.2-oxazaphosphorinane-3-acetate (diastereomer 2r compound 256). General procedure 4.
Starting materials: 4-Phenoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-leucine methyl ester.
13C NMR (CDCI3) δ 173.7, 160.9, 155.9, 133.9, 130.0, 124.9, 124.3, 119.8,
117.8, 66.1, 55.4, 52.0, 40.4, 38.4, 26.4, 24.5, 22.9, 21.5.
Preparation 57: (±)-Ethyl α-octyl-2-oχo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorepane-3-acetate (diastereomers lr compound 257). General procedure 6. Starting materials: Compound 206 and ethyl 2-iododecanoate. 13C NMR (CDCI3) δ 172.6, 160.4, 156.0, 133.5, 129.9, 125.0, 124.2, 119.8, 117.5, 65.4, 60.5, 59.3, 43.9, 31.9, 31.1, 29.8, 29.5, 29.3, 26.5, 22.7, 14.1, 13.9.
Preparation 58: (±)-Ethyl α-octyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorepane-3-acetate (diastereomers 2f compound 258). General procedure 6.
Starting materials: Compound 206 and ethyl 2-iododecanoate. MS. Calcd for C28H40NO5P 501.26; Found [M+H]+ = 502, [M+Na]+ = 524.
Preparation 59: (αfl)-Methyl α-(l-methylethyl)-2-oxo-2-(4-phenoxyphenyl)- lf3r2-oxazaphosphorinane-3-acetate (diastereomer lf compound 259). General procedure 4. Starting materials: 4-Phenoxyphenyl phosphonic dichloride and Λ -(3- hydroxypropyl)-D-valine methyl ester.
13C NMR (CDCI3) δ 172.4, 160.7, 155.8, 133.6, 130.0, 124.9, 124.4, 119.9, 117.7, 66.8, 63.0, 51.1, 41.0, 27.2, 26.7, 19.4, 19.3.
Preparation 60: (±)-Ethyl 2-oxo-2-(2-phenylethyl)-lf3f2-oxazaphosphorinane-3- acetate (compound 260).
General procedure 6.
Starting materials: Compound 207 and ethyl bromoacetate.
XH NMR (CDCI3) δ 7.25 (m, 5H), 4.39 (m, IH), 4.17 (m, 4H), 3.60 (dd,lH), 3.44 (m, IH), 3.05 (m, IH), 2.17 (m, 3H), 1.90 (m, IH), 1.61 (m, IH), 1.36 (m, IH),
1.26 (t, 3H).
Preparation 61: (+)- Methyl 2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorocane-3-acetate (compound 261). General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(5- hydroxypentyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.7, 162.2, 133.3, 122.2, 113.7, 66.0, 55.3, 51.8, 46.2, 45.4, 28.7, 25.2, 24.4.
Preparation 62: (±)-Methyl 2-oxo-2-phenyl-l,3.2-oxazaphosphorocane-3-acetate (compound 262). General procedure 4. Starting materials: Phenylphosphonic dichloride and /-(5-hydroxypentyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.6, 131.6, 131.4, 130.8, 128.2, 66.2, 51.8, 46.2, 45.4, 28.7, 25.1, 24.4.
Preparation 63: (±)-Methyl 2-heptyl-2-oxo-l,3,2-oxazaphosphorocane-3-acetate (compound 263). General procedure 4.
Starting materials: n-Heptylphosphonic dichloride and /V-(5-hydroxypentyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.9, 65.9, 51.8, 46.0, 44.8, 31.7, 30.9, 28.9, 28.6, 27.1, 25.2, 24.5, 22.6, 22.5, 14.1.
Preparation 64: (αK)-Methyl 2-(4-biphenylyl)-α-(l-methylethyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetate (diastereomer 1, compound 264).
General procedure 4.
Starting materials: 4-Biphenylylphosphonic dichloride and Λ/-(3-hydroxypropyl)-D- valine methyl ester.
*H NMR (CDCI3) δ 7.78 (m, 2H), 7.66 (m, 2H), 7.60 (m, 2H), 7.46 (m, 2H), 7.39 (m, IH), 4.48 (m, IH), 4.27 (m, IH), 3.92 (t, IH), 3.74 (m, IH), 3.60-3.30 (m,
IH), 3.42 (s, 3H), 2.21 (m, 2H), 1.99 (m, IH), 1.16 (d, 3H), 0.92 (d, 3H).
Preparation 65: (αfl)-Methyl 2-(4-biphenylyl)-α-(l-methylethyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetate (diastereomer 2, compound 265). General procedure 4.
Starting materials: 4-Biphenylylphosphonic dichloride and Λ/-(3-hydroxypropyl)-D- valine methyl ester.
XH NMR (CDCI3) δ 7.90 (m, 2H), 7.68 (m, 2H), 7.61 (m, 2H), 7.47 (m, 2H), 7.39 (m, IH), 4.53 (m, IH), 4.30 (m, IH), 3.82-3.66 (m, IH), 3.78 (s, 3H), 3.60 (dd, IH), 3.26 (m, IH), 2.12 (m, 2H), 1.84 (m, IH), 0.83 (d, 3H), 0.73 (d, 3H).
Preparation 66: (α ?)-Methyl 2-(4-biphenylyl)-2-oxo-α-phenylmethyl-lf3,2- oxazaphosphorinane-3-acetate (diastereomer 1, compound 266). General procedure 4. Starting materials: 4-Biphenylylphosphonic dichloride and Λ/-(3-hydroxypropyl)-D- phenylalanine methyl ester. XH NMR (CDCI3) δ 7.85 (m, 2H), 7.65 (m, 2H), 7.59 (m, 2H), 7.45 (m,3H), 7.37- 7.16 (m, 5H), 4.72 (m, IH), 4.30-4.05 (m, 2H), 3.53-3.30 (m, 3H), 3.48 (s, 3H), 3.16 (dd, IH), 1.91 (m, 2H).
Preparation 67: ( β)-Methyl 2-(4-biphenylyl)-2-oxo-α-phenylmethyl-l 3f2- oxazaphosphorinane-3-acetate (diastereomer 2f compound 267). General procedure 4.
Starting materials: 4-Biphenylylphosphonic dichloride and /V-(3-hydroxypropyl)-D- phenylalanine methyl ester. *H NMR (CDCI3) δ 7.56 (m, 2H), 7.47 (m, 2H), 7.40 (m, 3H), 7.25-7.15 (m,5H), 7.10 (m, 2H), 4.72 (m, IH), 4.54 (m, IH), 4.25-4.07(m, IH), 3.78 (s, 3H), 3.60 (m, IH), 3.24 (m, 2H), 2.94 (dd, IH), 2.23 (m, IH), 1.88 (m, IH).
Preparation 68: (±)-Ethyl 2- r4-(4-chlorophenyloxy)-phenyll -2-oxo-l,3,2- oxazaphosphorepane-3-acetate (compound 268).
General procedure 4.
Starting materials: 4-(4-Chlorophenoxy)phenylphosphonic dichloride and Λ/-(4- hydroxybutyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.3, 160.1, 154.6, 133.5, 130.0, 129.3, 125.1, 121.1, 117.8, 65.3, 61.0, 48.4, 47.3, 29.5, 26.5, 14.2.
Preparation 69: (±)-Ethyl 2- r4-(4-chlorophenyloxy)-phenylι -2-oxo-l,3,2- oxazaphosphorocane-3-acetate (compound 269).
General procedure 4. Starting materials: 4-(4-Chlorphenoxy)phenylphosphonic dichloride and Λ/-(5- hydroxypentyl)glycine methyl ester.
*H NMR (CDCI3) δ 7.94 (m, 2H), 7.32 (m, 2H), 7.05-6.94 (m, 4H), 4.47 (m, 2H),
4.16 (dq, 2H), 4.04 (m, IH), 3.71 (dd, IH), 3.18 (m, IH), 3.03 (m, IH), 2.00-
1.56 (m, 5H), 1.44 (m, IH), 1.24 (t, 3H).
Preparation 70: (±)-Ethyl 2-(4'-bromo-4-biphenylyl)-2-oxo-l,3,2-oxaza- phosphorinane-3-acetate (compound 270).
General procedure 4.
Starting materials: 4'-Bromo-4-biphenylylphosphonic dichloride and Λ/-(3- hydroxypropyl)glycine ethyl ester.
XH NMR (CDCI3) δ 7.95 (m, 2H), 7.72-7.42 (m, 6H), 4.53 (m, IH), 4.26 ( , IH),
4.15 (q, 2H), 4.06 (dd, IH), 3.74 (dd, IH), 3.47 (m, IH), 3.31 (m, IH), 2.16 (m,
IH), 2.03 (m, IH), 1.23 (t, 3H). Preparation 71 : (±)-Ethyl 2-(4,-bromo-4-biphenylyl)-2-oxo-l,3f2-oxaza- phosphorepane-3-acetate (compound 271). General procedure 4. Starting materials: 4'-Bromo-4-biphenylylphosphonic dichloride and Λ/-(4- hydroxybutyl)glycine ethyl ester.
13C NMR (CDCI3) δ 171.3, 143.1, 139.2, 132.0, 131.9, 129.8, 128.8, 126.8, 122.3, 65.4, 61.0, 48.6, 47.4, 29.5, 26.6, 14.2.
Preparation 72: (±)-Methyl 2-(4'-bromo-4-biphenylyl)-2-oxo-l,3r2-oxaza- phosphorocane-3-acetate (compound 272).
General procedure 4.
Starting materials: 4'-Bromo-4-biphenylylphosphonic dichloride and Λ/-(5- hydroxypentyl)glycine methyl ester. *H NMR (CDCI3) δ 8.02 (m, 2H), 7.63 (m, 2H), 7.58 (m, 2H), 7.47 (m, 2H), 4.50
(m, 2H), 4.07 (m, IH), 3.77 (m, IH), 3.71 (s, 3H), 3.23 (m, IH), 3.05 (m, IH),
2.00-1.33 (m, 6H).
Preparation 73: (±)-Ethyl 2-oxo-2-r2-(l-naphtyl)-ethyll-1.3.2-oxaza- phosphorinane-3-acetate (compound 273).
General procedure 4.
Starting materials: 2-(l-naphtyl)ethylphosphonic dichloride and Λ/-(3- hydroxypropyl)glycine ethyl ester.
13C NMR (CDCI3) δ 170.7, 137.6, 133.9, 131.5, 128.9, 127.0, 126.1, 125.7, 125.6, 123.5, 67.0, 61.1, 49.8, 47.2, 28.4, 26.2, 25.9, 14.2.
Preparation 74: (±)-Ethyl 2-phenyl-2-thioxo-lf3,2-oxazaphosphorinane-3-acetate (compound 274). General procedure 4. Starting materials: Thio-phenylphosphonic dichloride and Λ/-(3- hydroxypropyl)glycine ethyl ester. i3C NMR (CDCI3) δ 170.2, 132.7, 132.4, 131.7, 128.6, 66.3, 61.0, 50.8, 47.0, 26.3, 14.2.
Preparation 75: (±)-Ethyl 2-phenyl-2-thioxo-1.3.2-oxazaphosphorepane-3-acetate (compound 275). General procedure 4. Starting materials: Thio-phenylphosphonic dichloride and Λ/-(4- hydroxybutyl)glycine ethyl ester.
13C NMR (CDCI3) δ 171.3, 135.4, 131.3, 130.5, 128.2, 64.7, 61.0, 49.9, 47.9, 29.1, 25.7, 14.2.
Preparation 76: (±)-Methyl 2-phenyl-2-thioxo-1.3.2-oxazaphosphorocane-3- acetate (compound 276). General procedure 4.
Starting materials: Thio-phenylphosphonic dichloride and Λ/-(5- hydroxypentyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.5, 135.7, 131.2, 130.6, 128.2, 66.0, 51.9, 46.9, 45.4, 28.3, 25.0, 24.2.
Preparation 77: (±)-Ethyl 2- r4-(4-chlorophenyloxy)-phenyπ -2-oxo-lf3,2- oxazaphosphorinane-3-acetate (compound 277).
General procedure 4.
Starting materials: 4-(4-chlorophenoxy)phenylphosphonic dichloride and Λ/-(3- hydroxypropyl)glycine ethyl ester.
13C NMR (CDCI3) δ 170.3, 160.6, 154.4, 134.2, 130.0, 129.5, 124.5, 121.2, 117.8, 66.9, 61.1, 49.3, 47.3, 26.1, 14.2.
Preparation 78: fα/?)-Methyl 2- r4-(4-chlorophenoxy)-phenyl1 -α-(2-methylethyl)- 2-oxo-l,3r2-oxazaphosphorinane-3-acetate (diastereomer 1, compound 278). General procedure 4. Starting materials: 4-(4-Chlorophenoxy)phenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-valine methyl ester.
13C NMR (CDCI3) δ 172.3, 160.3, 154.5, 133.6, 130.0, 129.5, 125.5, 121.1, 117.8, 66.8, 63.1, 51.1, 41.0, 27.2, 26.7, 19.4, 19.3.
Preparation 79: (αR)-Methyl 2- r4-(4-chlorophenoxy)-phenyll -α-(2-methylethyl)-
2-oxo-l,3.2-oxazaphosphorinane-3-acetate (diastereomer 2, compound 279).
General procedure 4.
Starting materials: 4-(4-chlorophenoxy)phenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-valine methyl ester. 13C NMR (CDCI3) δ 173.0, 160.6, 154.4, 134.5, 130.0, 129.6, 124.3, 121.2,
117.6, 66.0, 63.4, 51.8, 40.2, 27.6, 26.5, 19.6, 19.4. Preparation 80: (±)-Ethyl 2-(4-bromophenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetate (compound 280). General procedure 4.
Starting materials: 4-Bromophenylphosphonic dichloride and Λ/-(3- hydroxypropyl)glycine ethyl ester.
(CDCI3) δ 7.75 (m, 2H), 7.60 (m, 2H), 4.50 (m, IH), 4.22 (m, IH), 4.14 (q, 2H), 4.04 (dd, IH), 3.68 (dd, IH), 3.42 (m, IH), 3.27 (m, IH), 2.14 (m, IH), 2.00 (m, IH), 1.23 (t, 3H).
Preparation 81 : (±)-Ethyl 2-(4-bromophenyl)-2-oxo-lf3f2-oxazaphosphorepane-
3-acetate (compound 281).
General procedure 4.
Starting materials: 4Bromophenylphosphonic dichloride and /-(4- hydroxybutyl)glycine ethyl ester. 13C NMR (CDCI3) δ 171.2, 132.9, 131.5, 129.7, 126.6, 65.4, 61.1,
48.5, 47.4, 29.4, 26.5, 14.2.
Preparation 82: (±)-Ethyl 2-r4-(phenylmethoxy)phenyll-2-oxo-lf3,2- oxazaphosphorinane-3-acetate (compound 282). General procedure 4.
Starting materials: 4-(Phenylmethoxy)phenyiphosphonic dichloride and Λ/-(3- hydroxypropyl)glycine ethyl ester.
13C NMR (CDCI3) δ 170.4, 161.8, 136.3, 134.1, 128.7, 128.2, 127.5, 121.6,
114.9, 70.0, 66.7, 61.0, 49.3, 47.2, 26.1, 14.1.
Preparation 83: (±)-Ethyl 2-r4-(phenylmethoxy)phenyll-2-oxo-lr3,2- oxazaphosphorepane-3-acetate (compound 283).
General procedure 4.
Starting materials: 4-(Phenylmethoxy)phenylphosphonic dichloride and Λ/-(4- hydroxybutyl)glycine ethyl ester.
13C NMR (CDCI3) δ 171.4, 161.4, 136.5, 133.2, 128.7, 128.1, 127.5, 122.4,
114.7, 70.0, 65.2, 61.0, 48.6, 47.4, 29.5, 26.5, 14.2.
Preparation 84: (±)-Ethyl 2-r4-(phenylmethoxy)phenyn-2-oxo-1.3,2- oxazaphosphorocane-3-acetate (compound 284). General procedure 4.
Starting materials: 4-(Phenylmethoxy)phenylphosphonic dichloride and /V-(5- hydroxypentyl)glycine ethyl ester. lH NMR (CDCI3) δ 7.89 (m, 2H), 7.45-7.28 (m, 5H), 7.02 (m, 2H), 5.10 (s, 2H), 4.45 (m, 2H), 4.15 (dq, 2H), 4.02 (m, IH), 3.71 (dd, IH), 3.16 (m, IH), 3.01 (m, IH), 2.00-1.60 (m, 5H), 1.43 (m, IH), 1.23 (t, 3H).
Preparation 85: (±)-Ethyl 2-oxo-2-f4-(4-trifluoromethylphenoxy)phenyn-lf3f2- oxazaphosphorinane-3-acetate (compound 285). General procedure 4.
Starting materials: 4-(Trifluoromethylphenoxy)phenylphosphonic dichloride and /-(3-hydroxypropyl)glycine ethyl ester. XH NMR (CDCI3) δ 7.91 (m, 2H), 7.62 (m, 2H), 7.14-7.05 (m, 4H), 4.52 (m, IH), 4.24 (m, IH), 4.15 (q, 2H), 4.06 (dd, IH), 3.70 (dd, IH), 3.45 (m, IH), 3.29 (m, IH), 2.14 (m, IH), 2.03 (m, IH), 1.24 (t, 3H).
Preparation 86: (±)-Ethyl 2-oxo-2-r4-(4-trifluoromethylphenoxy)phenyll-lr3r2- oxazaphosphorepane-3-acetate (compound 286).
General procedure 4.
Starting materials: 4-(Trifluoromethylphenoxy)phenylphosphonic dichloride and
Λ/-(4-hydroxybutyl)glycine ethyl ester.
13C NMR (CDCI3) δ 171.4, 159.3, 159.0, 133.6, 127.3, 126.2, 119.0, 118.9, 65.4, 61.1, 48.4, 47.4, 29.5, 26.5, 14.2.
Preparation 87: (αK)-Methyl α-(2-methylethyl)-2-oxo-2-r4-(4- trifluoromethylphenoxy)phenyn-lr3f2-oxazaphosphorinane-3-acetate
(diastereomer 1, compound 287). General procedure 4.
Starting materials: 4-(trifluoromethylphenoxy)phenylphosphonic dichloride and
Λ -(3-hydroxypropyl)-D-valine methyl ester.
13C NMR (CDCI3) δ 172.3, 159.2, 159.1, 133.8, 127.4, 126.7, 126.0, 124.1,
119.0, 118.9, 66.9, 63.1, 51.1, 41.0, 27.2, 26.7, 19.4, 19.3.
Preparation 88: (α/?)-Methyl α-(2-methylethyl)-2-oxo-2-r4-(4- trifluoromethylphenoxy)phenyll-lr3r2-oxazaphosphorinane-3-acetate
(diastereomer 2, compound 288).
General procedure 4. Starting materials: 4-(Trifluoromethylphenoxy)phenylphosphonic dichloride and
/V-(3-hydroxypropyl)-D-valine methyl ester.
13C NMR (CDCI3) δ 173.0, 159.5, 159.0, 134.6, 127.4, 126.1, 125.6, 124.1,
119.2, 118.7, 66.1, 63.5, 51.8, 40.2, 27.6, 26.5, 19.7, 19.4. Preparation 89: (±)-Ethyl 2- r4-(4-bromophenoxy)-phenvπ -2-oxo-lr3r2- oxazaphosphorinane-3-acetate (compound 289). General procedure 4.
Starting materials: 4-(4-Bromophenoxy)phenylphosphonic dichloride and Λ/-(3- hydroxypropyl)glycine ethyl ester.
13C NMR (CDCI3) δ 170.3, 160.5, 155.0, 134.2, 133.0, 124.7, 121.6, 117.9, 117.0, 66.9, 61.1, 49.3, 47.3, 26.1, 14.2.
Preparation 90: (±)-Ethyl 2- r4-(4-bromophenoxy)-phenyli -2-oxo-lf3r2- oxazaphosphorepane-3-acetate (compound 290).
General procedure 4.
Starting materials: 4-(4-Bromophenoxy)phenylphosphonic dichloride and Λ/-(4- hydroxybutyl)glycine ethyl ester.
13C NMR (CDCI3) δ 171.4, 160.0, 155.3, 133.5, 132.9, 125.2, 121.4, 117.9, 116.7, 65.3, 61.0, 48.4, 47.3, 29.5, 26.5, 14.2.
Preparation 91 : (±)-Ethyl 2-(4-nitrophenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetate (compound 291). General procedure 4. Starting materials: 4-Nitrophenylphosphonic dichloride and Λ/-(4- hydroxybutyl)glycine ethyl ester.
13C NMR (CDCI3) δ 171.1, 149.8, 138.0, 132.6, 123.1, 65.9, 61.3, 48.4, 47.4, 29.4, 26.6, 14.2.
Preparation 92: (±)-Ethyl 2-r/V-(4-chlorobenzoyl)-4-aminophenyn-2-oxo-lr3r2- oxazaphosphorepane-3-acetate (compound 292).
Procedure: A solution of compound 291 in methanol was hydrogenated with Pd on carbon (10%) for 1 hour at atm. pressure. Filtration and concentration afforded ethyl 2-(4-aminophenyl)-2-oxo-l,3,2-oxazaphosphorepane-3-acetate. This crude aniline was dissolved in CH2CI2 with 3 equivalents triethylamine, the solution was cooled to 0 °C, and 2 equivalents of 4-chlorobenzoylchloride were added neat. After stirring overnight at r.t., the mixture was concentrated under reduced pressure, redissolved in ethylacetat and washed with water and brine. After filtration and evaporation, the title compound was purified by flash chromatography.
13C NMR (CDCI3) δ 171.2, 165.3, 141.6, 138.0, 133.1, 132.0, 129.2, 128.7, 125.3, 120.3, 65.4, 61.1, 48.8, 47.4, 29.4, 26.5, 14.2. Preparation 93: (±)-Ethyl 2-(Λ/-benzoyl-4-aminophenyl)-2-oxo-l,3,2- oxazaphosphorepane-3-acetate (compound 293).
Procedure: Similar to preparation 92, except that benzoylchloride was used instead of 4-chlorobenzoylchloride. 13C NMR (CDCI3) δ 171.3, 166.1, 141.4, 134.7, 132.3, 131.9, 128.6, 127.4, 125.5, 119.9, 65.3, 61.0, 48.7, 47.4, 29.5, 26.5, 14.2.
Preparation 94: (α/?)-Methyl α-(2-methylethyl)-2-oxo-2-(4-phenoxyphenyl)- l,3f2-oxazaphosphorinane-3-acetate (diastereomer 1, compound 294). General procedure 4.
Starting materials: 4-Phenoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-D-valine methyl ester.
13C NMR (CDCI3) δ 173.0, 161.1, 155.7, 134.4, 130.0, 124.4, 123.6, 120.0,
117.5, 66.0, 63.4, 51.7, 40.2, 27.5, 26.5, 19.6, 19.4.
Preparation 95: (±)-Ethyl α-butyl-2-(4-methoxyphenyl)-2-oxo-lf3,2- oxazaphosphorinane-3-acetate (diastereomers , compound 295).
General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-(±)-norleucine ethyl ester.
13C NMR (CDCI3) δ 172.7, 162.5, 133.9, 121.8, 113.9, 66.8, 60.7,
57.6, 55.3, 41.2, 29.4, 28.4, 26.9, 22.4, 14.1, 13.9.
Preparation 96: (±)-Ethyl α-butyl-2-(4-methoxyphenyl)-2-oxo-lf3,2- oxazaphosphorinane-3-acetate (diastereomers 2f compound 296).
General procedure 4.
Starting materials: 4-Methoxyphenylphosphonic dichloride and Λ/-(3- hydroxypropyl)-(±)-norleucine ethyl ester.
13C NMR (CDCI3) δ 173.1, 162.5, 133.8, 122.4, 113.9, 65.9, 60.9, 57.3, 55.3, 40.2, 29.1, 28.4, 26.5, 22.1, 14.2, 13.8.
Preparation 97: (±)-Ethyl 2-oxo-2-phenyl-lr3f2-oxazaphosphoronane-3-acetate (compound 297). General procedure 4. Starting materials: Phenylphosphonic dichloride and Λ/-(5-hydroxypentyl)glycine methyl ester.
13C NMR (CDCI3) δ 171.1, 131.9, 131.7, 130.4, 128.2, 60.9, 60.6, 45.9, 42.3, 27.7, 24.4, 19.1, 18.4, 14.2. Preparation 100: (α< )-2-(4-Methoxyphenyl)-α-(l-methylethyl)-2-oxo-l,3,2-ox- azaphosphorinane-3-acetic acid (diastereomer lr compound 300). General procedure 3. Starting materials: Compound 226. l NMR (CD3OD) δ 7.72 (m,2H), 7.07 (m, 2H), 4.46 (m, IH), 4.27 (m,lH), 3.89 (s, 3H), 3.73 (t,lH), 3.67-3.36 (m, 2H), 2.21 (m, 2H), 1.98 (m, IH), 1.16 (d, 3H), 1.02 (d, 3H).
Preparation 101 : (αR)-2-(4-Methoxyphenyl)-α-(l-methylethyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomer 2, compound 301).
General procedure 3.
Starting materials: Compound 227.
*H NMR (CD3OD) δ 7.86 (m,2H), 6.98 (m, 2H), 4.50 (m, IH), 4.33 (m,lH), 3.84
(s, 3H), 3.51 (m,lH), 3.37-3.10 (m, 2H), 2.13 (m, 3H), 0.81 (d, 3H), 0.54 (d, 3H).
Preparation 102: (αfl)-2-(4-Biphenylyl)-α-(l-methylethyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomer lr compound 302). General procedure 3. Starting materials: Compound 264.
*H NMR (CD3OD) δ 8.06 (m, 2H), 7.55 (bs, 4H), 7.35 (bs, 3H), 4.47 (m, 2H), 3.41 (m, IH), 3.23 (m, IH), 2.18 (m, 3H), 0.88 (bd, 3H), 0.45 (d, 3H).
Preparation 103: (αfl)-2-(4-Biphenylyl)-2-oxo-α-phenylmethyl-l,3f2- oxazaphosphorinane-3-acetic acid (diastereomer 1, compound 303).
General procedure 3.
Starting materials: Compound 266.
X NMR (CD3OD) δ 7.87 (m, 2H), 7.73 (m, 2H), 7.65 (m, 2H), 7.46 (m, 2H), 7.42-
7.25 (m, 5H), 7.21 (m, IH), 4.60 (m, IH), 4.16 (m, 2H), 3.60-3.28 (m, 3H), 3.14 (dd, IH), 1.90 (m, 2H).
Preparation 104: (αK)-2-(4-Biphenylyl)-2-oxo-α-phenylmethyl-l,3.2- oxazaphosphorinane-3-acetic acid (diastereomer 2, compound 304). General procedure 3. Starting materials: Compound 267. NMR (CD3OD) δ 7.54 (m, 2H), 7.49-7.25 (m, 7H), 6.99 (m, 3H), 6.89 (m, 2H), 4.51 (m, IH), 4.18 (m, 2H), 3.71-3.28 (m, 2H), 3.14 (m, IH), 2.85 (dd, IH), 2.14 (m, 2H). Preparation 105: (+)-2-Oxo-2-phenyl-lf3,2-oxazaphosphorepane-3-acetic acid (compound 305) General procedure 3. Starting materials: Compound 220. 13C NMR (DMSO-d6) δ 172.4, 131.3, 131.2, 130.8, 128.1, 64.7, 47.8, 46.9, 28.9, 25.9.
Preparation 106: (+)-2-Oxo-2-phenyl-lr3,2-oxazaphosphorocane-3-acetic acid (compound 306) General procedure 3.
Starting material : Compound 262.
13C NMR (DMSO-d6) δ 172.2, 131.4, 131.3, 130.9, 128.1, 65.3, 45.8, 45.3, 27.9,
24.6, 24.0.
Preparation 107 : (±)-α-Butyl-2-oxo-2-phenyl-l,3.2-oxazaphosphorepane-3-acetic acid (diastereomers lf compound 307)
General procedure 3.
Starting materials: Compound 221.
13C NMR (CD3OD) δ 175.3, 132.9, 132.6, 131.5, 129.3, 67.3, 61.0, 45.9, 31.9, 30.6, 30.5, 30.1, 23.5, 14.3.
Preparation 108 : (±)-α-Butyl-2-oxo-2-phenyl-l,3,2-oxazaphosphorepane-3-acetic acid (diastereomers 2f compound 308) General procedure 3. Starting materials: Compound 222.
XH NMR (CD3OD) δ 7.84 (m, 2H), 7.62 (m, IH), 7.54 (m, 2H), 4.79 (m, IH), 4.33 (m, IH), 4.25 (m, IH), 3.23 (m, IH), 3.06 (m, IH), 1.96 (m, 3H), 1.85 (m, IH), 1.72 (m, IH), 1.55 (m, IH), 1.23 (m, 2H), 1.00 (m, 2H), 0.77 (t, 3H).
Preparation 109 : (+)-2-(4-Methoxyphenyl)-2-oxo-1.3.2-oxazaphosphorinane-3- acetic acid (compound 309). General procedure: 3. Starting material : Compound 223. 13C NMR (CD3OD) δ 176.0, 164.8, 135.5, 115.3, 68.5, 56.0, 27.2.
Preparation 110: (±)-2-(4-Methoxyphenyl)-2-oxo-lr3r2-oxazaphosphorepane-3- πcetic acid (compound 310). General procedure: 3. Starting material: Compound 224.
Preparation 111 : (±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomers 1, compound 311). General procedure: 3.
Starting material: Compound 295.
13C NMR (DMSO-d6) δ 173.6, 161.6, 133.0, 122.5, 113.9, 67.1, 56.8, 55.2, 41.1,
28.6, 27.9, 26.4, 21.6, 13.8.
Preparation 112: (±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-lr3f2- oxazaphosphorinane-3-acetic acid (diastereomers 2f compound 312).
General procedure: 3.
Starting material: Compound 296.
13C NMR (CDCI3) δ 172.6, 163.7, 135.1, 118.0, 114.1, 66.5, 57.9, 55.5, 40.8, 27.8, 26.9, 26.1, 22.0, 13.8.
Preparation 113: (±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-lr3f2- oxazaphosphorepane-3-acetic acid (diastereomers lf compound 313). General procedure: 3. Starting material: Compound 228.
*H NMR (DMSO-d6) δ 7.63 (m, 2H), 6.98 (m, 2H), 4.45 (q, IH), 4.11 (m, IH), 4.03 (m, IH), 3.79 (s, 3H), 3.20-2.90 (m, 2H), 1.90-1.20 (m, 10H), 0.87 (bt, 3H).
Preparation 114: (+)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-lf3,2- oxazaphosphorepane-3-acetic acid (diastereomers 2, compound 314).
General procedure: 3.
Starting material: Compound 229.
*H NMR (DMSO-d6) δ 7.65 (m, 2H), 7.01 (m, 2H), 4.55 (q, IH), 4.05 (m, 2H), 3.80 (s, 3H), 3.09 (m, IH), 2.84 (m, IH), 1.90-1.20 (m, 6H), 1.10 (m, 2H), 0.86
(m, 2H), 0.67 (t, 3H).
Preparation 115: (+)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-lf3f2- oxazaphosphorocane-3-acetic acid (diastereomers 1, compound 315). General procedure: 3.
Starting material: Compound 230.
MS. Calcd for C18H28N05P 369.17, Found [M+H]+ = 370, [M-H]" =368. Preparation 116: (+)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorocane-3-acetic acid (diastereomers 2f compound 316). General procedure: 3. Starting material: Compound 231. MS. Calcd for C18H28N05P 369.17, Found [M+H]+ = 370, [M-H]" = 368.
Preparation 117: (+)- α-Allyl-2-(4-methoxyphenyl)-2-oxo-lf3f2- oxazaphosphorinane-3-acetic acid (diastereomers 1, compound 317). General procedure: 3. Starting material : Compound 232.
XH NMR (CD3OD) δ 7.78 (m, 2H), 7.02 (m, 2H), 5.95 (m, IH), 5.20 (m, IH), 5.12 (m, IH), 4.38 (m, IH), 4.20 (m, 2H), 3.85 (s, 3H), 3.38 (m, 2H), 2.66 (m, 2H), 2.06 (m, IH), 1.91 (m, IH).
Preparation 118: (±)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomers 2, compound 318).
General procedure: 3.
Starting material : Compound 233.
X NMR (CD3OD) δ 7.73 (m, 2H), 7.04 (m, 2H), 5.47 (m, IH), 5.02 (m, IH), 4.89 (bd, IH), 4.52 (m, IH), 4.30 (m, IH), 4.05 (m, IH), 3.86 (s, 3H), 3.31 (m, IH),
3.26 (m, IH), 2.56 (m, IH), 2.41 (m, IH), 2.21 (m, IH), 2.03 (m, IH).
Preparation 119: (αR)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomer 1, compound 319). General procedure: 3.
Starting material : Compound 236.
XH NMR (CD3OD) δ 7.82 (m, 2H), 7.07 (m, 2H), 4.46 (m, IH), 4.23 (m, 2H), 3.89
(s, 3H), 3.43 (m, 2H), 2.04 (m, 2H), 1.84 (m, 2H), 1.69 (m, IH), 1.05 (d, 3H),
1.03 (d, 3H).
Preparation 120: (α/?)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomer 2, compound 320).
General procedure: 3.
Starting material : Compound 237. NMR (CD3OD) δ 7.79 (m, 2H), 7.09 (m, 2H), 4.58 (m, IH), 4.36 (m, IH), 4.01
(m, IH), 3.90 (s, 3H), 3.57 (m, IH), 3.31 (m, IH), 2.27 (m, IH), 2.14 (m, IH),
1.62 (m, 2H), 1.42 (m, IH), 0.82 (d, 3H), 0.59 (d, 3H). Preparation 121 : (+)-2-(4-MethoxyphenyD- α-(2-methylpropyl)-2-oxo-l,3,2- oxazaphosphorepane-3-acetic acid (diastereomers lf compound 321). General procedure: 3. Starting material: Compound 238. XH NMR (CD3OD) δ 7.72 (m, 2H), 6.98 (m, 2H), 4.58 (m, IH), 4.30 (m, IH), 4.18 (m, IH), 3.83 (s, 3H), 3.21 (m, IH), 3.10 (m, IH), 2.03-1.55 (m, 7H), 1.03 (d, 3H), 0.98 (d, 3H).
Preparation 122: (+)-2-(4-MethoxyphenyD- α-(2-methylpropyl)-2-oxo-l,3,2- oxazaphosphorepane-3-acetic acid (diastereomers 2, compound 322).
General procedure: 3.
Starting material: Compound 239.
XH NMR (CD3OD) δ 7.72 (m, 2H), 7.03 (m, 2H), 4.72 (m, IH), 4.35 (m, IH), 4.16
(m, IH), 3.85 (s, 3H), 3.22 (m, IH), 3.01 (m, IH), 1.89 (m, 3H), 1.68 (m, 2H), 1.30 (m, 2H), 0.81 (d, 3H), 0.79 (d, 3H).
Preparation 123: (αS)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomer lf compound 323). General procedure: 3. Starting material: Compound 240.
13C NMR (DMSO-d6) δ 174.0, 161.8, 133.2, 122.5, 114.1, 67.3, 55.2, 55.2, 41.1, 38.1, 26.6, 24.1, 23.2, 21.4.
Preparation 124: (αS)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomer 2. compound 324).
General procedure: 3.
Starting material: Compound 241.
13C NMR (DMSO-d6) δ 174.1, 163.1, 162.0, 133.4, 122.8, 114.0, 66.4, 55.4, 54.9,
40.3, 37.6, 25.8, 24.0, 22.8, 21.0.
Preparation 125: (+)-2-(4-MethoxyphenyD- α-octyl-2-oxo-l,3,2- oxazaphosphorepane-3-acetic acid (diastereomers 1. compound 325).
General procedure: 3.
Starting material: Compound 242. XH NMR (CD3OD) δ 7.72 (m, 2H), 6.98 (m, 2H), 4.62 (m, IH), 4.18 (m, IH), 4.13
(m, 1H),3.83 (s, 3H), 3.21 (m, IH), 3.11 (m, IH), 2.00-1.20 (m, 18H), 0.90 (bt,
3H). Preparation 126: (±)-2-(4-Methoxyphenyl)- α-octyl-2-oxo-l,3,2- oxazaphosphorepane-3-acetic acid (diastereomers 2, compound 326). General procedure: 3. Starting material: Compound 243. XH NMR(CD3OD) δ 7.73 (m, 2H), 7.02 (m, 2H), 4.71 (m, IH), 4.25 (m, IH), 4.17 (m, IH), 3.85 (s, 3H), 3.17 (m, IH), 3.01 (m, IH), 1.90 (m, 3H), 1.77 (m, IH), 1.66 (m, IH), 1.52 (m, IH), 1.37-1.04 (m, 10H), 0.96 (m, 2H), 0.88 (m, 3H).
Preparation 127: (αfl)-2-(4-Methoxyphenyl)- 2-oxo-α-phenylmethyl-lr3,2- oxazaphosphorinane-3-acetic acid (diastereomer lf compound 327).
General procedure: 3
Starting material: Compound 246
13C NMR (CD3OD) δ 164.8, 139.2, 135.3, 130.9, 129.8, 128.0, 122.7, 115.5, 68.8,
56.3, 43.3, 37.9, 28.1.
Preparation 128: (αfl)-2-(4-Methoxyphenyl)- 2-oxo-α-phenylmethyl-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomer 2, compound 328).
General procedure: 3
Starting material: Compound 247. 13C NMR (CD3OD) δ 179.5, 164.4, 140.2, 136.1, 130.4, 129.3, 127.2, 119.6,
114.9, 67.8, 63.0, 55.9, 42.1, 36.2, 27.4.
Preparation 129: (±)-2-(4-Methoxyphenyl)- 2-oxo-α-propyl-l,3f2- oxazaphosphorinane-3-acetic acid (diastereomers lr compound 329). Compound 317 (0.18 mmol) was dissolved in methanol (4 ml), 10% Pd/C (25 mg) was added and the mixture was hydrogenated for 6h, filtered through celite and concentrated under reduced pressure to afford compound 329. *H NMR (CD3OD) δ 7.74 (m, 2H), 7.04 (m, 2H), 4.54 (m, IH), 4.32 (m, IH), 3.89 (m, IH), 3.86 (s, 3H), 3.54 (m, IH), 3.24 (m, IH), 2.22 (m, IH), 2.08 (m, IH), 1.74 (m, IH), 1.63 (m, IH), 1.17 (m, IH), 1.00 (m, IH), 0.72 (t, 3H).
Preparation 130: (+)-2-(4-Methoxyphenyl)- 2-oxo-α-propyl-l,3.2- oxazaphosphorinane-3-acetic acid (diastereomers 2r compound 330). Compound 318 (0.16 mmol) was dissolved in methanol (5 ml), 10% Pd/C (25 mg) was added and the mixture was hydrogenated for 5h, filtered through celite and concentrated under reduced pressure to afford compound 330. lH NMR (CD3OD) δ 7.80 (m, 2H), 7.02 (m, 2H), 4.40 (m, IH), 4.20 (m, IH), 4.04 (m, IH), 3.84 (s, 3H), 3.39 (m, 2H), 2.14-1.40 (m, 6H), 0.99 (t, 3H). Preparation 131 : (±)-α-Allyl-2-(4-methoxyphenyl)- 2-oxo-l,3,2- oxazaphosphorepane-3-acetic acid (diastereomer si. compound 331). General procedure: 3 Starting material : Compound 234. *H NMR (CD3OD) δ 7.73 (m, 2H), 6.98 (m, 2H), 5.93 (m, IH), 5.20 (m, IH), 5.13 (m, IH), 4.61 (m, IH), 4.35 (m, IH), 4.15 (m, IH), 3.83 (s, 3H), 3.20 (m, IH), 3.07 (m, IH), 2.75 (m, IH), 2.58 (m, IH), 1.88 (m, 2H), 1.78 (m, 2H).
Preparation 132: (+)-α-Allyl-2-(4-methoxyphenyl)- 2-oxo-l,3f2- oxazaphosphorepane-3-acetic acid (diastereomers 2, compound 332).
General procedure: 3
Starting material : Compound 235.
*H NMR (CD3OD) δ 7.72 (m, 2H), 7.00 (m, 2H), 5.50 (m, IH), 4.92 (m, IH), 4.77
(m, IH), 4.23 (m, IH), 4.11 (m, IH), 3.84 (s, 3H), 3.25 (m, IH), 2.95 (m, 2H), 2.52 (m, IH), 2.24 (m, IH), 2.06-1.72 (m, 3H), 1.62 (m, IH).
Preparation 133: (±)- α-Allyl-2-oxo-2-(4-phenoxyphenyl)- l,3r2- oxazaphosphorinane-3-acetic acid (diastereomers 1, compound 333). General procedure: 3 Starting material : Compound 250. l NMR (CD3OD) δ 7.82 (m, 2H), 7.41 (m, 2H), 7.20 (m, IH), 7.06 (m, 2H), 7.03 (m, 2H), 5.95 (m, IH), 5.21 (m, IH), 5.13 (m, IH), 4.41 (m, IH), 4.23 (m, 2H), 3.39 (m, 2H), 2.72 (m, IH), 2.62 (m, IH), 2.08 (m, IH), 1.92 (m, IH).
Preparation 134: (±)-α-Allyl-2-oxo-2-(4-phenoxyphenyl)- 1,3,2- oxazaphosphorinane-3-acetic acid (diastereomers 2, compound 334).
General procedure: 3
Starting material : Compound 252.
*H NMR (CD3OD) δ 7.77 (m, 2H), 7.42 (m, 2H), 7.21 (m, IH), 7.06 (m, 4H), 5.48 (m, IH), 5.03 (m, IH), 4.89 (m, IH), 4.54 (m, IH), 4.32 (m, IH), 4.10 (m, IH),
3.49 (m, IH), 3.28 (m, IH), 2.59 (m, IH), 2.45 (m, IH), 2.23 (m, IH), 2.04 (m,
IH).
Preparation 135: (+)- α-Butyl-2-oxo-2-(4-phenoxyphenyl)-l,3r2- oxazaphosphorepane-3-acetic acid (diastereomers 1, compound 335). General procedure: 3 Starting material : Compound 253. *H NMR (CD3OD) δ 7.77 (m, 2H), 7.41 (m, 2H), 7.20 (m, IH), 7.04 (m, 4H), 4.74 (m, IH), 4.26 (m, IH), 4.17 (m, IH), 3.40-2.90 (m, 2H), 2.00-0.84 (m, 10H), 0.77 (t, 3H).
Preparation 136: (+)-α-Butyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorepane-3-acetic acid (diastereomers 2, compound 336). General procedure: 3 Starting material : Compound 254.
:H NMR (CD3OD) δ 7.81 (m, 2H), 7.39 (m, 2H), 7.18 (m, IH), 7.03 (m, 2H), 6.98 (m, 2H), 4.65 (m, IH), 4.15 (m, IH), 3.97 (m, IH), 3.35 (m, IH), 310 (m, IH), 2.06-1.60 (m, 6H), 1.40 (m, 4H), 0.91 (bt, 3H).
Preparation 137: (αfl)-α-(2-Methylpropyl)-2-oxo-2-(4-phenoxyphenyl)-lf3r2- oxazaphosphorinane-3-acetic acid (diastereomer 1, compound 337). General procedure: 3 Starting material: Compound 255.
*H NMR (CD3OD) δ 7.81 (m, 2H), 7.41 (m, 2H), 7.20 (m, IH), 7.06 (m, 2H), 7.03 (m, 2H), 4.43 (m, IH), 4.21 (m, 2H), 3.40 (m, 2H), 2.00 (m, 2H), 1.79 (m, 2H), 1.66 (m, IH), 1.01 (d, 3H), 0.99 (d, 3H).
Preparation 138: (αfl)-α-(2-Methylpropyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomer 2f compound 338).
General procedure: 3
Starting material : Compound 256.
*H NMR (CD3OD) δ 7.79 (m, 2H), 7.41 (m, 2H), 7.21 (m, IH), 7.10-7.00 (m, 4H), 4.55 (m, IH), 4.34 (m, IH), 3.98 (m, IH), 3.53 (m, IH), 3.26 (m, IH), 2.24 (m,
IH), 2.09 (m, IH), 1.59 (m, 2H), 1.38 (m, IH), 0.79 (d, 3H), 0.58 (d, 3H).
Preparation 139: (+)-α-Octyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorepane-3-acetic acid (diastereomers 1, compound 339). General procedure: 3
Starting material : Compound 257. H NMR (CD3OD) δ 7.76 (m, 2H), 7.40 (m, 2H), 7.19 (m, IH), 7.05 (m, 2H), 7.00 (m, 2H), 4.64 (dq, IH), 4.17 (m, 2H), 3.15 (m, 2H), 2.02-1.25 (m, 18H), 0.90 (bt, 3H).
Preparation 140: (+)-α-Octyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorepane-3-acetic acid (diastereomers 2r compound 340). General procedure: 3 Starting material: Compound 258.
MS. Calcd for C26H35N05P 473.23, Found [M+H]+ = 474, [M-H]" = 472.
Preparation 141: (αβ)-α-(2-Methylethyl)-2-oxo-2-(4-phenoxyphenyl)-l,3f2- oxazaphosphorinane-3-acetic acid (diastereomer 1, compound 341).
General procedure 3.
Starting material: Compound 259.
13C NMR (CD3OD) δ 175.4, 162.6, 157.1, 134.8, 131.2, 125.7, 125.5, 121.1,
118.7, 69.1, 65.7, 42.8, 28.4, 27.9, 20.1, 20.0.
Preparation 142: (α ?)-α-(2-Methylethyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorinane-3-acetic acid (diastereomer 2, compound 342).
General procedure 3.
Starting material : Compound 294. 13C NMR (CD3OD) δ 178.6, 162.9, 156.9, 136.4, 131.3, 125.8, 124.3, 121.1,
118.2, 68.4, 67.3, 42.2, 27.3, 20.9, 19.6.
Preparation 143: (±)-2-(4-(4-Chlorophenoxy)-phenyl)-2-oxo-lf3,2- oxazaphosphorepane-3-acetic acid (compound 343). General procedure 3.
Starting material: Compound 268.
13C NMR (DMSO-d6) δ 173.1, 158.9, 154.5, 133.3, 130.0, 128.0, 126.6, 121.1,
117.5, 64.5, 48.8, 46.6, 29.0, 25.7.
Preparation 144: (aR)- 2-r4-(4-Chlorophenoxy)-phenyll-α-(2-methylethyl)- 2- oxo-l,3,2-oxazaphosphorinane-3-acetic acid (diastereomer 1, compound 344).
General procedure 3.
Starting material: Compound 278
13C NMR (CD3OD) δ 175.4, 162.0, 156.0, 135.0, 131.2, 130.6, 126.2, 122.4, 119.0, 69.1, 65.7, 42.8, 28.3, 27.9, 20.1, 20.0.
Preparation 145: (aR)- α-(2-Methylethyl)- 2-oxo-2-f4-(4- trifluoromethylphenoxy)-phenyn-lr3.2-oxazaphosphorinane-3-acetic acid (diastereomer 1, compound 345). General procedure 3.
Starting material: Compound 287
13C NMR (CD3OD) δ 174.8, 160.9, 160.8, 135.1, 128.6, 125.0, 120.4, 120.2, 69.2,
65.3, 42.7, 28.3, 27.8, 20.1, 19.9. Preparation 146: (aR)- α-(2-Methylethyl)- 2-oxo-2-r4-(4- trifluoromethylphenoxy)-phenyll-l,3r2-oxazaphosphorinane-3-acetic acid (diastereomer 2, compound 346). General procedure 3. Starting material: Compound 288
MS. Calcd for C2ιH23F3Nθ5P 457.13, Found [M+H] = 458, [M-H]" = 456.
Preparation 147: (+)-2-r4-(4-Bromophenoxy)-phenyπ-2-oxo-l,3,2- oxazaphosphorinane-3-acetic acid (compound 347). General procedure 3.
Starting material: Compound 289
13C NMR (CD3OD) δ 173.3, 162.3, 156.5, 135.3, 134.2, 125.6, 122.9, 119.1,
118.1, 69.1, 49.7, 48.5, 27.2.
Preparation 148: (+)-2-r4-(4-Bromophenoxy)-phenyπ-2-oxo-1.3,2- oxazaphosphorepane-3-acetic acid (compound 348).
General procedure 3.
Starting material: Compound 290
13C NMR (CD3OD) δ 176.9, 161.8, 156.7, 134.9, 134.2, 125.8, 122.8, 118.9, 117.9, 67.3, 50.8, 30.7, 27.9.
Preparation 149: (±)-2-(4-Nitrophenyl)-2-oxo-lf3,2-oxazaphosphorepane-3- acetic acid (compound 349). General procedure 3. Starting material: Compound 291.
XW NMR (DMSO-d6) δ 8.27 (m, 2H), 8.18 (m, 2H), 6.7 (bs, IH), 4.43 (q, IH), 4.11 (dd, IH), 3.90 (dd, IH), 3.60 (dd, IH), 2.93 (m, 2H), 1.87-1.50 (m, 4H).
Preparation 150: (±)-2-r/v-(4-Chlorobenzoyl)-4-aminophenyl1-2-oxo-l,3,2- oxazaphosphorepane-3-acetic acid (compound 350).
General procedure 3.
Starting material: Compound 292
XH NMR (DMSO-d6) δ 10.51 (bs, IH), 8.00 (m, 2H), 7.85 (m, 4H), 7.62 (m, 2H),
4.37 (q, IH), 4.03 (dd, IH), 3.87 (dd, IH), 3.59 (dd, IH), 2.95 (m, 2H), 1.85- 1.45 (m, 4H).
Preparation 151: (±)-2-(Λ/-Benzoyl-4-aminophenyl)-2-oxo-l,3f2- oxazaphosphorepane-3-acetic acid (compound 351). General procedure 3. Starting material: Compound 293
13C NMR (CD3OD) δ 174.4, 169.0, 143.6, 136.1, 133.4, 133.1, 129.7, 128.7, 126.5, 121.3, 67.2, 30.7, 27.7.
Preparation 152: (±)-2-Phenyl-2-thioxo-lr3,2-oxazaphosphorinane-3-acetic acid (compound 352).
Preparation 153: (+)-2-Phenyl-2-thioxo-l,3,2-oxazaphosphorepane-3-acetic acid (compound 353).
General procedure 3.
Starting material: Compound 275.
13C NMR (DMSO-d6) δ 172.2, 135.4, 131.1, 130.0, 128.1, 64.4, 48.9, 47.5, 28.5,
25.0.
Example 1: (±)-2-(4-Chlorophenoxy)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohvdroxamic acid (compound 101).
General procedure 2.
Starting material: Compound 210. 13C NMR (DMSO-de) δ 165.0, 149.5, 129.5, 128.5, 122.0, 70.2, 48.0, 47.6, 25.3.
Example 2: (+)-2-(4-Chlorophenoxy)-2-oxo-l,3f2-oxazaphosphorepane-3- acetohydroxamic acid (compound 102). General procedure 2. Starting material: Compound 211.
MS. Calcd for C12H16CIN2θ5P 334.05, Found [M + H]+ = 335, [M + Na]+ = 357.
Example 3: (±)-2-r(4-Bromophenyl)methyl]-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (compound 103). General procedure 2.
Starting material: Compound 212. lH NMR (DMSO-de) δ 10.0-8.0 (bs, 2H), 7.47 (m, 2H), 7.27 (m, 2H), 4.21 (m,
2H), 3.70-2.90 (m, 6H), 1.92 (m, IH), 1.49 (m IH). '
Example 4: (+)-2-r(4-Biphenylyl)methyll-2-oxo-lf3r2-oxazaphosphorinane-3- acetohydroxamic acid (compound 104). General procedure 2. Starting material: Compound 213. XH NMR (DMSO-d6) δ 11.0-8.0 (bs, 2H), 7.65 (m, 2H), 7.59 (m, 2H), 7.46 (m, 2H), 7.42-7.30 (m, 3H), 4.24 (m, 2H), 3.65-3.15 (m, 5H), 3.02 (m, IH), 1.94 (m, IH), 1.51 (m IH).
Example 5: (+)-2-(4-Biphenylyl)-2-oxo-lr3,2-oxazaphosphorinane-3-aceto- hydroxamic acid (compound 105). General procedure 2. Starting material: Compound 214.
*H NMR (DMSO-d6) δ 11.0-9.8 (bs, IH), 9.2-8.7 (bs, IH), 7.87 (m, IH), 7.80 (m, 3H), 7.72 (m, 2H), 7.51 (m, 2H), 7.42 (m, IH), 4.36 (m, IH), 4.13 (m, IH), 3.58 (m, 2H), 3.40-3.10 (m, 2H), 2.07 (m, IH), 1.86 (m, IH).
Example 6: (+)-2-(4-Biphenylyl)-2-oxo-lr3r2-oxazaphosphorepane-3-aceto- hydroxamic acid (compound 106). General procedure 2.
Starting material: Compound 215.
13C NMR (DMSO-de) δ 166.8, 142.9, 139.4, 131.7, 130.2, 129.1, 128.1, 126.9,
126.5, 64.8, 46.5, 29.0, 25.9.
Example 7: (±)-2-Heptyl-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid (compound 107).
General procedure 2.
Starting material: Compound 216.
*H NMR (DMSO-d6) δ 11.0-9.8 (bs, IH), 9.1-8.6 (bs, IH), 4.16 (m, 2H), 3.55 (dd, IH), 3.40-3.15 (m, 2H), 2.98 (m, IH), 2.05-1.60 (m, 4H), 1.55-1.12 (m, 10H),
0.87 (t, 3H).
Example 8: (±)-2-Heptyl-2-oxo-l,3.2-oxazaphosphorepane-3-acetohvdroxamic acid (compound 108). General procedure 2.
Starting material: Compound 217.
13C NMR (DMSO-de) δ 166.9, 63.5, 46.6, 46.4, 31.0, 30.1, 28.9, 28.2, 26.1, 25.6,
22.1, 22.0, 13.8.
Example 9: (+)-2-Oxo-2-r4-(phenylamino)phenyll-lf3,2-oxazaphosphorinane-3- acetohydroxamic acid (compound 109). General procedure 2. Starting material: Compound 218. *H NMR (DMSO-d6) δ 11.0-9.8 (bs, IH), 9.15-8.50 (m, 2H), 7.59 (m, 2H), 7.30 (m, 2H), 7.16 (m, 2H), 7.09 (m, 2H), 6.95 (m, IH), 4.29 (m, IH), 4.08 (m, IH), 3.70-2.80 (m, 4H), 2.00 (m, IH), 1.88 (m, IH).
Example 10: (±)-2-Oxo-2-phenyl-lf3r2-oxazaphosphorinane-3-acetohydroxamic acid (compound 110). General procedure 2. Starting material: Compound 219.
XH NMR (DMSO-e) δ 10.6-9.9 (bs, IH), 9.1-8.7 (bs, IH), 7.77 (m, 2H), 7.53 (m, 3H), 4.34 (m, IH), 4.10 (m, IH), 3.75-2.50 (m, 4H), 2.04 (m, IH), 1.82 (m, IH).
Example 11: (+)-2-Oxo-2-phenyl-l,3f2-oxazaphosphorepane-3-acetohydroxamic acid (compound 111). General procedure 2. Starting material: Compound 220.
13C NMR (DMSO-de) δ 166.7, 131.5, 131.3, 131.0, 128.2, 64.7, 46.5, 46.4, 29.0, 25.9.
Example 12: 2-Oxo-2-phenyl-l,3,2-oxazaphosphoronane-3-acetohydroxamic acid (compound 112).
General procedure 2.
Starting material: Compound 297.
XH NMR (DMSO-d6) δ 10.53 (bs, IH), 8.91 (bs, IH), 7.97 (m, 2H), 7.59-7.42 (m,
3H), 4.48 (m, IH), 4.01 (dd, IH), 3.88 (m, IH), 3.42 (m, IH), 2.89 (m, IH), 2.62 (m, IH), 1.90-1.60 (m, 2H), 1.58-1.05 (m, 6H).
Example 13: (+)-α-Butyl-2-oxo-2-phenyl-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (compound 113). General procedure 1. Starting material: Compound 307.
13C NMR (DMSO-d6) δ 168.1, 131.4, 131.1, 130.7, 128.1, 64.7, 55.0, 42.2, 31.2, 29.4, 28.7, 28.0, 21.9, 13.8.
Example 14: (±)-α-Butyl-2-oxo-2-phenyl-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (compound 114). General procedure 1. Starting material: Compound 308. XH NMR (DMSO-de) δ 10.60 (bs, IH), 8.86 (bs, IH), 7.72 (m, 2H), 7.56 (m, IH), 7.49 (m, 2H), 4.34 (m, IH), 4.11 (m, IH), 3.94 (m, IH), 2.84 (m, IH), 1.86-1.49 (m, 5H), 1.26 (m, IH), 1.09 (m, 2H), 0.85 (m, 2H), 0.67 (t, 3H).
Example 15: (±)-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (compound 115). General procedure 2. Starting material: Compound 223.
*H NMR (DMSO-e) δ 11.0-8.0 (m, 2H), 7.71 (m, 2H), 7.04 (m, 2H), 4.30 (m, IH), 4.06 (m, IH), 3.82 (s, 3H), 3.46 (m, 2H), 3.21 (m, 2H), 2.01 (m, IH), 1.85 (m, IH).
Example 16: (+)-2-(4-Methoxyphenyl)-2-oxo-lf3,2-oxazaphosphorepane-3- acetohydroxamic acid (compound 116). General procedure 2. Starting material : Compound 224.
13C NMR (DMSO-d6) δ 166.7, 161.5, 132.8, 122.7, 113.6, 64.4, 55.1, 46.4, 46.3, 28.9, 25.8.
Example 17: (+)-2-(4-Methoxyphenyl)-2-oxo-lr3,2-oxazaphosphoronane-3- acetohydroxamic acid (compound 117).
General procedure 2.
Starting material: Compound 225.
13C NMR (DMSO-de) δ 166.4, 161.6, 133.5, 122.4, 113.7, 59.6, 55.3, 44.0, 41.5,
27.3, 23.9, 18.5, 17.9.
Example 18: (αR)-2-(4-Methoxyphenyl)-α-(l-methylethyl)-2-oxo-lr3f2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer lf compound 118).
General procedure 1.
Starting material: Compound 300. XH NMR (CD3OD) δ 7.60 (m, 2H), 7.06 (m, 2H), 4.36 (m, IH), 4.11 (m, IH), 3.85
(s, 3H), 3.71 (m, IH), 3.42 (m, 2H), 2.30 (m, IH), 2.11 (m, IH), 1.86 (m, IH),
1.12 (d, 3H), 0.96-0.88 (d, 3H).
Example 19: fαfl)-2-(4-Methoxyphenyl)-α-(l-methylethyl)-2-oxo-lf3r2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 2, compound 119). General procedure 1. Starting material: Compound 301. 13C NMR (DMSO-d6) δ 167.9, 161.8, 133.6, 122.2, 113.7, 66.3, 60.4, 55.2, 25.7, 25.6, 19.3, 19.3.
Example 20: (+)- α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3.2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomers 1, compound 120).
General procedure 1.
Starting material: Compound 311.
13C NMR (DMSO-d6) δ 168.0, 161.5, 132.8, 122.5, 114.1, 67.2, 55.2, 53.9, 41.2,
29.4, 27.6, 26.7, 21.7, 13.8.
Example 21 : (+)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3f2-oxazaphosphorinane- 3-acetohydroxamic acid (diastereomers 2, compound 121). General procedure 1. Starting material: Compound 312. 13C NMR (CDCI3) δ 168.7, 163.3, 134.6, 119.6, 114.0, 66.4, 55.4, 55.0, 40.5, 27.8, 26.6, 26.3, 22.1, 13.9.
Example 22: (+)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3r2-oxazaphosphorepane- 3-acetohydroxamic acid (diastereomers 1, compound 122). General procedure 1.
Starting material: Compound 313.
13C NMR (DMSO-de) δ 168.2, 161.3, 132.6, 122.8, 113.6, 64.5, 55.1, 55.0, 42.1,
31.2, 29.4, 28.7, 28.0, 21.9, 13.9.
Example 23: (+)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3f2-oxazaphosphorepane-
3-aceto hydroxamic acid (diastereomers 2, compound 123).
General procedure 1.
Starting material: Compound 314.
13C NMR (DMSO-de) δ 168.1, 161.6, 132.7, 122.7, 113.7, 64.9, 55.2, 54.2, 41.0, 28.8, 28.4, 27.8, 27.5, 21.6, 13.6.
Example 24: f±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3f2-oxazaphosphorocane- 3-acetohvdroxamic acid (diastereomers 1, compound 124). General procedure 1. Starting material: Compound 315.
H-) NMR (DMSO-d6) δ 10.77 (bs, IH), 8.75 (bs, IH), 7.59 (m, 2H), 6.99 (m, 2H), 4.26 (m, IH), 3.94 (m, 2H), 3.80 (s, 3H), 3.53 (m, IH), 2.82 (m, IH), 1.93-1.40 (m, 8H), 1.27 (m, 2H), 1.17 (m, 2H), 0.84 (t, 3H). Example 25: (+)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorocane- 3-acetohydroxamic acid (diastereomers 2, compound 125). General procedure 1. Starting material: Compound 316. MS. Calcd for C18H29N205P 384.18, Found [M+H]+ = 385, [M-H]" = 383.
Example 26: (+)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane- 3-acetohydroxamic acid (diastereomers 1, compound 126). General procedure 1. Starting material: Compound 317.
13C NMR (DMSO-d6) δ 167.4, 161.6, 134.4, 132.8, 122.5, 117.4, 114.1, 67.1, 55.2, 53.6, 41.1, 34.2, 26.6.
Example 27: (+)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane- 3-acetohvdroxamic acid (diastereomers 2, compound 127).
General procedure 1.
Starting material: Compound 318.
13C NMR (DMSO-d6) δ 167.6, 162.0, 134.5, 133.7, 121.6, 117.3, 113.9, 66.7,
55.2, 54.0, 32.8, 25.7.
Example 28: (+)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-lf3f2-oxazaphosphorepane-
3-acetohydroxamic acid (diastereomers 1, compound 128).
General procedure 1.
Starting material: Compound 331. 13C NMR (DMSO-de) δ 167.5, 161.4, 134.6, 132.7, 122.7, 117.5, 113.7, 64.5,
55.1, 54.5, 42.0, 35.6, 29.0, 28.7.
Example 29: (+)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-lr3,2-oxazaphosphorepane- 3-acetohvdroxamic acid (diastereomers 2, compound 129). General procedure 1.
Starting material: Compound 332. l NMR (DMSO-de) δ 10.54 (bs, IH), 8.87 (bs, IH), 7.64 (m, 2H), 7.03 (m, 2H), 5.39 (m, IH), 4.94 (dd, IH), 4.81 (dd, IH), 4.33 (m, IH), 4.05 (m, 2H), 3.81 (s 3H), 2.81 (m, IH), 2.39 (m, IH), 2.07 (m, IH), 1.76 (m, 2H), 1.57 (m, 2H).
Example 30: (gβ)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3.2- oxazaphosphorinane-3-acetohvdroxamic acid (diastereomer lf compound 130). General procedure 1. Starting material: Compound 319.
13C NMR (DMSO-d6) δ 168.0, 161.6, 132.8, 122.4, 114.1, 67.2, 55.2, 52.1, 41.1,
26.7, 24.0, 22.8, 21.9.
Example 31: (αfl)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-lr3,2- oxazaphosphorinane-3-acetohvdroxamic acid (diastereomer 2, compound 131). General procedure 1. Starting material: Compound 320.
13C NMR (DMSO-d6) δ 168.1, 162.0, 133.5, 121.9, 113.9, 66.5, 55.3, 52.0, 40.1, 37.3, 25.8, 23.7, 22.3, 21.8.
Example 32: (αS)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-lf3r2- oxazaphosphorinane-3-acetohvdroxamic acid (diastereomer 1, compound 132). General procedure 1. Starting material: Compound 323.
13C NMR (DMSO-de) δ 168.1, 161.5, 132.8, 122.5, 114.1, 67.2, 55.2, 52.1, 41.1,
26.8, 24.0, 22.8, 21.9.
Example 33: (αS)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-lf3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 2, compound 133).
General procedure 1.
Starting material: Compound 324.
13C NMR (DMSO-de) δ 168.1, 162.0, 133.5, 122.0, 113.9, 66.5, 55.3, 52.0, 40.1,
37.3, 25.8, 23.7, 22.3, 21.8.
Example 34: (±)-2-(4-MethoxyphenyD- α-(2-methylpropyl)-2-oxo-l,3,2- oxazaphosphorepane-3-acetohydroxamic acid (diastereomers 1, compound 134).
General procedure 1.
Starting material : Compound 321. 13C NMR (DMSO-d6) δ 168.1, 161.3, 132.7, 122.7, 113.6, 64.5, 55.1, 53.2, 41.9,
40.5, 29.3, 28.7, 24.3, 22.5, 22.4.
Example 35: (+)-2-(4-Methoχyphenyl)- g-(2-methylpropyl)-2-oxo-l,3,2- oxazaphosphorepane-3-acetohydroxamic acid (diastereomers 2, compound 135). General procedure 1.
Starting material: Compound 322.
XH NMR (DMSO-de) δ 10.3 (bs, IH), 8.85 (bs, IH), 7.64 (m, 2H), 7.03 (m, 2H),
4.31 (m, IH), 4.03 (m, 2H), 3.80 (s, 3H), 2.82 (m, IH), 1.75 (m, 2H), 1.56 (m, 3H), 1.30-0.88 (m, 2H), 0.75 (d, 3H), 0.69 (d, 3H).
Example 36: (+)-2-(4-MethoxyphenyO- α-propyl-2-oxo-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomers 1, compound 136).
General procedure 1.
Starting material: Compound 329.
*H NMR (DMSO-d6) δ 10.40 (bs, IH), 8.85 (bs, IH), 7.56 (m, 2H), 7.03 (m, 2H),
4.25 (m, IH), 3.95 (m, 2H), 3.81 (s, 3H), 3.57 (m, IH), 3.16 (m, IH), 1.96-1.20
(m, 6H), 0.92 (t, 3H).
Example 37: (±)-2-(4-MethoxyphenyD- α-propyl-2-oxo-1.3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomers 2, compound 137). General procedure 1. Starting material: Compound 330. *H NMR (DMSO-de) δ 10.57 (bs, IH), 8.86 (bs, IH), 7.67 (m, 2H), 7.06 (m,
2H),4.36-4.10 (m, 2H), 3.82 (s, 3H), 3.62 (m, IH), 3.48 (m, IH), 3.10 (m, IH), 2.01 (m, IH), 1.90 (m, IH), 1.58 (m, IH), 1.44 (m, IH), 1.03 (m, IH), 0.88 (m, IH), 0.65 (t, 3H).
Example 38: (+)-2-(4-Methoxyphenyl)- α-octyl-2-oxo-l,3,2-oxazaphosphorepane-
3-acetohydroxamic acid (diastereomers 1, compound 138).
General procedure 1.
Starting material: Compound 325.
13C NMR (CDCI3) δ 168.2, 161.3, 132.6, 122.8, 113.7, 64.5, 55.1, 42.3, 31.5, 31.2, 29.4, 28.9, 28.8, 28.5, 25.8, 22.0, 13.9.
Example 39: (+)-2-(4-Methoxyphenyl)- α-octyl-2-oxo-l,3,2-oxazaphosphorepane- 3-acetohydroxamic acid (diastereomers 2, compound 139). General procedure 1. Starting material: Compound 326.
XH NMR (DMSO-de) δ 10.55 (bs, IH), 8.84 (bs, IH), 7.64 (m, 2H), 7.02 (m, 2H), 4.31 (m, IH), 4.07 (m, IH), 3.91 (q, IH), 3.80 (s, 3H), 3.22 (m, IH), 2.84 (m, IH), 1.85-0.93 (m, 18H), 0.84 (t, 3H).
Example 40: (α/?)-2-(4-Methoxyphenyl)-2-oxo-α-phenylmethyl-l,3.2- oxazaphosphorinane-3-acetohvdroxamic acid (diastereomer 1, compound 140).
General procedure 1.
Starting material: Compound 327 *H NMR (CD3OD) δ 7.64 (m, 2H), 7.32-7.15 (m, 5H), 7.04 (m, 2H), 4.21 (m, 2H), 4.10 (m, IH), 3.84 (s, 3H), 3.83 (m, IH), 3.43 (m, IH), 3.31 (m, IH), 3.06 (dd, IH), 1.87 (m, 2H).
Example 41: (αS)-2-(4-Methoxyphenyl)-2-oxo-α-phenylmethyl-l,3r2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 1, compound 141). General procedures: 3 followed by 1
Starting material: Compound 244 (the intermediate carboxylic acid was not characterized). XH NMR (CD3OD) δ 7.54 (m, 2H), 7.23-7.05 (m, 5H), 6.94 (m, 2H), 4.12 (m, 2H), 3.99 (m, IH), 3.75 (s, 3H), 3.72 (m, IH), 3.40-3.18 (m, 2H), 2.96 (dd, IH), 1.79 (m, 2H).
Example 42: (αS)-2-(4-Methoxyphenyl)-2-oxo-α-phenylmethyl-l,3f2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 2f compound 142).
General procedures: 3 followed by 1
Starting material: Compound 245 (the intermediate carboxylic acid was not characterized).
XH NMR (DMSO-de) δ 10.55 (bs, IH), 8.90 (bs, IH), 7.23-7.16 (m, 3H), 7.10-6.94 (m, 4H), 6.78 (m, 2H), 4.27 (m, IH), 4.05 (m, 2H), 3.78 (s, 3H), 3.63 (m, IH),
3.12 (m, IH), 2.90 (m, 2H), 2.06 (m, IH), 1.75 (m, IH).
Example 43: (±)-2-Oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (compound 143). General procedure 2.
Starting material: Compound 248. H NMR (DMSO-de) δ 10.5-8.5 (m, 2H), 7.78 (m, 2H), 7.45 (m, 2H), 7.23 (m,
IH), 7.11 (m, 2H), 7.05 (m, 2H), 4.32 (m, IH).
Example 44: (±)-2-Oxo-2-(4-phenoxyphenyl)-lr3,2-oxazaphosphorepane-3- aceto hydroxamic acid (compound 144).
General procedure 2.
Starting material: Compound 249.
XH NMR (DMSO-de) δ 11.0-10.1 (bs, IH), 9.3-8.5 (bs, IH), 7.82 (m, 2H), 7.44 (m, 2H), 7.22 (m, IH), 7.10 (m, 2H), 7.03 (m, 2H), 4.35 (m, IH), 4.05 (m, IH),
3.82 (m, IH), 3.54 (m, IH), 2.91 (m, 2H), 1.88-1.43 (m, 4H). Example 45: (±)-2-Oxo-2-(4-phenoxyphenyl)-1.3,2-oxazaphosphorocane-3- acetohydroxamic acid (compound 145). General procedure 2. Starting material: Compound 250. XH NMR (DMSO-de) δ 10.1 (bs, IH), 8.89 (bs, IH), 7.89 (m, 2H), 7.44 (m, 2H), 7.22 (m, IH), 7.09 (m, 2H), 7.02 (m, 2H), 4.23 (m, IH), 4.04-3.80 (m, 2H), 3.43 (m, IH), 2.94 (m, 2H), 1.89-1.20 (m, 6H).
Example 46: (+)-α-Allyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane- 3-acetohydroxamic acid (diastereomers 1, compound 146).
General procedure 1.
Starting material: Compound 333.
13C NMR (DMSO-de) δ 167.6, 160.0, 155.2, 134.4, 134.0, 130.2, 124.7, 124.4,
119.6, 117.4, 117.4, 66.9, 54.0, 40.3, 32.9, 25.7.
Example 47: (+)-α-Allyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomers 2f compound 147).
General procedure 1.
Starting material: Compound 334. *H NMR (DMSO-d6) δ 10.3 (bs, IH), 9.2 (bs, IH), 7.63 (m, 2H), 7.45 (m,
2H),7.23 (m, IH), 7.11 (m, 2H), 7.04 (m, 2H), 5.76 (m, IH), 5.17 (m, IH), 5.09
(m, IH), 4.26 (m, IH), 4.10 (m, IH), 3.98 (m, IH), 3.61 (m, IH), 3.17 (m, IH),
2.50 (m, 2H), 1.89 (m, IH), 1.70 (m, IH).
Example 48: fαfl)-α-(2-Methylpropyl)-2-oxo-2-(4-phenoxyphenyl)-lf3f2- oxazaphosphorinane-3-acetohvdroxamic acid (diastereomer 1, compound 148).
General procedure 1.
Starting material: Compound 337.
13C NMR (DMSO-d6) δ 168.0, 159.9, 155.3, 133.9, 130.2, 125.1, 124.4, 119.4, 117.6, 66.8, 52.0, 37.4, 25.9, 23.7, 22.3, 21.9.
Example 49: (α ?)-g-(2-Methylpropyl)-2-oxo-2-(4-phenoxyphenyl)-lf3f2- oxazaphosphorinane-3-acetohvdroxamic acid (diastereomer 2, compound 149). General procedure 1. Starting material: Compound 338.
13C NMR (DMSO-de) δ 168.0, 159.6, 155.1, 133.1, 130.2, 125.4, 124.4, 119.7, 117.5, 67.4, 52.1, 41.0, 26.7, 24.0, 22.8, 21.9. Example 50: (αK)-g-(2-Methylethyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 1, compound 150). General procedure: 1. Starting material: Compound 341 XH NMR (DMSO-de) δ 10.64/9.51 (s, IH), 8.82/8.63 (s, IH), 7.56 (m, 2H), 7.45 (m, 2H), 7.23 (m, IH), 7.11 (m, 2H), 7.04 (m, 2H), 4.28 (m, IH), 3.96 (m, IH), 3.64 (m, IH), 3.53 (t, IH), 3.14 (m, IH), 2.15 (m, IH), 1.94 (m, IH), 1.69 (m, IH), 1.01 (d, 3H), 0.82 (d, 3H).
Example 51: (αK)-α-(2-Methylethyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 2, compound 151).
General procedure: 1.
Starting material: Compound 342
*H NMR (DMSO-d6) δ 10.4 (bs, IH), 8.87 (s, IH), 7.76 (m, 2H), 7.45 (m, 2H), 7.23 (m, IH), 7.13-7.01 (m, 4H), 4.28 (m, 2H), 3.56 (m, IH), 3.16 (m, IH), 3.08
(m, IH), 2.19-1.74 (m, 3H), 0.72 (d, 3H), 0.50 (d, 3H).
Example 52: (±)-g-Butyl-2-oxo-2-(4-phenoxyphenyl)-lr3.2-oxazaphosphorepane-
3-acetohvdroxamic acid (diastereomers lr compound 152). General procedure: 1.
Starting material: Compound 335.
*H NMR (DMSO-d6) δ 10.66 (bs, IH), 8.72 (bs, IH), 7.67 (dd, 2H), 7.44 (bt, 2H),
7.22 (bt, IH), 7.10 (bd, 2H), 6.99 (dd, 2H), 4.36 (q, IH), 4.16-3.75 (m, 3H),
2.74 (m, IH), 1.90-1.12 (m, 10H), 0.88 (t, 3H).
Example 53: (±)-α-Butyl-2-oxo-2-(4-phenoxyphenyl)-1.3.2-oxazaphosphorepane-
3-acetohydroxamic acid (diastereomers 2. compound 153).
General procedure: 1.
Starting material: Compound 336. *H NMR (DMSO-de) δ 10.58 (bs, IH), 8.86 (bs, IH), 7.72 (m, 2H), 7.44 (m, 2H),
7.22 (m, IH), 7.07 (m, 2H), 7.05 (m, 2H), 4.33 (m, IH), 4.09 (m, IH), 3.92 (q,
IH), 3.31 (m, IH), 2.84 (m, IH), 1.88-1.50 (m, 4H), 1.29 (m, 2H), 1.11 (m, 2H),
0.87 (m, 2H), 0.70 (t, 3H).
Example 54: (±)-α-Octyl-2-oxo-2-(4-phenoxyphenyl)-1.3,2-oxazaphosphorepane- 3-acetohydroxamic acid (diastereomers lr compound 154). General procedure: 1. Starting material : Compound 339. MS. Calcd for C26H37N205P 488.24, Found [M+H]+ = 489, [M-H]" = 487.
Example 55: (±)- α-Octyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2- oxazaphosphorepane-3-acetohydroxamic acid (diastereomers 2, compound 155).
General procedure: 1.
Starting material: Compound 340.
XH NMR (DMSO-d6) δ 10.65 (bs, IH), 8.71 (bs, IH), 7.67 (m, 2H), 7.44 (m, 2H),
7.22 (m, IH), 7.10 (m, 2H), 6.99 (dd, 2H), 4.36 (q, IH), 4.17-3.75 (m, 3H), 2.75
(m, IH), 1.89-1.10 (m, 18H), 0.87 (t, 3H).
Example 56: (±)-2-Oxo-2-(2-phenylethyl)-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (compound 156). General procedure 2. Starting material: Compound 260. *H NMR (DMSO-de) δ 11.0-9.2 (bs, IH), 9.2-8.5 (bs, IH), 7.28 (m, 4H), 7.19 (m, IH), 4.21 (m, 2H), 3.63 (dd, IH), 3.42-3.20 (m, 2H), 3.00 (m, IH), 2.76 (m, 2H), 2.28-1.88 (m, 3H), 1.72 (m, IH).
Example 57: (±)-2-(4-Methoxyphenyl)-2-oxo-l,3f2-oxazaphosphorocane-3- acetohydroxamic acid (compound 157).
General procedure 2.
Starting material: Compound 261.
13C NMR (DMSO-de) δ 166.5, 161.6, 133.1, 123.0, 113.6, 65.3, 55.3, 44.7, 44.6,
28.1, 24.6, 24.1.
Example 58: (+)-2-Oxo-2-phenyl-lf3f2-oxazaphosphorocane-3-acetohydroxamic acid (compound 158).
General procedure 2.
Starting material : Compound 262. 13C NMR (DMSO-de) δ 166.3, 131.7, 131.3, 131.1, 128.1, 65.5, 44.6,44.5, 28.0,
24.5, 24.2.
Example 59: (±)-2-Heptyl-2-oxo-l,3,2-oxazaphosphorocane-3-acetohydroxamic acid (compound 159). General procedure 2.
Starting material: Compound 263.
13C NMR (DMSO-d6) δ 166.5, 64.8, 44.5, 43.9, 31.0, 30.1, 28.2, 27.9, 26.2, 24.7,
24.1, 22.0, 22.0, 13.8. Example 60: (α£)-2-(4-Biphenylyl)-g-(l-methylethyl)-2-oxo-1.3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 2, compound 160). General procedure 1. Starting material: Compound 302. MS. Calcd for C20H25N2O4P 388.16, Found [M + H]+ = 389,[M + Na]+ = 411.
Example 61: (+)-2- r4-(4-Chlorophenyloxy)-phenyll-2-oxo-l,3,2- oxazaphosphorepane-3-acetohydroxamic acid (compound 161). General procedure 2. Starting material: Compound 268.
13C NMR (DMSO-de) δ 166.6, 159.0, 154.4, 133.3, 130.0, 128.0, 126.1, 121.2, 117.5, 64.6, 46.4, 28.9, 25.8.
Example 62: (+)-2- r4-(4-Chlorophenyloxy)-phenyll-2-oxo-l,3,2- oxazaphosphorocane-3-acetohydroxamic acid (compound 162).
General procedure 2.
Starting material: Compound 269.
13C NMR (DMSO-de) δ 166.2, 159.0, 154.4, 133.4, 130.0, 128.0, 126.4, 121.1,
117.5, 65.5, 44.3, 27.9, 24.4, 24.0.
Example 63: (α ?)-2- r4-(4-Chlorophenyloxy)-phenyl1-α-(2-methylethyl)-2-oxo- l,3,2-oxazaphosphorinane-3-acetohydroxamic acid (compound 163).
General procedure 1.
Starting material: Compound 344. *H NMR (DMSO-de) δ 10.64 (bs, IH), 8.81 (s, IH), 7.58 (m, 2H), 7.49 (m, 2H),
7.14 (m, 2H), 7.07 (m, 2H), 4.28 (m, IH), 3.97 (m, IH), 3.66 (m, IH), 3.52 (m,
IH), 3.14 (m, IH), 2.16 (m, IH), 1.94 (m, IH), 1.70 (m, IH), 1.01 (d, 3H), 0.82
(d, 3H).
Example 64: (±)-2-(4,-Bromo-4-biphenylyl)-2-oxo-lf3f2-oxazaphosphorinane-3- acetohydroxamic acid (compound 164).
General procedure 2.
Starting material: Compound 270.
XH NMR (DMSO-de) δ 10.4 (bs, IH), 9.0 (bs, IH), 7.93-7.74 (m, 4H), 7.69 (bs, 4H), 4.36 (m, IH), 4.13 (m, IH), 3.69-3.13 (m, 4H), 2.06 (m, IH), 1.86 (m, IH).
Example 65: (±)-2-(4,-Bromo-4-biphenylyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (compound 165). General procedure 2.
Starting material: Compound 271.
13C NMR (DMSO-de) δ 166.6, 141.5, 138.4, 131.8, 131.7, 130.6, 128.9, 126.3,
121.6, 64.7, 46.4, 46.3, 28.9, 25.8.
Example 66: (±)-2-(4'-Bromo-4-biphenylyl)-2-oxo-l,3,2-oxazaphosphorocane-3- acetohvdroxamic acid (compound 166). General procedure 2. Starting material: Compound 272. MS. Calcd for C19H22BrN204P 452.05, Found [M-H]" = 451.
Example 67: (+)- 2-r2-(l-Naphtyl)-ethyll-2-oxo-l,3f2-oxazaphosphorinane-3- acetohydroxamic acid (compound 167). General procedure: 2. Starting material: Compound 273
13C NMR (CDCI3) δ 166.9, 136.7, 133.9, 131.3, 129.0, 127.3, 126.3, 125.8, 125.7, 125.6, 123.2, 67.0, 49.6, 47.4, 27.3, 26.0, 25.8.
Example 68: (+)-2-Phenyl-2-thioxo-l,3,2-oxazaphosphorinane-3-acetohydrox- amic acid (compound 168). General procedure 2. Starting material: Compound 274. 13C NMR (DMSO-d6) δ 165.2, 132.7, 132.2, 131.2, 128.5, 66.3, 49.4, 46.5, 25.5.
Example 69: (±)-2-Phenyl-2-thioxo-l,3r2-oxazaphosphorepane-3-acetamide
(compound 169).
General procedure 2.
Starting material: Compound 275.
13C NMR (DMSO-d6) δ 166.5, 135.6, 130.9, 130.1, 128.0, 64.3, 47.3, 46.9, 28.4, 24.8.
Example 70: (+)-2-Phenyl-2-thioxo-1.3r2-oxazaphosphorocane-3-acetamide (compound 170). General procedure 2. Starting material: Compound 276.
13C NMR (DMSO-de) δ 166.0, 136.0, 130.9, 130.4, 128.0, 65.5, 44.9, 44.4, 27.5, 24.1, 23.8. Example 71: (+)-2- r4-(4-Chlorophenyloxy)-phenyh -2-oxo-l,3,2-oxazaphos- phorinane-3-acetohydroxamic acid (compound 171). General procedure: 2 Starting material: Compound 277. 13C NMR (DMSO-d6) δ 165.7, 159.4, 154.2, 133.7, 130.0, 128.2, 125.7, 121.4, 117.7, 67.1, 47.9, 47.1, 25.4.
Example 72: (+)-2-(4-Bromophenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (compound 172). General procedure 2.
Starting material: Compound 280.
*H NMR (DMSO-d6) δ 10.6-9.8 (bs, IH), 9.2-8.7 (bs, IH), 7.71 (m, 4H), 4.34 (m,
IH), 4.12 (m, IH), 3.95-3.30 (m, 2H), 3.25 (m, 2H), 2.05 (m, IH), 1.83 (m, IH).
Example 73: (+)-2-(4-Bromophenyl)-2-oxo-lr3,2-oxazaphosphorepane-3- acetohydroxamic acid (compound 173).
General procedure 2.
Starting material: Compound 281.
13C NMR (DMSO-de) δ 166.5, 133.0, 131.1, 130.7, 125.2, 64.8, 46.4, 46.3, 28.8, 25.8.
Example 74: (±)-2-Oxo-2-(4-phenylmethoxyphenyl)-l,3r2-oxazaphosphorinane- 3-acetohydroxamic acid (compound 174). General procedure 2. Starting material: Compound 282.
XH NMR (DMSO-d6) δ 7.72 (m, 2H), 7.50-7.30 (m, 5H), 7.12 (m, 2H), 5.17 (s, 2H), 4.30 (m, IH), 4.07 (m, IH), 3.46 (m, 2H), 3.22 (m, 2H), 2.01 (m, IH), 1.85 (m, IH).
Example 75: (+)-2-Oxo-2-(4-phenylmethoxyphenyl)-l,3,2-oxazaphosphorepane-
3-acetohydroxamic acid (compound 175).
General procedure 2.
Starting material : Compound 283.
13C NMR (DMSO-de) δ 166.7, 160.5, 136.6, 132.8, 128.4, 127.8, 127.6, 123.0, 114.4, 69.2, 64.5, 46.3, 28.9, 25.7.
Example 76: (+)-2-Oxo-2-(4-phenylmethoxyphenyl)-l,3,2-oxazaphosphorocane- 3-acetohydroxamic acid (compound 176). General procedure 2. Starting material: Compound 284.
13C NMR (DMSO-de) δ 166.3, 160.5, 136.6, 133.0, 128.4, 127.8, 127.6, 123.2, 114.3, 69.1, 65.2, 44.4, 27.9, 24.5, 24.0.
Example 77: (±)-2- r2-(4-Chlorophenoxy)-phenyll -2-oxo-l,3f2-oxazaphos- phorepane-3-acetohydroxamic acid (compound 177).
Compound 177 was isolated as a by-product from the synthesis of compound 161 (example 61). 13C NMR (DMSO-de) δ 166.9, 157.8, 155.7, 133.6, 133.3, 129.6, 127.2, 123.4, 122.9, 120.5, 119.2, 64.5, 47.3, 47.2, 28.8, 26.0.
Example 78: (±)-2-Oxo-2-f4-(4-trifluoromethylphenoxy)-phenyn-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid (compound 178). General procedure 2.
Starting material: Compound 285.
13C NMR (DMSO-de) δ 165.7, 159.0, 158.2, 133.8, 127.5, 126.9, 124.2, 124.1,
119.1, 118.9, 67.2, 47.9, 47.1, 25.4.
Example 79: (+)-2-Oxo-2-r4-(4-trifluoromethylphenoxy)-phenyl]-l,3,2- oxazaphosphorepane-3-acetohydroxamic acid (compound 179).
General procedure 2.
Starting material: Compound 286.
13C NMR (DMSO-de) δ 166.6, 159.2, 157.8, 133.4, 127.5, 127.2, 124.1, 124.1, 118.9, 118.8, 64.7, 46.4, 28.9, 25.8.
Example 80: (αK)-g-(2-Methylethyl)-2-oxo-2-r4-(4-trifluoromethylphenoxy)- phenyl1-lr3r2-oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 1, compound 180). General procedure 1.
Starting material: Compound 287.
MS. Calcd for C21H24F3N205P 472.14, Found [M+H]+ = 473, [M-H]" = 471.
Example 81 : (αft)-α-(2-Methylethyl)-2-oxo-2-r4-(4-trifluoromethylphenoxy)- phenyll-lr3.2-oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 2r compound 181). General procedure 1. Starting material: Compound 288. MS. Calcd for C21H24F3N205P 472.14, Found [M+H]+ = 473, [M-H]" = 471.
Example 82: (±)-2- r4-(4-Bromophenoxy)-phenyl1 -2-oxo-l,3,2-oxazaphos- phorinane-3-acetohvdroxamic acid (compound 182). General procedure 2.
Starting material: Compound 289. H NMR (DMSO-de) δ 10.1 (bs, IH), 8.8 (bs, IH), 7.79 (m, 2H), 7.61 (m, 2H),
7.13-7.05 (m, 4H), 4.33 (m, IH), 4.11 (m, IH), 3.49 (m, 2H), 3.25 (m, 2H), 2.04
(m, IH), 1.85 (m, IH).
Example 83: (±)-2- r4-(4-Bromophenoxy)-phenyπ -2-oxo-l,3,2-oxazaphos- phorepane-3-acetohydroxamic acid (compound 183).
General procedure 2.
Starting material: Compound 290. 13C NMR (DMSO-de) δ 166.6, 158.9, 154.9, 133.3, 132.9, 126.2, 121.5, 117.6,
116.0, 64.6, 46.4, 28.9, 25.8.
Example 84: (±)-2-(4-nitrophenyl)-2-oxo-lf3r2-oxazaphosphorepane-3- acetohydroxamic acid (compound 184). General procedure 2.
Starting material: Compound 291.
*H NMR (CDCI3) δ 10.5 (bs, IH), 8.9 (bs, IH), 8.24 (m, 2H), 8.04 (m, 2H), 4.60
(m, IH), 4.22 (dd, IH), 3.83 (m, 2H), 3.07 (m, 2H), 1.78 (m, 4H).
Example 85: (±)-2-rΛ/-(4-Chlorobenzoyl)-4-aminophenyll-2-oxo-l,3f2-oxazaphos- phorepane-3-acetohydroxamic acid (compound 185).
General procedure 2.
Starting material: Compound 292.
13C NMR (DMSO-de) δ 166.7, 164.6, 141.6, 136.5, 133.3, 131.7, 129.6, 128.4, 126.1, 119.5, 64.6, 46.5, 46.3, 28.9, 25.8.
Example 86: (+)-2-(Λ/-Benzoyl-4-aminophenyl-2-oxo-l,3f2-oxazaphosphorepane- 3-acetohvdroxamic acid (compound 186). General procedure 2. Starting material: Compound 293.
13C NMR (DMSO-d6) δ 166.7, 165.8, 141.8, 134.6, 131.7, 131.7, 128.3, 127.7, 125.8, 119.4, 64.5, 46.5, 46.3, 28.9, 25.8. Example 87: Capsules containing compound 161.
Compound 161 was dissolved in fractionated coconut oil to a final concentration of 10 mg/ml. Ten parts by weight of gelatine, 5 parts by weight of glycerine, 0.08 parts by weight of potassium sorbate, and 14 parts by weight of distilled water were mixed together with heating and formed into soft gelatine capsules. These were then filled each with 500 μl of the oily solution of compound 161.
Example 88: Tablet containing compound 161 Compound 161 (active substance) 50 mg
Lactose 125 mg
Starch 12 mg
Methyl cellulose 2 mg
Sodium carboxymethyl cellulose 10 mg Magnesium stearate 1 mg
The active substance, lactose and starch are mixed to a homogeneous state in a suitable mixer and moistened with a 5 per cent aqueous solution of methyl cellulose 15 cps. The mixing is continued until granules are formed. If necessary, the wet granulation is passed through a suitable screen and dried to a water content of less than 1% in a suitable drier, e.g. fluid bed or drying oven. The dried granules are passed through a 1 mm screen and mixed to a homogeneous state with sodium carboxymethyl cellulose. Magnesium stearate is added, and the mixing is continued for a short period of time. Tablets with a weight of 200 mg are produced from the granulation by means of a suitable tabletting machine.
Example 89: Formulation for injection containing compound 161. Compound 161 (active substance) 1%
Sodium chloride q.s.
Ethanol 10%
Water for injection to make 100%
The active substance is dissolved in ethanol (10%) then water for injection made isotonic with sodium chloride is added to make 100%. The mixture is filled into ampoules and sterilised.

Claims

WHAT WE CLAIM IS:
1. A compound of general formula I
wherein Y is O or S; n is 1, 2, 3 or 4;
X represents hydroxamic acid, carboxylic acid, phosphonic acid, acetylthiomethyl or a mercaptomethyl group; Rl is
wherein E, when present represents a bond or methylene or ethylene, optionally substituted with halogen, hydroxy, cyano, nitro, (Cι-6)alkyl, haloalkyl, carboxy, amino, alkylamino, hydroxyalkyl, (Cx^al oxy or alkylcarbonyl; s and t are independently 0, 1, 2 or 3;
A and A' independently represent a bond, or a saturated or unsaturated cyclic or heterocyclic hydrocarbon di- or triradical, optionally substituted with (Cr5)alkoxy, (C1.6)alkyl, phenyl, hydroxy, thio, Cι-6alkylthio, amino, halogen, cyano, cyanomethyl, trifluoromethyl, nitro, carboxy, -CONH2, haloalkyl, alkylamino, hydroxyalkyl, alkylcarbonyl, -CONHR12 or -CONR12R12 wherein R12 is a ( . θ)alkyl group or the residue of a natural α-amino acid; Z represents a bond, O, S, C(O), C(0)NR7, NR7C(0) or NR7, wherein R7 is hydrogen, hydroxy, branched or straight, saturated or unsaturated hydrocarbon radical, optionally substituted with halogen, hydroxy, cyano, nitro, haloalkyl carboxy, amino, alkylamino, hydroxyalkyl, alkoxy or alkylcarbonyl ; R5 represents a bond, alkane or alkene diradical, one or more ether diradicals (R- O-R') or amine diradicals (R-N-R'), wherein R and R' independently represent alkane or alkene diradicals with a C-content from 0 to 3; R6 represents hydrogen, hydroxy, halogen, cyano, nitro, branched or straight, saturated or unsaturated hydrocarbon radical, optionally substituted with halogen, hydroxy, cyano, nitro, haloalkyl, amino, alkylamino, carboxy, hydroxyalkyl, alkoxy or alkylcarbonyl; NR8R9, C(0)NR8R9, C(0)R8, C(0)OR8, S(0)2R9, wherein each R8 and R9 independently represent hydrogen, halogen, a branched or straight, saturated or unsaturated hydrocarbon radical, optionally substituted with halogen, hydroxy, cyano, nitro, haloalkyl, hydroxyalkyl, alkoxy or alkylcarbonyl;
R2 represents hydrogen, (Cι-8)alkyl, (C2.5)alkenyl, (C3-8)cycloalkyl, aryl(C0.6)alkyl or heteroaryl(C0-6)alkyl; provided that when A, A', Z and R5 are all bonds, and s and t are both 0 (zero), then R6 is not hydrogen; or a salt, hydrate or solvate thereof.
2. A compound according to claim 1 wherein X is hydroxamic acid or carboxylic acid;
Rl is (Cι-ι2)alkyl, phenyl(Co-δ)alkyl, (d-6)alkylphenyl, or phenoxy, or a group RlOBRll where B represents a bond, a divalent (Cι-6)alkyl, oxygen, NH, sulphur or keto group, RIO and Rll independently represent a phenyl or pyrridyl group, any of which may be substututed with (Cι-6)alkoxy, (Cι-e)alkyl, phenyl, hydroxy, thio, (Cι-6)alkylthio, amino, halogen, cyano, cyanomethyl, trifluoromethyl, nitro, carboxy, -CONH2, C0NHR12, or -CONR12R12, wherein R12 is a (Cι-6)alkyl or the residue of a natural α-amino acid;
R2 is hydrogen, (Cι_5)alkyl, (C2.6)alkenyl, (C3.8)cycloalkyl, phenyl(Cι-6)alkyl, heteroaryl(C0-6)alkyl; Y is oxygen or sulphur; n is 1,2 or 3; or a salt, hydrate or solvate thereof.
3. A compound according to any one of the preceding claims wherein X represents CONHOH, Y represents oxygen and n=2.
4. A compound according to claim 1 wherein Rl is selected from the group consisting of alkoxyphenyl, phenoxyphenyl optionally substituted with halogen, halogen substituted hydrocarbon radical or cyano, phenylalkyl or naphtylalkyl both optionally substituted with halogen, phenyl optionally substituted with halogen or nitro, hydrocarbon radical, biphenyl optionally substituted with halogen, benzylphenoxyl, phenyl-(NH)-C(0)-phenyl optionally substituted with halogen or cyano, and methoxy.
5. A compound according to claim 4 wherein Rl is selected from the group consisting of 4-methoxyphenyl, 4-(4-chloro-phenoxy)-phenyl, 4-(4- bromophenoxy)-phenyl, 4-(4-trifluoromethylphenoxy)-phenyl, 4 ' bromo-4- biphenylyl, Λ/-(4-chlorbenzoyl)-4-aminophenyl, 4-nitrophenyl, Λ/- benzoyl -4- aminophenyl and 4-phenoxyphenyl.
6. A compound according to claim 1 wherein R2 is selected from the group consisting of hydrogen, (Cι.8)alkyl, (C2.6)alkenyl and aryl(C0-6)alkyl.
7. A compound according to claim 6 wherein R2 is selected from the group consisting of hydrogen, isopropyl, allyl, isobutyl, n-butyl, n-octyl and benzyl.
8 A compound according to the preceding claims which is selected form the group consisting of:
(±)-2-(4-Chlorophenoxy)-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-(4-Chlorophenoxy)-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(±)-2-[(4-Bromophenyl)methyl]-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid. (±)-2-[(4-Biphenylyl)methyl]-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2-(4-Biphenylyl)-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(+)-2-(4-Biphenylyl)-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(±)-2-Heptyl-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic (±)-2-Heptyl-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(±)-2-Oxo-2-[4-(phenylamino)phenyl]-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2-Oxo-2-phenyl-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-Oxo-2-phenyl-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid. (±)-2-Oxo-2-phenyl-l,3,2-oxazaphosphoronane-3-acetohydroxamic acid
(±)-α-Butyl-2-oxo-2-phenyl-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(±)-α-Butyl-2-oxo-2-phenyl-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid. (±)-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid. (±)-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphoronane-3-acetohydroxamic acid.
(α ?)-2-(4-Methoxyphenyl)-α-(l-methylethyl)-2-oxo-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 1).
(α ?)-2-(4-Methoxyphenyl)-α-(l-methylethyl)-2-oxo-l,3,2-oxazaphosphorinane- 3-acetohydroxamic acid (diastereomer 2).
(±)- α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 1).
(±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 2). (±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1).
(±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2).
(±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorocane-3- acetohydroxamic acid (diastereomers 1).
(±)-α-Butyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorocane-3- acetohydroxamic acid (diastereomers 2).
(±)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 1). (±)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 2,).
(±)-α-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1,).
(±)-g-Allyl-2-(4-methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2).
(g/?)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 1, compound 130).
(α ?)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 2). (αS)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 1).
(αS)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 2). (±)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorepane-
3-acetohydroxamic acid (diastereomers 1).
(±)-2-(4-Methoxyphenyl)- α-(2-methylpropyl)-2-oxo-l,3,2-oxazaphosphorepane-
3-acetohydroxamic acid (diastereomers 2). (±)-2-(4-Methoxyphenyl)- α-propyl-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 1).
(±)-2-(4-Methoxyphenyl)- α-propyl-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 2,).
(±)-2-(4-Methoxyphenyl)- α-octyl-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1).
(±)-2-(4-Methoxyphenyl)- g-octyl-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2,).
(g ?)-2-(4-Methoxyphenyl)-2-oxo-g-phenylmethyl-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomer 1). (αS)-2-(4-Methoxyphenyl)-2-oxo-α-phenylmethyl-l,3,2-oxazaphosphorinane-3- aceto hydroxamic acid (diastereomer 1).
(αS)-2-(4-Methoxyphenyl)-2-oxo-α-phenylmethyl-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomer 2).
(+)-2-Oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-Oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid.
(±)-2-Oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorocane-3-acetohydroxamic acid. (±)-α-Allyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomers 1.).
(±)-α-Allyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-3- aceto hydroxamic acid (diastereomers 2).
(αR)-α-(2-Methylpropyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane- 3-acetohydroxamic acid (diastereomer 1).
(α ?)-α-(2-Methylpropyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-
3-acetohydroxamic acid (diastereomer 2).
(α/?)-α-(2-Methylethyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomer 1). (α ?)-α-(2-Methylethyl)-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomer 2).
(±)-α-Butyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1). (±)-α-Butyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2).
±)-α-Octyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 1). (+)- α-Octyl-2-oxo-2-(4-phenoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid (diastereomers 2).
(±)-2-Oxo-2-(2-phenylethyl)-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-(4-Methoxyphenyl)-2-oxo-l,3,2-oxazaphosphorocane-3-acetohydroxamic acid. (±)-2-Oxo-2-phenyl-l,3,2-oxazaphosphorocane-3-acetohydroxamic acid.
(±)-2-Heptyl-2-oxo-l,3,2-oxazaphosphorocane-3-acetohydroxamic acid
(compound 159).
(α/?)-2-(4-Biphenylyl)-α-(l-methylethyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid (diastereomer 2). (±)-2- [4-(4-Chlorophenyloxy)-phenyl]-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid. (+)-2- [4-(4-Chlorophenyloxy)-phenyl]-2-oxo-l,3,2-oxazaphosphorocane-3- acetohydroxamic acid.
(α ?)-2- [4-(4-Chlorophenyloxy)-phenyl]-α-(2-methylethyl)-2-oxo-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-(4'-Bromo-4-biphenyIyl)-2-oxo-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2-(4'-Bromo-4-biphenylyl)-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid. (±)-2-(4'-Bromo-4-biphenylyl)-2-oxo-l,3,2-oxazaphosphorocane-3- acetohydroxamic acid.
(±)- 2-f2-(l-Naphtyl)-ethyl]-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-Phenyl-2-thioxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid. (±)-2-Phenyl-2-thioxo-l,3,2-oxazaphosphorepane-3-acetamide.
(±)-2-Phenyl-2-thioxo-l,3,2-oxazaphosphorocane-3-acetamide.
(±)-2- [4-(4-Chlorophenyloxy)-phenyI] -2-oxo-l,3, 2-oxazaphosphorinane-3- acetohydroxamic acid.
(+)-2-(4-Bromophenyl)-2-oxo-l,3,2-oxazaphosphorinane-3-acetohydroxamic acid.
(±)-2-(4-Bromophenyl)-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid. (±)-2-Oxo-2-(4-phenylmethoxyphenyl)-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid.
(+)-2-Oxo-2-(4-phenylmethoxyphenyl)-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid. (±)-2-Oxo-2-(4-phenylmethoxyphenyl)-l,3,2-oxazaphosphorocane-3- acetohydroxamic acid.
(±)-2- [2-(4-Chlorophenoxy)-phenyl] -2-oxo-l,3, 2-oxazaphosphorepane-3- acetohydroxamic acid
(±)-2-Oxo-2-[4-(4-trifluoromethylphenoxy)-phenyl]-l,3,2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2-Oxo-2-[4-(4-trifluoromethylphenoxy)-phenyl]-l,3,2-oxazaphosphorepane-3- aceto hydroxamic acid.
(α ?)-α-(2-Methylethyl)-2-oxo-2-[4-(4-trifluoromethylphenoxy)-phenyl]-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 1,). (αfl)-α-(2-Methylethyl)-2-oxo-2-[4-(4-trifluoromethylphenoxy)-phenyl]-l,3,2- oxazaphosphorinane-3-acetohydroxamic acid (diastereomer 2).
(±)-2- [4-(4-Bromophenoxy)-phenyl] -2-oxo-l,3, 2-oxazaphosphorinane-3- acetohydroxamic acid.
(±)-2- [4-(4-Bromophenoxy)-phenyl] -2-oxo-l,3, 2-oxazaphosphorepane-3- acetohydroxamic acid.
(±)-2-(4-nitrophenyl)-2-oxo-l,3,2-oxazaphosphorepane-3-acetohydroxamic acid
(±)-2-[/V-(4-Chlorobenzoyl)-4-aminophenyl]-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid.
(±)-2-(Λ/-Benzoyl-4-aminophenyl-2-oxo-l,3,2-oxazaphosphorepane-3- acetohydroxamic acid; and the corresponding carboxylic acids.
9. An isomer of a compound according to any claims 1-8, in pure form, or a mixture of isomers of said compounds.
10. A pharmaceutical composition containing an effective amount of one or more of the compounds of claims 1-9 as an active ingredient, together with pharmaceutically acceptable carriers and/or auxiliary agents.
11. A method for the treatment or prophylaxis of diseases or conditions involving tissue breakdown, inflammation comprising or proliferative disorder comprising administering to a patient in need thereof an effective amount of a compound according to claim 1-10.
12. A method according to claim 11 wherein the disease or condition is arthritis, rheumatoid arthritis, osteoarthritis, osteopenias, oteroporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, skin agning, tumour metastasis, invasion or growth, multiple sclerosis, psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours angiofibroma or hemangiomas.
13. The use of a compound of formula I according to any claims 1-9 for the manufacture of a medicament for the treatment of diseases or conditions involving tissue breakdown, inflammation or proliferative disorder.
14. The use according to claim 13 wherein the condition or disease is arthritis, rheumatoid arthritis, osteoarthritis, osteopenias, oteroporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, skin agning, tumour metastasis, invasion or growth, multiple sclerosis, psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours angiofibroma or hemangiomas.
EP01949275A 2000-07-18 2001-07-03 Matrix metalloproteinase inhibitors Expired - Lifetime EP1303527B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21903100P 2000-07-18 2000-07-18
US219031P 2000-07-18
PCT/DK2001/000464 WO2002006293A1 (en) 2000-07-18 2001-07-03 Matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
EP1303527A1 true EP1303527A1 (en) 2003-04-23
EP1303527B1 EP1303527B1 (en) 2004-09-29

Family

ID=22817531

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01949275A Expired - Lifetime EP1303527B1 (en) 2000-07-18 2001-07-03 Matrix metalloproteinase inhibitors

Country Status (20)

Country Link
US (1) US6521606B2 (en)
EP (1) EP1303527B1 (en)
JP (1) JP2004504326A (en)
KR (1) KR20030018053A (en)
CN (1) CN1443190A (en)
AT (1) ATE277938T1 (en)
AU (2) AU7047901A (en)
BR (1) BR0112558A (en)
CA (1) CA2416015A1 (en)
DE (1) DE60106048T2 (en)
DK (1) DK1303527T3 (en)
ES (1) ES2228906T3 (en)
HU (1) HUP0302904A3 (en)
IL (1) IL153563A0 (en)
MX (1) MXPA03000277A (en)
PL (1) PL360371A1 (en)
PT (1) PT1303527E (en)
RU (1) RU2270835C2 (en)
SI (1) SI1303527T1 (en)
WO (1) WO2002006293A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
WO2003059921A1 (en) * 2002-01-18 2003-07-24 Leo Pharma A/S Mmp inhibitors
CN1732023A (en) * 2002-12-27 2006-02-08 血管技术国际股份公司 Compositions and methods of using collajolie
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP1919895A2 (en) * 2005-08-02 2008-05-14 Lexicon Pharmaceuticals, Inc. 2-aminoaryl pyridines as protein kinases inhibitors
WO2008122115A1 (en) * 2007-04-09 2008-10-16 Methylgene Inc. Inhibitors of histone deacetylase
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
US4618692A (en) * 1981-09-03 1986-10-21 Asta-Werke Aktiengesellschaft 4-carbamoyloxy-oxazaphosphorins
FR2567129B1 (en) * 1984-07-06 1986-12-05 Adir NOVEL OXAAZAPHOSPHORIN DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PL140732B1 (en) * 1984-07-31 1987-05-30 Polska Akad Nauk Centrum Method of obtaining 2-/2-halogenethylamino/-2-oxo-3-/2-halogenethylo/-1,3,2-oxazophosphorianytes
WO1997032604A1 (en) * 1996-03-07 1997-09-12 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
BR9713182A (en) * 1996-08-28 1999-11-03 Procter & Gamble Phosphonic acid amides as matrix protease metallo inhibitors
US6420586B1 (en) * 2000-08-15 2002-07-16 University Of Kansas Amino acid-derived cyclic phosphonamides and methods of synthesizing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0206293A1 *

Also Published As

Publication number Publication date
US6521606B2 (en) 2003-02-18
WO2002006293A1 (en) 2002-01-24
DE60106048D1 (en) 2004-11-04
BR0112558A (en) 2003-07-22
CN1443190A (en) 2003-09-17
RU2270835C2 (en) 2006-02-27
PT1303527E (en) 2005-01-31
US20020103166A1 (en) 2002-08-01
ATE277938T1 (en) 2004-10-15
AU7047901A (en) 2002-01-30
HUP0302904A3 (en) 2005-02-28
DK1303527T3 (en) 2005-01-31
AU2001270479B2 (en) 2005-06-30
DE60106048T2 (en) 2006-02-09
JP2004504326A (en) 2004-02-12
PL360371A1 (en) 2004-09-06
MXPA03000277A (en) 2004-04-05
CA2416015A1 (en) 2002-01-24
KR20030018053A (en) 2003-03-04
SI1303527T1 (en) 2005-04-30
EP1303527B1 (en) 2004-09-29
IL153563A0 (en) 2003-07-06
HUP0302904A2 (en) 2003-12-29
ES2228906T3 (en) 2005-04-16

Similar Documents

Publication Publication Date Title
KR101262400B1 (en) Aminocarboxylic acid derivative and medicinal use thereof
Sørensen et al. Cyclic phosphinamides and phosphonamides, novel series of potent matrix metalloproteinase inhibitors with antitumour activity
JPH10509719A (en) Matrix metalloprotease inhibitor
JPH11514673A (en) Phosphinate-based inhibitors of matrix metalloproteases
KR101327635B1 (en) Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
KR20140003464A (en) Phosphorous derivatives as chemokine receptor modulators
JP2010001298A (en) Plasma carboxypeptidase b inhibitor
EP1303527B1 (en) Matrix metalloproteinase inhibitors
PL177661B1 (en) Intercellura substance metaloprotease inhibitor
AU2001270479A1 (en) Matrix metalloproteinase inhibitors
JP2008536911A (en) Phosphonate-treated fluoroquinolone, its antibacterial analogues and methods for preventing and treating bone and joint infections
JP2023538768A (en) Inhibitor of Pseudomonas aeruginosa virulence factor LasB
IE911165A1 (en) Novel compounds
EP1470138B1 (en) Mmp inhibitors
NZ255878A (en) Phosphono-substituted tetrazoles and medicaments thereof
CA2443709A1 (en) Novel cyclo azaphospha hydrocarbons
AU2002338287A1 (en) Novel cyclo azaphospha hydrocarbons

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030218

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20031023

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHRISTENSEN, METTE, KNAK

Inventor name: BLAEHR, LARS, KRISTIAN, ALBERT

Inventor name: SORENSEN, MORTEN, DAHL

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60106048

Country of ref document: DE

Date of ref document: 20041104

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20040404020

Country of ref document: GR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Ref country code: PT

Ref legal event code: SC4A

Effective date: 20041202

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2228906

Country of ref document: ES

Kind code of ref document: T3

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20050616

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20050621

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20050622

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20050629

Year of fee payment: 5

Ref country code: GB

Payment date: 20050629

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20050704

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050718

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20050720

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20050721

Year of fee payment: 5

Ref country code: FI

Payment date: 20050721

Year of fee payment: 5

Ref country code: CH

Payment date: 20050721

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20050722

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20050726

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20050727

Year of fee payment: 5

Ref country code: ES

Payment date: 20050727

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050731

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20050819

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20050831

Year of fee payment: 5

ET Fr: translation filed
26N No opposition filed

Effective date: 20050630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060703

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060703

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060703

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060703

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060731

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060731

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060731

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060731

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070103

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20070103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070201

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070201

LTLA Lt: lapse of european patent or patent extension

Effective date: 20060703

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060703

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20070201

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20070330

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20070405

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20060704

BERE Be: lapsed

Owner name: *LEO PHARMA A/S

Effective date: 20060731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060703